Immunological Techniques Applied to Triacylglycerol Rich Lipoproteins in Postprandial Plasma and Tissue Slices. by Mohd-Esa, Norhaizan.
IMMUNOLOGICAL TECHNIQUES APPLIED TO 
TRIACYLGLYCEROL RICH LIPOPROTEINS IN 
POSTPRANDIAL PLASMA AND 
TISSUE SLICES
A Thesis presented for the degree of Doctor of Philosophy
by
Norhaizan Mohd.-Esa 
February 2001
The Nutrition and Food Science Research Centre 
School of Biological Sciences 
University of Surrey 
Guildford
ProQuest Number: 27693979
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27693979
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
For my beloved parents
ACKNOWLEDGEMENTS
I am most gratefiil and deep appreciation to Dr Barry J. Gould and Dr. Bruce A. 
Griffin whom I much respect for their continuous encouragement, advises and 
guidance.
I am indebted to Dr. J. Wright for his helping in all the clinical aspect in ethanol 
study, Professor Mike J. Davies from the Histopathology Department, Medical 
School, St George’s Hospital for donation of human tissues, the suggestion and 
support received from Professor Gordon Fern in immuno-localisation chapter, and Dr 
Julie Howarth for the facilities in Histopathology Laboratory. Many thanks also go to 
Dr David Lamb, Dr Gail Isherwood, Dr Amelia Fareday, Dr Tony Avades, Dr. 
Shelagh Hampton and Charlotte Nicols for their technical support and also to Dr Eric 
Ah-Sing for his invaluable assistance in all technical matters especially in HPLC.
I am very gratefiil to those involved in my studies and all the volunteers who made the 
ethanol studies possible.
I also would like to express my gratitude to my dear lab mates, Najat, Andy, Sam, 
Bea, Wendy, Syrah, Karen, for their friendship also to Anne for a good friend and a 
brilliant co-woker in ethanol study, Nigel and Paul for their fiin to cheer me up in the 
lab, and Mrs Jones and Win for their warm smile early in the morning which will long 
be remembered. My thanks are also due too, to my sponsor. Government of Malaysia 
for the financial.
I also wish to acknowledge Kak Ainol, Hari, Abang Man for their continuous advice, 
emotionally supports throughout the last few years. A special thanks is due to 
Hisham Zakaria for his love and emotionally support. Last, but definitely not least, 
the loving, support and understand of my parents and family in Malaysia deserves a 
special note of thanks.
ABSTRACT
Apolipoprotein B-48 (apo B-48) is the specific transport protein of dietary fat, which 
is packaged as chylomicrons (CM) in enterocytes. Each CM or its remnant (CMR) 
contains one molecule of apo B-48 which remains within the particle until removal 
fi*om plasma, making it an ideal marker for the metabohsm of postprandial 
lipoproteins. By using our specific antiserum against apo B-48, which recognises the 
C-terminal end of the protein, an improved method for the immuno-detection and 
semi-quantitation of apo B-48 was developed which was 25-to 50-fold more sensitive 
than staining with Coomassie Brilliant Blue. This technique was relatively simple 
and the sample did not need a pre-dehpidation step. In addition, samples with high 
protein concentrations but low levels of apo B could be used directly in the sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) method without an 
ultracentrifiigation step. Furthermore, the separation of apo B-48 fi*om apo B-lOO was 
improved using a 3-16% (w/v) acrylamide gradient gel. In addition, this immuno­
detection method has the ability to quantify both apo B-48 and apo B-100 in the same 
blot, which reduces the amount of sample and time needed for apo B quantification.
The apo B-48 specific antiserum and monoclonal antibody to the C-terminal end of 
apo B-lOO were also used to examine the tissue localisation of these two 
apolipoproteins, of which the N-terminal 2152 amino acids are identical. Three types 
of human tissues were used: fatty streak, aorta and coronary artery. Immuno- 
cytochemistry was applied to human ileum and liver to check whether the system was 
working before it was applied to aorta and coronary artery. Apo B-48-containing 
lipoproteins were clearly visualised in ileum tissue whereas apo B-lOO-containing 
lipoproteins were detected by strong staining in the liver. Macrophages are known to 
be involved in the early stage of atherosclerosis (fatty streak). They are present in 
high concentrations in the foamy area in the intima layer of aorta and coronary arteiy. 
Apo B-48-containing lipoproteins and apo B-lOO-containing lipoproteins were present 
in the same area as macrophages, which suggests a role for both lipoproteins in 
causing the accumulation of lipid in these tissues. In addition, apo B-lOO was also 
detected in the media area, which is rich in smooth muscle cells.
Postprandial lipaemia is observed following the acute ingestion of ethanol. However, 
the effect of ethanol on apo B-48-containing lipoproteins when ethanol is consumed 
with a fatty meal has not been thoroughly investigated. To address this issue, we used 
an oral-fat load test in which CM metabolism was followed by analysis of 
triacylglycerol (TAG), apo B-48 and retinyl esters (RE). Ethanol consumption 
together with the test meal compared to control increased the area under the curve 
(AUC) for plasma-TAG (P<0.01) and TAG rich lipoprotein (TAGRL)-TAG 
(P<0.05). Even though the AUC for plasma-apo B-48 and RE were not significantly 
increased, the levels remained elevated after the test meal, which included ethanol, 
compared with control, mainly between 5-8 hours postprandially. The postprandial 
profile of plasma-apo B-48 induced by ethanol, as measured by SDS-PAGE was 
significantly higher than control (P<0.05) after analysis by repeated measure 
ANOVA. The post-heparin lipoprotein lipase activities (PHLA) decreased about 13% 
(not significant) by ethanol. However, there was an inverse relationship between 
PHLA and plasma TAG (r=0.881, f <0.005). This probably explains the delayed 
clearance of TAGRL after ethanol intake. The AUC of plasma non-esterified fatty 
acid (NEFA) was reduced after the ingestion of ethanol (P<0.01) particularly in the 
late postprandial phase (>5 hours) of the study in contrast to insulin, which was higher 
than in the controls in the early postprandial phase (not significant). However, no 
significant differences were evident for plasma-cholesterol, total protein and apo B 
and the levels of high density lipoprotein (HDL)-cholesterol and low density 
lipoprotein (LDL)-cholesterol were also not significantly changed. This study 
demonstrates that the elevated TAG levels in the postprandial state after ethanol 
consumption is partly due to the accumulation of intestinally-derived lipoprotein 
particles.
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CHAPTER ONE 
LITERATURE REVIEW
1.1 CORONARY HEART DISEASE (CHD)
1.1.1 Definition
Coronary heart disease (CHD) is also called coronary atherosclerosis, coronary artery 
disease or ischaemic heart disease (Patel, 1989). It refers to the narrowing of the 
coronary arteries due to the deposition of cholesterol and other substances in the 
smooth muscle cells (SMC) of the inner arterial wall. The process also includes the 
proliferation and migration of SMC from a deeper layer of the artery wall. These 
form an irregular thickening of the inner wall of the artery which eventually become 
fibrous, calcified plaques that reduce the size of the arterial lumen, and decrease the 
elastic properties of the arteries. The narrowing of the artery causes the heart to work 
harder to circulate the blood. The roughening of the artery wall also promotes the 
formation of blood clots, which can block the artery (Voet and Voet, 1992).
1.1.2 Risk factors for CHD
The precise underlying causes of CHD have not been discovered. However, there are 
a number of factors known to influence risk of CHD. These factors can be divided 
into: i) age, gender and family history which cannot be altered; ii) high blood 
pressure, hypercholesterolemia, obesity and diabetes that are modifiable physiological 
factors, and; iii) behaviour such as diet, smoking, lack of exercise and ethanol 
consumption (Marmot and Poulter, 1992). This study is mainly concerned with lipid, 
so the intention will be to emphasise those risk factors closely associated with the 
levels of lipid in the blood, a high level of low density lipoprotein (LDL)-cholesterol, 
an increase in plasma triacylglycerol (TAG) and a low level of high density 
lipoprotein (HDL)-cholesterol, which are all interrelated risk factors.
1.2 LIPOPROTEINS
1.2.1 Definition
Lipoproteins are spherical macromolecular complexes, with marked heterogeneity in 
particle size, hydrated density and composition. They are composed of highly 
hydrophobic lipids, TAG and some cholesteryl esters within the core, and surrounded 
by relatively hydrophilic lipids, phospholipids and free cholesterol as well as proteins 
on the periphery of the lipoprotein molecules. The proteins in lipoproteins are called 
apolipoproteins or apoproteins (apo) which have hydrophobic domains which dip into 
the core and anchor the protein to the particle, and hydrophilic domains which are 
exposed at the surface (Frayn, 1997). Apolipoproteins have several different 
functions; the solubilisation and stabilisation of the emulsion of lipids in plasma, 
determination of the structure of the lipoproteins, they serve as cofactors and 
modulators of enzymatic reactions, they manage the export of lipid out of cells and 
direct lipid to target organs by specific receptor interaction, and in addition they may 
have other specific functions such as interfering with platelet aggregation and 
lipoprotein uptake (Norum, 1992). Their fimctions are summarised in Table 1.1.
1.2.2 Structure and functions
Lipoproteins can be classified according to their fimctions and physical 
characteristics. In addition, they may also be classified by their apolipoprotein 
content, especially with the growing evidence that apohpoproteins, particularly apo A 
and B (Tadey and Purdy, 1995), are better markers of CHD than serum cholesterol 
levels (Naito, 1988). However, hydrated density remains the most common form of 
lipoprotein classification. Thus, lipoproteins are generally separated into five 
different classes as listed in Table 1.2.
1.2,2,1 Chylomicron (CM)
CM are droplets of reprocessed lipid formed within epithelial cells of the small 
intestine during lipid absorption which function as transport vehicles of exogenous
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(dietary) TAG and cholesterol from the intestine to their site of utilisation and storage 
in tissues. CM are large particles with diameters ranging from 100-1000 nm and 
8^400 (Fruchart and Shepherd, 1989). Their size is determined by the flux of TAG 
through the cells of the intestine during fat absorption (Hayashi et a l, 1990; Martin et 
a l, 1994). CM have a hydrophilic surface consisting of various phospholipids, 
cholesterol and a small percentage of protein (1%) of which apo B-48 (MW~265 
kDa) is the major apolipoprotein, and a core of neutral lipids, mainly TAG which 
makes up about 90-98% of the weight of CM, and cholesteryl esters. A typical CM 
contains 1% cholesteryl esters and 2% cholesterol (Green and Glickman, 1981). The 
fatty acid composition of the TAG generally reflects the fatty acid composition of the 
diet; the phosphohpids primarily contain stearic acid, and the cholesteryl esters 
contain oleic and linoleic acids (Cohn, 1998).
1.2.2,2 Very Low Density Lipoprotein (VLDL)
VLDL particles are secreted continuously from the liver (Chan, 1992). VLDL 
functions to deliver lipid (mainly TAG) from the liver to peripheral tissues. In 
contrast to CM and their remnants, they are characterised by their apo B-lOO content 
besides apo C-I, C-II, C-in, and apo E. They are composed of a spectrum of particles 
ranging in size from 30-70 nm and density from 0.950 to 1.006 kg/1 (Fruchart and 
Shepherd, 1989). The chemical composition as percentage of weight of VLDL are 
9% protein, 20% phospholipids, 10% cholesterol ester, 6% unesterified cholesterol 
and 55% TAG (Barakat et a l, 1996).
L2.2.3 Low Density Lipoprotein (LDL)
LDL particles that are isolated from human plasma by ultracentrifugation in the range 
1.019-1.063 kg/1 vary in molecular size from 2 to 3.5 x 10^  Da with the mean 
diameter 20 nm (Fruchart and Shepherd, 1989). In general, lipid comprises 78% of 
the mass of the LDL particles and protein makes up the remaining 20% (Frayn, 1997). 
Thç inain apolipoprotein present in LDL is apo B-lOO, which is required for 
interaction with the LDL receptor. Generally LDL fimction as the principal plasma 
carriers of cholesterol delivering cholesterol from the liver to peripheral tissues, 
primarily the adrenals and adipose tissue and can also return cholesterol to the liver.
L2.2.4 High Density Lipoprotein (HDL)
HDL are the smallest and most dense of the plasma lipoproteins. Like other plasma 
lipoproteins, they consist of a hydrophobic core (mainly eholesteryl esters plus a 
small amount of TAG) surrounded by a surface monolayer of phospholipids, 
unesterified cholesterol and apolipoprotein. The main apolipoproteins of HDL are 
apo A-I and apo A-II although they also act as reservoirs for small amounts of apo Cs 
and apo E. HDL originate in the liver and intestine and interact with the other 
lipoproteins. They have an opposing function to LDL. Their best-documented 
function is as the acceptors of cholesterol released from extrahepatie tissues through 
the action of lecithin cholesterol acyl transferase (LCAT). This reaction is the first 
step of the pathway of reverse cholesterol transport, the process whereby cholesterol 
is transported from peripheral tissues to the liver for recycling or for excretion in bile. 
The cholesterol esters of HDL can also be transferred to VLDL and LDL through the 
action of the HDL-assoeiated enzyme, cholesterol ester transfer protein (CETP). 
There is evidence that HDL also have functions that appear to be unrelated to their 
role in cholesterol transport, such as to bind lipopolysaccharide and to protect 
erythrocytes against the generation of pro-coagulant activity (Barter and Rye, 1996).
i.2.2.5 Lipoprotein [a]
Lipoprotein [a] is an additional lipoprotein subclass, which consist of LDL-like 
particles rich in cholesterol esters. In Lp [a], the highly polymorphic and glycosylated 
apo [a] is covalently linked by a single disulfide bridge to apo B-lOO, the main protein 
moiety of LDL (Lippi et ah, 1996) and it has a high degree of sequence homology 
with plasminogen (Me Lean et al, 1987). Lp [a] particles have about the same lipid 
composition as LDL particles, but because of the addition of apo [a], they are larger 
and denser than LDL particles (Lippi et ah, 1996).
1.3 TRIACYLGLYCEROL RICH LIPOPROTEINS (TAGRL)
TAGRL are a heterogeneous group of large lipoprotein particles derived from either 
the liver (VLDL) or from the intestine (CM) (Havel, 1994). Both CM and VLDL 
contain one molecule of apo B (Phillips et a l, 1997), which is required for the 
assembly of the particles in the cell and secretion there from (Havel and Kane, 1994). 
These proteins remain with the particle throughout their catabolism (Havel, 1994).
1.3.1 CM metabolism
CM are assembled by the intestinal mucosa and then secreted into the intestinal lymph 
via the thoracic duct before draining into the left subclavian vein (Tso and Balint, 
1986). Once in the blood, CM acquire apo Cs and apo E from HDL particles in 
exchange for apo A-I (Erkelens et a l, 1981). Their metabolic processing now begins 
with the hydrolysis of some surface and core lipids via the actions of endothelial cell 
heparan sulfate proteoglycan (HSPG)-bound lipoprotein lipase (LPL). LPL is 
expressed in a number of peripheral tissues including adipose tissue, skeletal and 
cardiac muscle and mammary gland. LPL expression is regulated by hormones, 
particularly insulin, and its action permits the targeted dehvery of fatty acids to sites 
of storage or of utilisation for the production of energy (Eekel, 1989). Lipolysis of 
CM by LPL is dependent on the presence of apo C-II, which is acquired from HDL in 
the circulation during CM maturation. The hydrolysis of CM-TAG continues for 
about 5-10 minutes (Grundy and Mok, 1976) until approximately 80-90% of the TAG 
has been removed and CM become smaller in size. The monoacylglyeerides and free 
fatty acids (FFA) produced are rapidly transported to parenchyma cells across the 
endothelium for oxidation, particularly in muscle, or re-esterified for storage in 
adipose tissue, or they may be transported to the liver where they are oxidised or 
esterified. During the hydrolysis of TAG, a substantial portion of phospholipid, apo 
A and apo C are also transferred to HDL (Schaefer et a l, 1982). The CM-TAG 
depleted remnants, which are called CMR, are much smaller with a diameter ranging 
from 50-100 nm and are similar in size to VLDL.
CMR still contains eholesteryl ester and apo B-48 (Redgrave, 1976). During this 
degradative process, apo E is transferred from HDL and this protein allows for the 
uptake and recognition of CMR. The exact mechanism whereby CMR interact with 
various ligands on the surface of hepatoeytes has received a lot of attention recently. 
As reviewed by Mahley and Ji (1999), the plasma clearance of intestinally derived 
remnant lipoproteins by the liver is a process that probably involves 3 steps. Firstly, 
the sequestration of the remnants within the Space of Disse, where apo E secreted by 
hepatoeytes enhances remnant binding and uptake. The Space of Disse, also contains 
an abundance of HSPG, which mediates this enhanced binding. Apo E receptors 
recognise a positively charged region of this apolipoprotein, which is rich in arginine 
and lysine side chains. Next, the remnants are further processed in the Space of Disse 
by LPL attached to remnant and hepatic lipase (HL) before being endocytosed by 
hepatoeytes. The lipid component of the remnants is either stored, excreted with bile 
or re-secreted in a rhythmic fashion as TAG-rieh VLDL particles (Patseh et al., 1987).
Several receptors have been proposed that might be involved in the clearance of CMR 
from the plasma:
1. LDL-reeeptor tapo E/apo B1
This receptor with 160 kDa protein expressed in all mammalian cell types (Yamamoto 
et a l, 1984), and can be responsible for up to 75% of total remnant uptake (Ishibashi 
et a l, 1996; Mahley et a l, 1991) and approximately 50% of CM clearance (Havel,
1995).
2. LDL-reeeptor related protein g^-macroglobulin (HRP-a^Ml receptor 
LRP-aiM receptor has molecular size of 600 kDa and is expressed strongly in 
hepatoeytes (Herz et a l, 1988). It has been shown to clear approximately 20% of the 
remnants (De Faria et a l, 1996) enriched with apo E or containing lipoprotein lipase 
and is thought to provide a back-up mechanism in the absence of the LDL-reeeptor 
(Hussain et a l, 1991; Beisiegel et a l, 1994) in liver cells and in fibroblasts. The 
binding characteristics for CMR-associated apo E is similar to those of the LDL- 
reeeptor (Martin et a l, 2000).
3. (3-VLDL receptor (van Diik et aA.1991: Takahashi et a l, 1995)
This protein can lead to the endoeytosis of lipoproteins and can bind CMR in the 
presence of additional apo E or lipoprotein lipase (Niemier et a l, 1996). Its 
localisation in the heart, skeletal muscle, and adipose tissue, however, precludes a role 
in hepatic uptake; the receptor could contribute to the non-hepatie uptake of remnants.
4. Asialoglveoprotein TASPGl receptor
This receptor is possibly a binding site for LDL and CMR but LDL bind with a much 
lower affinity to the ASPG receptor than remnants (Windier et a l, 1991).
5. Lipolvsis stimulated receptor (LSR)
This membrane protein is activated by the present of free fatty acids in the lipid 
particle (Bihain and Yen, 1992) and is distinct from the LDL receptor and LRP (Yen 
et a l, 1994). Like the LDL-reeeptor, LSR also binds both apo B and apo E (Mann et 
al, 1995).
6. Macrophage cell surface protein
This receptor with size 200/235 kDa was identified by Gianturco and colleagues
(1994), recognises either apo B-48 or large apo B-lOO TAGRL particles (Gianturco et 
al, 1998). The receptor-binding domain is within apo B-48 (or an equivalent in apo 
B-lOO) near the LPL-binding domain, but not a heparin-binding domain and is 
expressed primarily by reticuloendothelial cells: monocytes, macrophages and 
endothehal cells. Immuno-cytoehemistry also shows the presence of this receptor in 
human atherosclerotic lesion foam cells and has been cloned recently by Brown et al 
(2000).
In addition to apo E phenotype, HE and apo C-II also appear to be important in the 
regulation of receptor mediated remq^pt removal (Havel, 1994). Although the exact 
mechanism remains to be elucidated, it is suggested that HL may influence the 
conformation of apo E, thereby increasing the affinity for the LRP and/or LDL- 
reeeptor (Demacker et al, 1991). In contrast to nascent CM, CMR have a half-life of 
several hours as shown recently in a kinetic study using heavy isotopes by Welty et ah
(1999). They illustrated that lipoproteins eontaining either apo B-lOO or apo B-48 
were removed from the VLDL density range at similar rates.
1.3.2 VLDL metabolism
The metabolism of VLDL, whieh are synthesised in the liver as endogenous lipid 
transport vehicles, is similar to that of CM in many respects (Havel, 1989). They are 
also degraded by LPL along the capillary endothelium but TAG in these smaller 
VLDL particles is hydrolysed more slowly. After interaction with LPL, VLDL 
become smaller remnant particles, also termed intermediate density lipoprotein (IDL) 
and enriched with apo E. Large IDL, like CMR are cleared directly by the liver via 
the LDL-reeeptor and the hypothetical remnant receptor (Yamada et al, 1988) and 
cholesterol is removed from the body by excretion into the bile (Cabezas and 
Erkelens, 2000). Smaller IDL, derived from smaller VLDL particles, are less likely to 
be taken up into the liver via the LDL-reeeptor (Yamada et al, 1987). They are 
further degraded possibly by a second lipolytic enzyme HL on hver cell surfaces and 
eventually lose their E and C apolipoprotein as well as almost all their component 
TAG, become more dense particles of the LDL (Havel, 1984). LDL have a much 
longer residence time in blood (2-3 days) compared to CM and VLDL remnants (days 
vs minute to hours). Because of their long residence time, the number of LDL 
particles in the blood greatly exceeds that of their precursors (Gotto et a l, 1986).
The summary of inter-relationships and metabohsm of five different classes of 
lipoprotein is illustrated in Figure 1.3
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Figure 1.3. Lipoprotein inter-relationships and metabolism.
Dietary fat is carried in chylomicrons, and endogenous (hepatic) fat in VLDL, to 
peripheral tissues where lipoprotein lipase (LPL) hydrolyses the triacylglycerol for 
energy supply or storage. Chylomicron remnants (CMR) are removed by the liver. 
VLDL remnants (IDL) are either removed by the liver or converted to LDL, the main 
cholesterol-carrying particles. LDL either provide cholesterol to peripheral tissues or 
are removed by the liver. HDL act as reverse cholesterol transport vehicles returning 
cholesterol from cholesterol-replete tissues to the liver or for interchange with other 
lipoproteins.
(Reckless, 1994)
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1.4 APOLIPOPROTEIN B
Apo B exists in two fonns termed apo B-lOO and apo B-48 that have apparent 
molecular weights of 549,000 and 264,000, respectively (Chan, 1992). In humans, 
apo B-48 is produced only by the intestine, whereas apo B-lOO originates from the 
liver even though the intestine may be competent for apo B-lOO production (Dullaart 
et al, 1986). In contrast with humans, both forms of apo B are synthesised and 
secreted by rat liver (Spark and Marsh, 1981). Under well-preserved conditions (i.e. 
the presence of antibiotics and antioxidants) apo B-lOO and apo B-48, have been 
detected by sodium dodeeyl sulphate-polyaerylamide gel electrophoresis (SDS- 
PAGE) and immunoblotting in rat intestine (Hoeg et al, 1990 and Levy et a l, 1990). 
Both apo B-48 and apo B-lOO are encoded on chromosome 2 by a single gene that 
contains 29 exons and 28 introns. Apo B-lOO whieh contains 4536 amino acid 
residues (Yang et al, 1986) is the major apohpoprotein of VLDL, IDL, LDL and 
lipoprotein [a]. Apo B-lOO contains two regions that show similarity to the LDL 
receptor binding domain of apo E, but only the region spanning amino acid residues 
3359-3367 exhibits a high degree of conservation among animal species and 
maintains a strong net positive charge (Law and Seott, 1990).
Apo B-48 is synthesized in the absorptive enteroeytes of the intestine, particularly in 
the duodenum, and plays a key role in the packaging of alimentary fats into 
chylomicrons (Havel and Kane, 1995; Young et a l, 1995). The biosynthesis of apo 
B-48 depends on post-transeriptional events that occur within the nucleus. The apo 
B-48 mRNA is transcribed from the same gene as apo B-lOO mRNA. However, the 
cystidine at nucleotide 6666 is change to a uridine by a mechanism termed post- 
transcriptional editing. This substitution converts codon 2153 of the apo B transcript 
from CAA, specifying glutamine, to the translational stop codon UAA. Apo B-48 
thus corresponds to the amino-terminal half of apo B-lOO, contains 2152 amino acid 
residues with an isoleucine at the carboxyl terminus, and is devoid of the binding 
domain for the LDL receptor (Powell et a l, 1987; Chen et a l, 1987).
On an equal mass basis, apo B-48 has lower histidine and higher arginine contents 
than apo B-100. The most striking differences are in the sulphur-containing amino
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acids. Apo B-48 has a 53% higher content of cysteine and 28% higher content of 
methionine than apo B-100. Among aromatic amino acids, both phenylalanine and 
tryptophan are lower in apo B-48 (16% and 25%, respectively). These differences 
may affect the dye binding, chromogenicity and absorption at 280nm of the two apo B 
species. In addition, apo B-48 contains more hydrophlic glycine (20%) and less 
hydrophobic isoleucine (19%) residues. Together with the lower aromatic amino acid 
content, this may result in an enhanced water solubility of apo B-48 compared to apo 
B-100 (Lee, 1996).
1.5 MECHANISM BY WHICH TAGRL LEVELS PREDISPOSES 
TOCHD
As defined in section 1.1.1, atherosclerosis is a disease of the arteries caused by 
accumulation of eholesteryl ester on the inner wall of the intima. The fact that a low 
concentration of HDL and high concentration of LDL are well-defined predictors of 
premature CHD has been known for sometime. However, CM are the principle 
carriers of absorbed dietary fat and cholesterol in the bloodstream and the first stage 
in their degradation takes place in contact with the vascular endothelium. In 1979, 
Zilversmit postulated that CMR generated from LPL hydrolysis in the circulation 
during the postprandial period were atherogenic and could cause cholesterol 
deposition in the arterial wall.
This hypothesis received support from several clinical angiographic, animal 
experimental and cell studies. For instance, the consistence finding of enhanced 
postprandial lipaemia in the patients with CHD (Patseh et ah, 1992; Groot et ah, 
1991) and in those at increased risk of disease such as non insulin dependent diabetes 
mellitus (NIDDM) (Lewis et al, 1991). They had higher apo B-48 and apo B-100 
levels in both fasting and postprandial states compared to controls and also delayed 
clearance of TAG and retinyl palmitate (RP) (Curtin et a l, 1996). The data from the 
studies in vitro by Ellsworth et a l (1986) found that TAGRL, especially CMR that are 
found in abundance in the postprandial phase, could promote the rapid accumulation 
of cholesterol within arterial cells and it was later suggested that this may be relevant
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to the development of atherosclerosis and coronary thrombosis (Moehizuki et al, 
1996).
Data from the Atherosclerosis Risk in Communities Study suggested that atherogenic 
risk is most highly correlated with the presence of postprandial TAG-rieh CM and 
VLDL remnants (Sharrett et a l, 1995). Furthermore, Austin et al (1998) indicated 
that a 1 mmoFl increase in the concentration of fasting TAG caused a 14% increase in 
CHD for men and a 37% increase in women.
Controversy exists as to which type of lipoprotein is responsible for the association 
between postprandial TAG and atherosclerosis. Ginsberg et al (1995) and Weintraub 
et al (1996) suggested that the delayed clearance of postprandial TAG of CMR is 
associated with CHD, whereas other clinical studies suggest a role for VLDL in CHD 
(Phillips et al, 1993; Tomvall et al, 1993). In contrast to the above however, 
Goldberg et al (1998) suggested that apo B-48 and apo B-100 containing lipoproteins 
are equally atherogenic. This is due to the observation of a common proteoglycan- 
binding site in the NHz-terminal region of both types of apo Bs, which may be 
sufficient for the interaction of lipoprotein with glyeoeonjugates produced by 
endothelial and SMC. Hence, roles for both CM and VLDL in atherosclerosis will be 
discussed in this section.
The major determinant of atherogenieity of TAGRL, may be related to at least four 
factors; their size, cholesterol ester content, apolipoprotein composition (Grundy and 
Vega, 1992) or the tendency of their lipoproteins to be modified (Goldberg et a l, 
2000). Postprandial lipaemia is important as a factor in atherosclerosis but this may 
be either through direct or indirect effects. The direct role is through the production 
of atherogenic remnants whieh have the ability to mediate cholesterol influx into the 
arterial wall intima in humans (Zilversmit, 1979; Mamo and Wheeler, 1994; Shaikh et 
al, 1991). Alternatively, the metabolism of TAGRL could cause compositional 
changes in other lipoproteins implicated in predisposing to atherosclerosis 
(Miesenbock and Patseh, 1992). Atherosclerosis is strongly linked to a collection of 
abnormalities in endogenous lipoproteins measured in the fasting or postabsorptive 
plasma known as the atherogenic lipoprotein phenotype (ALP). The ALP is 
characterised by a moderate increase in fasting plasma TAG levels, especially large
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TAG-rich VLDL, the predominance of abnormally small, dense LDL and HDL 
particles, and low levels of HDL.
Both CM and VLDL are substrates of LPL so they will compete for removal of TAG 
by LPL (Brunzell et a l, 1973; Karpe et a l, 1994). The competition between these 
lipoproteins becomes particularly marked in the postprandial period when there is an 
influx of CM into the circulation. Large CM particles are the preferred substrate for 
LPL, probably because the large TAG content of these lipoprotein particles increases 
their susceptibility to hydrolysis by LPL (Fisher et a l, 1995). If so, the size of the 
particle is an important determinant of its rate of clearance (Potts et a l, 1991). This 
result is supported by a previous study (Grundy and Mok, 1976) demonstrating that 
CM are cleared more rapidly from the plasma than VLDL. Furthermore, Saheki et al 
(1991) observed that the responses of VLDL to LPL treatment might depend mainly 
upon the surfacexore relationship of VLDL rather than its apoliporotein composition, 
except in rare clinical eases such as apo C-II deficiency. Preferential clearance of CM 
(apo B-48) TAG by LPL during the alimentary period impedes the hydrolysis of 
VLDL-TAG leading to the accumulation and longer residence time of VLDL particles 
in the circulation.
A high plasma level of TAGRL arising from either increased production or reduced 
catabolism, will lead to an increased exchange of TAG from these lipoproteins for 
eholesteryl esters, as well as unesterified cholesterol, derived from HDL and LDL 
through a process mediated by CETP (Deekelbaum et a l, 1982). Furthermore, it has 
been demonstrated that the CETP activity increases during postprandial lipaemia. 
Slow clearance of TAGRL molecules allows more time for CETP activity. This bi­
directional exchange will produce TAG-enriehment of HDL and LDL. Subsequently, 
these TAG-enriehed HDL and LDL particles are catabolised by HL, whieh is most 
active against the smaller lipoprotein particles (Patseh et al, 1987). The HDL 
become smaller and denser and they are cleared from the blood stream more rapidly, 
so that fewer are available to return cholesterol to the liver from the periphery 
(Packard, 1995).
On the other hand, following this bi-directional exchange, CM and VLDL particles 
will contain less protein, more free and esterified cholesterol and less TAG
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(Eisenberg, 1984). The IDL and CMR formed may then be engulfed by macrophages, 
whieh take the excess cholesterol into the artery wall and deposit it in the developing 
atheromatous plaques. As stated by Floren et al (1981) remnant particles, as they 
become smaller as a fonction of lipolysis, are more efficiently internalised by human 
arterial SMC and consequently are more effective in decreasing LDL-reeeptor 
activity. Additionally, these abnormal VLDL have been demonstrated to have a slow 
delipidation rate and a decreased fractional conversion of VLDL to LDL. TAG- 
enriehment of LDL will eventually lead to a reduction in the relative cholesterol 
content of LDL and to an increase in the concentration of small dense LDL in the 
plasma (LDL III). These are a highly atherogenic form of LDL, whieh are associated 
with a significant (4- to 6-fold) increase in CHD risk (Griffin et a l, 1999). They are 
poorly recognised by the LDL-reeeptor mediated clearance mechanism (Austin et al, 
1988). Hence, they stay in the plasma compartment for longer, have a longer life, and 
they are more readily and easily taken up by macrophages to create foam cells 
(Packard, 1995). They may undergo oxidative modification especially if they contain 
less lipid-soluble antioxidants, such as vitamin E. This oxidatively modified LDL 
might induce cell death either directly or following stimulation of superoxide radical 
production (Heinecke et al, 1986). LDL oxidation will also induce monocyte 
migration into the sub-intima, the conversion of monocytes to macrophages and the 
expression of oxidised-LDL receptor (Steinberg, 1993).
HL, in contrast to LPL, acts on smaller, cholesterol-rieh lipoproteins, ranging in size 
from small VLDL to HDL. It is also believed to facilitate the clearance of CMR, 
either, by exposing apo E on their surface, whieh then acts as the ligand for the 
remnant receptor, or, by sequestering the remnant in the proximity of these hepatic 
receptors. The important role of apo E in activating HL has been shown from the 
findings by Thuren and eo-workers (1992). Hashimoto et al (1997) suggested CM 
could take up more apo E than VLDL, in exchange for apo A-I and apo A-IV, which 
are not present in VLDL. Thus, it is possible that the concentration and size 
distribution of small CMR may also be a fonction of TAG level, mediated through 
competitive interaction with HDL and as a consequence generating small, dense LDL 
and HDLg.
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A review by Roche (2000) concludes that postprandial events could interact with the 
process of thrombosis. In particular, TAGRL have the ability to activate coagulation 
factor Vn (Roche and Gibney, 1997) whieh is positively associated with CHD 
mortality (Ruddock and Meade, 1994).
1.6 LIPID ABNORMALITIES IN DIABETES
Hypertriglyeeridaemia is the most common lipid abnormality of diabetes, especially 
in inadequately treated or untreated patients. It has been used as a marker for insulin 
resistant and atherogenic metabolic abnormalities. Besides hyperglycaemia, 
dyslipidaemia is also an obvious contributor to increased atherosclerotic risk in 
diabetes mellitus, whereas usual risk factors account for only 25-50% (Kreisberg, 
1998). In fact, vascular disease accounts for more than 60% of the morbidity and 
mortality of diabetes (Barakat et a l, 1996). Atherosclerotic lesions are similar in both 
diabetic and non-diabetic patients, but they are more diffuse and extensive when 
associated with diabetes; in such patients the liofemoral, popliteal and tibial vessels 
are more affected (Reckless, 1994).
Patients with both insulin dependent diabetes mellitus (IDDM) and NIDDM share a 
similar risk (Georgopoulos, 1999) but this discussion will concentrate more on 
NIDDM. NIDDM is also referred to as Type II (adult onset) diabetes. NIDDM is the 
most common form of human diabetes and is often associated with obesity. Subjects 
with NIDDM have a 2-to 4-fold increased risk of both dyslipidaemia and premature 
CHD when compared to non-diabetic subjects (Howard, 1987; Georgopoulos, 1999). 
Dyslipidaemia in NIDDM is similar to that in the metabohc syndrome, with mild to 
moderate hypertriacylglycerol caused by overproduction of TAGRL, mainly VLDL- 
TAG (Taskinen, 1990), the presence of small dense LDL and a low concentration of 
HDL-eholesterol. A high serum-TAG is an independent predictor of CHD without 
necessarily being accompanied by severe hypercholesterolaemia (Howard, 1987). 
Relatively small and dense TAGRL (Svedberg flotation (Sf) 12-60) have been shown 
to be associated with angiographic severity in both diabetic and non-diabetie 
individuals whereas NIDDM with moderate CHD had high levels of both Sf 12-60
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and larger and lighter Sf 60-400 particles. Further research has also indicated that the 
risk correlates positively to the postprandial levels of apo B-48 in the Sf 20-60 fraction 
which suggest that CMR may only be involved in the early stages of atherogenesis 
(Steiner, 1998). This observation received support from Mero et al. (2000), who 
showed that postprandial apo B-48 and apo B-100 clearance was delayed in NIDDM 
diabetic patients, even in those with only mild CHD.
Insulin is important in glucose and carbohydrate metabohsm. In addition, it also has 
other metabolic effects including those on protein and lipid metabolism (Frayn and 
Coppack, 1992). Insulin resistance is a term used to describe a metabolic state in 
which the action of insulin is impaired. It is an indicator for NIDDM (Eekel et a l,
1995) who have increased plasma glucose levels. As a consequence of the elevation 
in plasma glucose levels, the insulin concentration is also raised (hyperinsulinaemia) 
as a compensatory mechanism to try to maintain normoglycaemia (Barakat et a l,
1996). Insulin has both a stimulatory and inhibitory effect on VLDL synthesis and 
secretion. As shown by Sparks and Sparks (1996), long-term exposure (>24 hours) of 
cultured hepatoeytes to insulin, increased the synthesis and secretion of VLDL whieh 
may account for their elevated levels of VLDL-TAG. The prolonged exposure to 
insulin in NIDDM causes down-regulation of the insulin receptor (Caro et a l, 1986). 
The loss of insulin sensitivity causes a high rate of lipolysis in muscle and rapid 
supply of NEFA from adipose tissue, which is normally inhibited by an increase in 
plasma insulin concentration. Mobilisation of adipose tissue fatty acids into the portal 
circulation can lead to increased TAG synthesis in the hver.
Insulin also has an important function in the regulation of LPL, the enzyme 
responsible for the hydrolysis of TAG to give fatty acids, whieh are then taken up by 
adipose tissue (Frayn and Coppack, 1992). The action of insulin in the activation of 
adipose tissue LPL is essential for the normal clearing of postprandial lipaemia. Early 
studies by Taskinen et al (1982) found that defects in the amount of LPL activity in 
adipose tissue from NIDDM patients with hyperlipidaemia with type I 
hyperlipoproteinaemia caused reduced CM-TAG hydrolysis in the peripheral tissue. 
As a result, more postprandial TAG returns to the hver (Sadur and Eckel, 1982) and 
fiirther stimulates the production of hepatic TAGRL (Bergman et al, 1971; Goldberg, 
1996). Furthermore, LPL when compared to other lipases is rather sensitive to product
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inhibition. Alternatively, it is possible that free fatty aeids may abolish the effect of 
the activator protein, apo C-II (Ohvecrona et ah, 1992).
The higher level of CM during the early hours after a fatty meal might be associated 
with a higher rate of production and secretion of CM by enteroeytes (Syvanne et al, 
1994; Curtin et a l, 1996). They proposed that an intestinal abnormality in 
hypertriglyeeridaemie individuals, as shown in diabetic animals, might cause newly 
absorbed fat to be more efficiently packaged than in individual with a normal fasting 
TAG concentration.
An impaired hepatocellular uptake of CMR in NIDDM might also cause 
accumulation of intestinally derived particles during the early postprandial hours. A 
study by Martin et al (1994) showed that in insulin-deficient rats, the transportation 
of apo B-48 in lymph was not affected but it was associated with a defect in the 
expression of the receptor for the uptake of CMR. Also in a rat model of ageing and 
insulin resistance, a delayed clearance of CMR was due at least in part, to a decrease 
in the hepatic expression of the LDL and LRP receptor (Field and Gibbon, 2000).
The number, rather than the size, of TAGRL particles is a more important determinant 
of the plasma TAG concentration in NIDDM (Steiner et a l, 1998). This relationship 
is stronger in women than in men and it is independent of HDL and LDL 
concentrations (Tkac et al, 1997). The high level of TAGRL particles appears to 
drive the exchange of TAG, from these lipoproteins in exchange for cholesterol ester 
from HDL, whieh is facilitated by higher levels of CETP in NIDDM (Bagdade et a l,
1993). This generates a TAG-enriehed HDL. When this TAG is hydrolysed, the 
resultant smaller HDL particle is cleared rapidly from the circulation (Ginsberg,
1996). This might explain the low level of HDL in NIDDM patient. The small size 
of TAGRL enables them to infiltrate the blood vessel wall where they are oxidised, 
bind to receptors on macrophages and are ingested, leading to the development of the 
atherosclerotic lesion. Compared with postprandial control subjects, all TAGRL 
subfraetions isolated from IDDM patients had elevated cholesterol levels and an 
increased tendency to cause eholesteryl ester accumulation in macrophages and were 
therefore potentially atherogenic (Georgopoulos, 1999).
19
More recently. Smith and Mamo (2000) proposed another mechanism for the raised 
level of TAG-rich remnant Hpoprotein particles in NIDDM. Amylin, a pancreatic 
peptide, has been shown to induce a state of peripheral insulin resistance and is 
present in high concentration in NIDDM patients. It could influence the kinetics of 
TAGRL in vivo and in vitro by reducing CM uptake, most probably by regulating 
lipoprotein receptors either directly, or via modulation of insulin activity. The 
presence of high concentrations of CM and their remnants in the circulation results in 
exaggerated and more prolonged postprandial lipaemia through competition with 
VLDL for their common removal mechanism by LPL.
1.7 HOW DIET CAN INFLUENCE THE STRUCTURE AND 
METABOLIC FUNCTION OF TAGRL
The amount and the type of food that we consume are major determinants of 
atherosclerosis (Mann, 1997). However, the element of risk that relates to diet can be 
controlled (Patel, 1989). On the other hand, the postprandial triaeylglycerolaemia 
response may also be modified by dietary factors.
Compared to the clearance of eholesteryl ester, the absorption of dietary lipid (TAG) 
has a greater impact upon the plasma clearance of the TAG moiety (Maranhao et al.,
1996). The changes in size, structure and composition of CM in response to dietary 
lipid, alters their uptake by the hver from plasma (Quarfordt and Goodman, 1966; 
Redgrave et a l, 1988; Lambert et a l, 1995) and subsequently provides a link to the 
development of CHD (Grundy and Denke, 1990). CM size is also important because 
it is related to the ratio of surface phospholipid: to core TAG and thus determines the 
availability of postprandial phospholipid for transfer to HDL (Sakr et al, 1997).
In humans, as in the rat, the concentration and size of TAGRL has been shown to be 
infiueneed by the amount, type and quality of TAG absorbed and transported from the 
diet, with larger particles being secreted under conditions of increased TAG transport 
(Bennett and Norum, 1978; Hayashi et a l, 1990). TAGRL size are also dependent on 
the time course of ingestion, as reported by Sakr et al (1997) with larger CM being
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secreted in the early phase of digestion from a polyunsaturated fatty acid (PUFA)-rieh 
meal. In addition, hepatic uptake and the subsequent metabohsm of cholesterol from 
CMR is also influenced by the type of fat in the diet as well as the fatty acid 
composition of the particles themselves (Lambert et a l, 2000).
1.7.1 Type of fatty acid
1.7.1.1 Saturatedfatty acid (SFA)
It is well known that a high intake of SFA is linked to CHD. In the diet, SFA exist 
with various chain lengths, the most frequently occurring being stearic (18:0), 
palmitic (16:0), myristic (14:0) and laurie (12:0) acids. However, not all SFA are 
equally potent in raising plasma cholesterol. Myristic and palmitic acid are the most 
effective while stearic acid and fatty acids with 10 or less carbon atoms appear to 
have no cholesterol elevating effects. The link between high intakes of SFA and 
CHD may be through at least two separate mechanisms. First, SFA of 12-16-earbon 
chain lengths increase total LDL-eholesterol concentrations and secondly a high 
intake of SFA tends to encourage the liver to produce cholesterol and make the blood 
more prone to clot. It has also been suggested that their cholesterol raising properties 
result from saturation and suppression of the LDL receptor pathway.
CMR concentrations in serum are increased after SFA ingestion compared with 
PUFA ingestion (Demacker et a l, 1991) or by long-ehain SFA in the sn-2 position on 
the TAG structure (Redgrave et al, 1988). Apo B output is also higher in response to 
palmitic acid compared with linoleic acid (PUFA) (Renner et a l, 1986). In contrast, 
studies by Hayashi et al (1990) show that apo B synthesis appears to be essentially 
constant during fasting and active absorption. The size of CM particles rather the 
number is known to increase in response to the active absorption of lipid.
The increased concentration of CMR might be due to the delayed clearance of these 
particles from the circulation (Groot et al, 1988; Levy et al, 1991; Mortimer et a l,
1994). One possible cause for the delayed clearance of CMR is the smaller size of 
CMR produced from a high-SFA diet. This has been shown in experiments 
conducted with in vitro that Caco-2 cells exposed to the fatty acid 16:0 (palmitic
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acid). Some fatty acid was incorporated into phospholipid, and the particles secreted 
were smaller and displayed a density in the IDL-LDL range. But when the fatty acid 
was 18:2, TAG was secreted in the form of larger CM with little phospholipid being 
formed (Van Greevenbroek et a l, 1995). The smaller CMR produced from long- 
ehain SFA, especially with stearic acid in the sn-1 and sn-3 positions is associated 
with their poor absorption of long chain SFA compared to those with predominantly 
unsaturated fatty acid. Therefore they must traverse a longer length of the intestine 
before absorption and the resulting CM should be smaller (larger phospholipid/TAG 
ratio) (Ockner et al, 1972; Carey et a l, 1983; Bergstedt et a l, 1990).
Another explanation for the delayed clearance of smaller CM produced from saturated 
TAG is via LPL activity. As shown from the study by Murphy et al (1993) in Wistar 
Albino rats, the fatty acid composition in the diet could alter LPL gene expression 
through mechanisms which are still unclear.
1.7.1.2 Monounsaturatedfatty acid (MUFA)
Oleic acid found in olive and rapeseed oil is the most common MUFA in the diet. 
Recent studies have demonstrated that a high intake of MUFA produced beneficial 
effects by reducing the risk of CHD, particularly in NIDDM. Ohve oil, whieh is rich 
in oleie acid (55-83% of total fatty acid), had the greatest benefit in lowering CHD by 
18% compared to an average American diet (Kris-Etherton et a l, 1999).
Oleic acid is considered neutral with respect to plasma total cholesterol because it has 
an effect similar to that of carbohydrate in lowering cholesterol (Grundy and Denke, 
1990). Furthermore, a study by Thomsen et al (1999a) on persons at higher risk of 
developing NIDDM showed that a high-MUFA diet gave an effect similar to that of a 
high-earbohydrate diet in lowering LDL-eholesterol, TAG and apo B levels but 
produced sHghtly higher levels of HDL-eholesterol.
In contrast with PUFA, oleie acid lowers the plasma concentration of total and LDL- 
eholesterol without causing a decrease in the concentration of HDL-eholesterol 
(Grundy and Denke, 1990; Mensink and Katan, 1989). However, both diets showed 
similar effects on glucose and lipid level when NIDDM subject were given a diet rich
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in MUFA or PUFA when the content of total fat, cholesterol, SFA and fibre were the 
same, whereas the blood pressure was reduced only by MUFA (Thomsen et al,
1995).
No significant effect on fasting TAG levels in healthy subjects was shown after the 
intake of a diet enrich in ohve oil when compared with PUFA enrichment (Ginsberg 
et al, 1990) but there was a significant decrease when compared with a high SFA diet 
(Berry et a l, 1991). In addition, a MUFA enriched diet also showed no significant 
effects on glucose, insulin or fatty acid responses compared to SFA diet (Thomsen et 
al, 1999b).
According to De Bruin et al (1993), apo B-48 concentration were higher after a diet 
enriched in olive oil compared to soybean oil (PUFA). They suggested that this might 
be due to either olive-oil-CMR having a slower removal rate by HL than does 
soybean-CMR, or that olive oil increased the total number of CM produced. The high 
concentration of CMR will produce competition with HDL for HL, therefore 
preventing the postprandial decrease in HDL-eholesterol. They also indicated that the 
HDL conserving effect of olive oil may be related to the presence of higher numbers 
of olive-oil-CM, up to 4 hours postprandially, compared with the soybean diet. The 
prolonged circulation of CM after olive oil could have resulted in more CM-surfaee 
fragments being produced by LPL and these could have been used as constituents for 
new HDL particles (Kuusi et a l, 1989). The HDL-eonserving effect of MUFA 
feeding agrees with the HDL-eonserving effects observed for high-dose supplements 
of olive oil in long term dietary studies and in contrast, the HDL-eholesterol reducing 
effects of PUFA seen with soybean-oil diets (Grundy and Denke, 1990).
L 7.1.3 Polyunsaturated fatty acid (PUFA)
Several studies have compared the effect of PUFA as well as MUFA on CM and 
CMR metabolism (De Bruin et a l, 1993) and on CM size (Kalogeris and Story, 1992) 
in human subjects.
Diets rich in PUFA, both n-6 and n-3, reduce postprandial CM and CMR levels by 
more than 50% (Weintraub et al, 1988). Large CM are produced after ingestion of
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PUFA compared with VLDL-size particles secreted after ingestion of SFA. This may 
be explained by unsaturated fatty aeids, whieh have a lower melting point and a 
greater affinity for the fatty acid binding protein (Oekner and Manning, 1976), being 
transported more rapidly into enteroeytes and thus giving rise to larger CM than SFA. 
The larger sized PUFA-rich CM are more rapidly cleared fi*om serum compared with 
small and/or SFA-rieh CM (Weintraub et a l, 1988; Levy et a l, 1991) due to 
differences in susceptibility to lipolytic enzymes (Coiffier et a l, 1987; Weintraub et 
al, 1988). The higher susceptibility is due to the composition of CM and not 
specifically due to the acyl groups in TAG, because LPL has no substrate preference 
for PUFA in in vitro assay systems (Coiffer et a l, 1987).
The incorporation of PUFA into VLDL leads to the production of larger VLDL 
particles, as suggested by Shepherd and Packard (1987) which will be cleared rapidly 
fi-om the circulation without being converted into LDL. As shown in human studies, a 
marked reduction in LDL synthetic rate occurs when linoleic acid replaces SFA in the 
diet and there is a slight rise in the fi-aetional catabolic rate of LDL (Ilingworth et a l, 
1981; Cortese et al, 1983).
Supplementation of the human diet with PUFA also demonstrated enhanced clearance 
of CMR and lower concentrations of plasma VLDL as compared with a supplement 
of SFA (Demacker et al, 1991). However, high-dose dietary supplements of linoleic 
acid, the major PUFA of vegetable oils, such as soybean oil, induced a decrease in 
plasma total and LDL-eholesterol as well as an unfavourable lowering of HDL- 
eholesterol (Grundy and Denke, 1990; Eisenberg, 1984). The mechanism responsible 
for the lowering of LDL-eholesterol is thought to be through an increase in hepatic 
LDL-reeeptor activity (Spady and Dietschy, 1989) and not due to an increased 
number of receptors (Sorci-Thomas et a l, 1989). Peroxidation in LDL-unsaturated 
fatty acid is also reduced when compared to SFA and leads to increased hepatic LDL 
removal, causing LDL levels to fall (Parfitt et a l, 1994).
In addition to other effects on lipid metabolism, PUFA may also improve insulin 
resistance, since diet-induced alterations in membrane composition, achieved by 
alteration of PUFA/SFA diet, improved insulin-stimulated glucose transport, 
oxidation and lipogenesis in adipocytes from diabetic rats (Field et al, 1994).
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L 7.L4 n-3 PUFA (EPAH)HA)
The major n-3 PUF As in fish oil are eieosapentaenoie acid (EPA) and 
docosahexaenoic (DHA), very-long-ehain derivatives of alpha-linolenic acid. They 
show similar inhibitory effects to n-6 PUFA on lipogenic enzymes and VLDL 
production, but in contrast they markedly reduce postprandial (CM and CMR) and 
fasting (VLDL) TAG levels (Grundy and Denke, 1990) by up to 60% (Weintraub et 
fl/., 1988; Demacker et a l, 1991). A daily supplement of 2-5 g of EPA/DHA has been 
recommended since it results in a 20-40% reduction in fasting circulating TAG levels 
(Sanner, 2000). Furthermore a recent finding by Westphal et al (2000), demonstrated 
that treatment of hypertriaeylglyeerolaemic men with n-3 PUFA reduced the fasting 
VLDL-TAG concentration by 44% and postprandial CM and VLDL by 49-6% and 
36-4 %, respectively, whereas CMR were reduced only in the late postprandial phase.
The mechanism for the hypolipidaemic action of the n-3 fatty acids in fish oil is well 
documented. The synthesis of TAG and VLDL in the liver is greatly inhibited by n-3 
fatty acids, especially by their inhibition of diacylglycerol aeyl transferase (Rustan et 
a l, 1988), phosphatidate phosphohydrolase (Marsh et a l, 1987), malic enzyme and 
glueose-6-phosphate dehydrogenase (Jen et a l, 1989). This leads to a decreased flux 
of fatty acid into TAG and a concurrent increase in phospholipid synthesis and fatty 
acid oxidation (Rustan et a l, 1988). This inhibitory effect of n-3 has been confirmed 
in in vitro studies in humans and other species. At the same time that VLDL 
synthesis is inhibited the turnover of VLDL in the plasma is also shortened which 
could further decrease TAG levels. The reduction of endogenous TAGRL production 
has been shown in kinetic studies by Harris et al (1990) and could promote CM 
removal as both hpoproteins compete for LPL-mediated removal from the circulation. 
As demonstrated by Weintraub et al (1988), the presence of n-3 PUFAs in a meal 
also promotes the removal of TAGRL from the circulation and postheparin LPL 
acitivity (PHLA) is significantly greater after a n-3 PUFA meal compared with a 
SFA-rieh test meal (Zampelas et al, 1994). Rat studies have shown that fish-oil 
consumption leads to significantly higher expression of adipose tissue LPL messenger 
RNA (Murphy et a l, 1993), which suggests that n-3 PUFA supplementation increases 
LPL-mediated TAGRL clearance (Roche and Gibney, 2000).
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Another possible meehanism for the effect of fish oil consumption on postprandial 
lipaemia is through the chronic, but not acute ingestion of fish oil whieh might inhibit 
the synthesis or secretion of CM from the enteroeytes (Harris et ah, 1988) whieh also 
received support from the rat studies by Brown et al. (1997). The effect of (n-3) fatty 
acids on the suppression or synthesis of both hepatic and intestinal apo B secretion in 
humans has also received support from Tinker et al. (1999).
Studies by Sullivan et al. (1986) showed that a moderate intake of fish oil caused the 
production of smaller than normal VLDL particles. These smaller VLDL particles are 
more readily converted to LDL and they can also compete with LDL for uptake by the 
LDL-reeeptor, hence increasing the LDL plasma level (Sanders, 1990). However, 
according to Karakas et al. (1995), the increase in LDL-eholesterol did not appear to 
cause acceleration in in vivo catabolism of VLDL into LDL. They proposed that the 
increase in fasting LDL-eholesterol might be mediated by other mechanisms, such as 
a decrease in clearance of VLDL.
The combination of fish oil combined with a low cholesterol, low SFA diet has been 
shown to produce complementary effects. The total plasma cholesterol and LDL- 
eholesterol were lowered by the low cholesterol and low SFA diet, whereas plasma- 
TAG and VLDL were decreased by the fish oil. A Hfelong diet rich in fish may also 
be protective against atherosclerosis. As shown by Pakala et al. (1999), among the 
fatty aeids tested only DHA and EPA could block the mitogenie effect of serotonin on 
vascular SMC. This effect moreover, when coupled with other known anti­
thrombotic actions appears to have an important potential role in the control of CHD 
and other atherosclerotic disorders.
1.7.2 Carbohydrate
High carbohydrate diets have beneficial effects by lowering total cholesterol and 
LDL-eholesterol but increase TAG concentration and decrease HDL-eholesterol. The 
review by Kris-Etherton et al. (1999) stated that for every 1 mg/dl decrease in HDL- 
eholesterol, there is an increase of 2.3% of the risk of CHD. Therefore this diet could 
potentially adversely affect CHD risk.
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Chen et al (1993) and Jeppesen et al (1995) have shown that inereasing the 
earbohydrate content of mixed meals will stimulate the secretion of VLDL-TAG and 
enhance the magnitude of postprandial lipeamia. Furthermore, studies in patients 
with NIDDM who were given a low-fat, high carbohydrate diet were found to have 
increased PHLA, and an increased postprandial accumulation of TAGRL of intestinal 
origin. In addition they also have long tolerance of insulin and TAG concentration 
(Chen et a l, 1995), and can lower LDL levels by 10 % (Howard et a l, 1991). When 
compared to a high-fat diet, the apohpoprotein composition of fasting TAGRL and 
HDL for both diets was similar. The only difference was that a high-earbohydrate 
diet induced postprandial transfer of apo C-I from HDL to TAGRL (O’Brien et a l, 
1993).
An increase in the plasma TAG concentration in response to a low-fat, high- 
earbohydrate diet is at least partly due to an increase in the hepatic production rate of 
VLDL-TAG (Review by Grundy and Denke, 1990). Even though the activity of 
plasma postheparin LPL was increased by this diet, suggesting that plasma VLDL- 
TAG removal is also increased, the increase in activity is not sufficient to prevent an 
increase in the plasma VLDL-TAG concentration. These results indicate that the 
secretion rate of hepatic VLDL-TAG was greater than the increase in their removal 
rate from plasma (Chen et a l, 1995). This contrasts with the observation made by 
Campos et al (1995) who found that the low clearance rate of TAG produced by a 
high-earbohydrate diet might be due to low activity of LPL and HL.
An increase in the synthesis of VLDL-TAG not only increases TAGRL to be cleared 
by the TAG removal pathway, but will be accompanied by a decrease or retarded 
lipolysis of all TAGRL from plasma including CM and CMR (Chen et a l, 1995) via 
LPL (Blades and Garg, 1995). It is also believed that an increased intake of 
earbohydrate induces an adaptive suppression in the oxidation of NEFA in response to 
a lower fat intake. This leads to the increased re-ineorporation of NEFA into TAG in 
the liver, an increased synthesis of VLDL and further enhanced postprandial lipaemia.
However, Park et al (1999) proposed an alternative idea. They proposed that a high 
earbohydrate, low fat diet reduced VLDL-TAG clearance but that it does not increase 
VLDL-TAG secretion or de novo lipogenesis. CMR present in the fasting state may
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contribute to elevated TAG levels by competing ^vith VLDL-TAG for lipolysis and by 
providing a source of fatty acid for hepatic VLDL-TAG synthesis. Their explanation 
was supported by an earher study by Cazzolato et al. (1985) who showed that apo B- 
48 is always present in the fasting VLDL fraction of Italian normoHpidaemie subjects 
(a typical diet contains 55% of calories from earbohydrate). From this observation, 
Park et al. (1999) concluded that the assembly, production and clearance of elevated 
plasma VLDL-TAG in response to a low fat high earbohydrate diet are different when 
the elevated TAG is due to a higher-fat diet. The same diet fed to mildly 
hyperinsulinaemic subjects also delays both VLDL and CM clearance without 
affecting TAG production (review by Baum and Brown, 2000).
The type of earbohydrate given also influences the postprandial response. Diets rich 
in monosaccharides appear to raise TAG levels more than diets high in complex 
carbohydrate (Roche, 1999). Fructose, compared to sucrose, can stimulate 
lipogenesis and an increase in VLDL production (Park et ah, 1999). A high- 
carbohydrate/high-fibre diet does not increase plasma insulin and TAG 
concentrations. The ability of dietary fibre to retard food digestion and nutrient 
absorption might have an important influence on lipid and earbohydrate metabolism 
(Riccardi and Rivellese, 1991; Lairon, 1996).
Although carbohydrate could reduce the risk of CHD, as a reduction of 1% in total 
LDL-eholesterol results in approximately a 1.5% decrease in the incidence of CHD 
(Kris-Etherton et al, 1999), Sanders (1990) suggested that the lowering effect is no 
more effective than can be obtained with a modified fat diet. In additions, high 
earbohydrate diets have a number of disadvantages compared with modified fat diets. 
They are less palatable, they lower the concentration of HDL-eholesterol, are lower in 
natural antioxidants and may impair glyeaemie control in certain individuals.
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1.8 STUDIES OF POSTPRANDIAL LIPAEMIA
Measurement of plasma TAG has usually been limited to the fasting state, which only 
provides 68% accuracy, suggesting that posptrandial TAG levels measured for 6-8 
hours may be more accurate indicators of the presence of angiographically proven 
CHD (Patseh et a l, 1992). Since TAG metabolism is a highly dynamic process, a 
single TAG measurement does not reflect the changes of TAGRL in daily life, 
especially in Western societies where people often eat three times each day and are 
therefore in the postprandial state for most of the day (Zilversmit, 1979). A few 
methods have been used in order to investigate postprandial lipaemia.
1.8.1 Standardised oral fat loading test
A fasting blood sample (baseline value) is taken. Then the subjects are given a 
standardised meal. Further blood samples are collected over a particular period of 
time. Analysis of the postprandial response is dependent on the parameter of interest. 
The response is normally expressed as the incremental change in plasma 
concentration following the meal, that is the ‘area under the curve’ (AUC). In 
contrast to fasting TAG, postprandial lipaemia as determined by a standardised oral 
fat loading, test, is highly reproducible and depends mostly on the amount of fat 
ingested (Weintraub et a l, 1987; Brown et a l, 1992).
1.8.2 Intravenous fat tolerance tests following re-injection of labelled CM and 
radioactively labelled artificial TAGRL
Studies of CM metabolism have also been done using emulsion models of CM in rats 
by Redgrave and Maranhao (1985) and in patients with CHD (Maranhao et al, 1996). 
In this technique, a labelled TAG-rich emulsion was injected intravenously into 
subjects previously fed a fatty test meal. Plasma samples were then eoUeeted at pre- 
established intervals and the radioactivity in aliquots of plasma were measured in a 
scintillation counter. An emulsion labelled with ^H-triolein and ^"^C-eholesteryl 
oleate, to mimic the metabolic behaviour of CM, was injected intravenously in the 
patients (Vinagre et al, 2000; Santos et a l, 2000). All of these methods are 
sophisticated, need to be performed in metabolic ward units under strictly
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standardised conditions and require the presence of specialised personnel, and are 
therefore not widely used.
1.8.3 Diurnal capillary TAG profiles
In a preliminary report by Van Oostrom et al (1999), whieh was reviewed by 
Cabezas and Erkelens (2000), diurnal capillary TAG profiles were shown to correlate 
well with fasting TAG, body fat mass and insulin sensitivity. They also claimed that 
these profiles correlated with postprandial triacylglyceroleamia after one acute oral fat 
loading test and demonstrated significant gender differences, whieh is in agreement 
with data obtained by strictly standardised oral fat loading tests.
Recently, Smith and colleagues (1999) claimed that measurements of fasting apo B- 
48 were able to predict postprandial dyslipidaemia, whieh would eliminate the need 
for oral fat loading tests, whieh are time-consuming and expensive to perform.
1.9 ISOLATION AND DETECTION OF CM AND THEIR 
REMNANTS
In order to characterise the structure and function of CM and CMR in relation to their 
role in an ALP, it has become very important to develop methods for the separation of 
these lipoprotein particles fi-om human plasma. However, accurate measurement and 
characterisation of TAGRL are difficult for several reasons: 1) due to their rapid 
metabolism particularly of CM, 2) they exist in plasma at relatively low 
concentrations, 3) they are very heterogenous in size, density, lipid and apolipoprotein 
composition at different stages of catabolism. These qualities make it difficult to 
differentiate the remnants from their TAG-rieh precursors. Various methods have 
been used to isolate the classes of lipoproteins, which rely mainly upon physical 
differences in size, hydrated density and charge.
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1.9.1 Separation of TAGRL according to density
Being rich in lipid, lipoprotein particles are lighter than proteins. Their hydrated 
density varies according to the lipid/protein ratio in the molecule and is inversely 
related to their diameter. This characteristic permits their fractionation by 
ultracentrifiigation. Ultracentrifugation is a traditional technique and is the most 
widely used method for isolating CM and their remnants; analytical, sequential, or 
density gradient ultracentrifugation have all been used to isolate lipoproteins. In the 
fixed angle ultracentrifugal separation procedure, the object is to increase, in a step­
wise fashion, the solvent density of the plasma by progressive addition of an 
appropriate salt such as potassium bromide. This results in the separation of 
apparently discrete fractions of increasing density. For separation of lipoproteins by 
rate zonal ultracentrifugal separation, a salt gradient is established in the rotor prior to 
introduction of the plasma sample whose lipoproteins are then separated by flotation. 
The fractionation can be achieved either by attainment of equilibrium or on the basis 
of differential flotation. Although separation by ultracentrifugation provides a 
convenient and rapid analysis of the plasma lipoproteins, it does not separate 
CM/CMR and VLDL because of their overlapping flotation rate and because both 
have similar densities, less than 1.006 (Redgrave et ah, 1976). There is also evidence 
that the combination of high salt concentration and repeated high-speed 
ultracentrifugation causes modification in lipoprotein structure and a stripping of 
apolipoproteins (Fainaru et ah, 1977; Cheung and Wolf, 1988). In addition, a 
prolonged ultracentrifiigation time has been show to induce changes in the LDL 
particle composition and also to affect the LDL subclass pattern (Griffin et a l, 1994). 
Ultracentrifiigation also requires costly and specialised equipment that is not readily 
available in most clinical laboratories.
1.9.2 Separation of TAGRL according to their size
Separation of hpoproteins on the basis of molecular size can be achieved by gel 
chromatography. 2% agarose has been shown to be an effective quantitative method 
for resolution of lipoproteins with larger molecular size such as CM and VLDL, while 
4% and 6% agarose are more suitable for the separation of LDL from HDL (Sata et 
a l, 1970, 1972). However, this method is time consuming. Karakas et al (1994)
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used fast protein liquid chromatography (FPLC). This technique enables very small 
amounts of sample to be used for rapid separation, but protein mixtures from cell 
extracts still need some form of preliminary fractionation prior to study. Hidaka et al 
(1990) used high-performance liquid chromatography (HPLC), monitored at 280 nm, 
to quantitate apo B-48. They used a column packed with hydrophilic silica gel with a 
pore size of 300 Â. Apolipoprotein (5-10 pg) in 10 pi were eluted with 0.1% SDS, 
0.2 mol/1 NaCl, and 10 mmol/1 sodium phosphate buffer (pH 7.0) at a flow rate of 0.4 
ml/min. Apo B-48 and apo B-lOO were separated Avith retention times of 12.1 and 
16.9 min, respectively. Separation of apo B species by HPLC was also performed by 
Schwandt et al (1986) using gel-permeation chromatography. The separation and 
quantitative analysis of apolipoprotein variants has also been performed using 4% 
agarose column chromatography (Spark and Spark, 1996). Isolated lipoprotein or 
whole plasma/serum was applied to a column directly after dilution with sample 
buffer similar to SDS-PAGE and eluted with phosphate buffer (pH 7.4) containing 
1% SDS at a flow rate 5.3 ml/hour and apo B-lOO was eluted at volume 130 ml 
whereas apo B-48 at volume 150 ml.
More recently, Saviana et a l (2000), has purified apo B-48 from chylous ascites by a 
single step purification using the Bio-Rad Model 491 Prep Cell with a 5% 
polyacrylamide gel column which was eluted in 0.1% SDS containing Tris-glycine 
buffer.
Another possibility is to use chemical precipitation (Burstein et a l, 1970). Although 
this method is fast and economical, it is currently limited to the isolation of only 
certain lipoprotein fractions such as HDL or those that contain apo B.
1.9.3 Identification of TAGRL according to lipid composition
A number of laboratories utilise TAG alone as a marker for CM kinetics. However, 
TAG is primarily cleared as a consequence of lipolysis and it therefore provides little 
information with respect to the metabolism of the atherogenic remnant forms of 
postprandial lipoproteins. Nevertheless, plasma TAG measurement remains an 
important parameter that is readily performed.
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Inclusion of retinyl esters (RE) or vitamin A in the test meal provides a more specific 
method for measuring the intestinal contribution to human alimentary lipaemia than 
monitoring TAG alone. It is assumed that RE is not removed during particle lipolysis 
(Cohn 1994) and remains in the CMR core until uptake by the liver (Weintraub et a l, 
1987; Berr, 1992). It was thought that transfer of RE to other lipoprotein particles is 
minimal, particularly during the first 8 to 12 hours after a fat load (Wilson et a l, 
1983; Berr and Kern, 1984). However, the quantification of RE by HPLC is laborious 
and time consuming and furthermore, the assumption that RE are always associated 
with apo B-48-containing lipoprotein is not totally accurate (Karpe et a l, 1995). RE 
has been detected in apo B-100-containing TAGRL (Cohn et a l, 1993) and in LDL 
and HDL at later postprandial time points (Krasinski et a l, 1990). In addition, there 
are differences in the nature of RE as explained by Lovegrove et al (1999):
i) The type of RE used (oil, water miscible and tablet form) is important when 
RE is administered orally due to the variables of gastric metabolism and 
gastrointestinal absorption. For example, non-water miscible RP has been 
reported to give a significantly delayed response resulting fi-om delayed 
absorption.
ii) The type of fat incorporated into the test meal has also been reported to 
influence the degree of delay.
1.9.4 Separation and quantification of TAGRL according to apolipoprotein 
composition
Evidence from many studies has shown that molecules of apo B do not exchange 
between different lipoprotein particles, in contrast to other smaller plasma 
apolipoproteins and lipid, making them an ideal marker to distinguish the plasma 
lipoproteins of hepatic and intestinal origin (Simon et a l, 1987; Krasinski et a l, 
1990). However the concentration of the apo B-48-containing lipoproteins in plasma 
is very small (1-5 pg/ml) which is between 100-to 1000-fold lower than the 
concentration of apo B-lOO (Karpe and Hamsten, 1994). This has hindered the 
development of methods for the separation and quantification of apo B-containing 
particles on the basis of their apolipoprotein content.
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The most popular and simplest method to separate, quantify and analyse the apo B 
variants is by scanning of the stained protein bands after SDS-PAGE of intact 
lipoproteins or dehpidized and redissolved apoproteins. Different strengths of 
acrylamide have been used in SDS-PAGE, such as 3-10% (Kotite et ah, 1995), 4-7% 
(Campos et a l, 1996), 3-20% (Karpe et a l, 1996), and 5-20% (Isherwood, 1996). 
The proteins can be stained with Coomassie Brilliant Blue R-250 (Poapst et a l, 1987; 
Karpe et a l, 1996; Kotite et a l, 1995) or gamma counting of radio-iodinated 
lipoprotein can be used (Zilversmit and Shea, 1989). The methods used are normally 
based on ratios with respect to apo B-lOO (Simon et a l, 1987). However, on an equal 
mass basis, apo B-48 and apo B-lOO have different amino acids composition and 
these differences may affect the dye binding, chromogenicity and absorption at 280 
nm (Lee, 1996). The low concentration of apo B-48-containing lipoproteins in the 
plasma means that this method is usually working near the limit of its sensitivity. 
Western Blotting is another method, which is more sensitive and specific. After 
separation of the apolipoproteins by SDS-PAGE, the proteins are transferred and 
concentrated on the surface of a membrane. Apo B-48/apo B-lOO can then be 
detected by using a commercial polyclonal antibody against apo B that is widely 
available. This is followed by quantification using densitometric scanning.
Immunochemical separation using antibodies to various apolipoproteins on the 
lipoprotein surface has gained attention recently from many clinical investigations. 
Each lipoprotein class can be separated fi-om the others by an appropriate antibody or 
combination of antibodies. This technique has been used to isolate apo B-48 fi-om 
apo B-IOO-TAGRL in order to determine their respective lipid and apolipoprotein 
compositions, abilities to bind to cell surface receptors, and contributions to 
postprandial lipidaemia. Separation by an immunochemical method offers several 
advantages; it provides the highest specificity for separation and isolation of 
lipoprotein on the basis of their apolipoprotein content. On the other hand, the use of 
immunochemical techniques for determining the two apo B species may be restricted 
by several circumstances; the amino acid sequence of apo B-48 is identical to the N- 
terminal 48% of apo B-100. This prevented antibodies from being raised specifically 
to apo B-48.
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Several researchers have used an antibody raised against apo B-100 as a ligand for 
immunoaffmity chromatography in order to separate apo B-100-containing 
lipoprotein particles from those containing-apo B-48. For instance, Kotite et al
(1995) used immunoaffmity with two monoclonal antibodies to apo B-100 (JIH and 
4G3), Bjorkegren et a l (1998) employed monoclonal 4G3 and 5E11 against the C- 
terminal end of apo B-100, and monoclonal 2G8 by Mekki et al (1999). 
Apolipoprotein B-48 can be recovered in the non-retained fraction, and the apo B-100 
lipoproteins can be released from the immunoaffinity matrix under conditions that 
disrupt the antibody-antigen interaction.
Some antisera have been produced against synthetic peptides representing the 
carboxyl terminus of apo B-48 and shown to be apo B-48 specific (Yao et al, 1992) 
and also from our laboratory (Peel et a l, 1993). Furthermore, quite recently, Uchida 
and colleagues (1998) established a monoclonal antibody against human apo B-48 (B- 
48-151). The successful production of antisera against apo B-48 allows quantitation 
of apo B-48-containing lipoprotein particles in serum using sensitive and rapid assays 
such as competitive enzyme-linked immunosorbent assay (ELISA) (Lovegrove et a l,
1996) and sandwich ELISA (Uchida et a l, 1998). However, so far, there is no report 
of using these antibodies to separate the CM/CMR from VLDL/IDL.
Heparin-Sepharose chromatography is another method that has been used to separate 
apo B-48-containing lipoproteins (Hashimoto et a l, 1997), and subfractionation of 
VLDL based on its apo E content (Gomez-Coronado et a l, 1993; Yang et a l, 1993). 
Heparin interacts specifically with apo B and apo E in the lipoprotein and it has been 
suggested that the interaction could be between positively charged groups on the 
apolipoprotein and anionic groups on heparin (Tadey and Purdy, 1995).
1.9.5 Remnant-like lipoprotein particle (RLP) separation
Takeichi et al (1999) suggested that the RLP-cholesterol level was more strongly 
correlated with the severity score of CHD than LDL-cholesterol. These particles have 
been shown to be elevated in CHD and diabetic patients (Nakajima et a l, 1993; 
Tanaka et a l, 1995; McNamara et a l, 1996) and are also rapidly taken-up by 
macrophages (Tomono et al, 1994). The technique to separate RLP particles has
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been developed by Nakajima et al (1993). It is based on the immunochemical 
separation of RLP using a monoclonal antibody Avith unique epitopes to apo B-100 
(JI-H) to remove LDL and most VLDL particles together with a monoclonal anti apo 
A-I to separate HDL and CM from the whole blood serum. The supernatant contains 
CMR and VLDL remnants, both of which are enriched in apo E. Cholesterol in the 
unbound fraction is measured with a sensitive enzymatic assay and has been shoAvn to 
compare favourably to ultracentrifiigation and electrophoretic techniques, and 
provides a convenient and economical approach to measuring TAGRL remnant in 
routine clinical laboratories.
1.10 AIMS
The initial phase of the project focused upon the development of a reliable method for 
the rapid isolation of CM/CMR from TAGRL by immunoaffinity chromatography 
which was based on using a novel anti-apo B-48, which recognises the C-terminal end 
of apo B-48 (Peel et al., 1993). In order to determine the integrity of the particles 
after purification, the particles were to be characterised in terms of their physical, 
chemical and functional properties. The second aim of this project was to investigate 
the use of an existing ELISA for the measurement of apo B-48 in the plasma and 
infranatant and to further optimise immuno-detection and the semi-quantitation of apo 
B-48 and apo B-100-containing lipoproteins. These methods were then to be applied 
to the investigation of the concentration and distribution of TAGRL in postprandial 
plasma, and to fiirther characterise dietary-induced changes in plasma-TAG in 
relation to CHD. In addition the direct role of TAGRL in CHD was to be investigated 
in tissue slices using immunocytochemistry methods.
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CHAPTER TWO 
MATERIALS AND METHODS
2.1 GENERAL MATERIALS
2.1.1 Reagents
Aprotinin (kallikrein inactivator), benzamidine, gentamicin sulphate, chloramphenicol, 
Folin Ciocalteu phenol reagent, human serum albumin (Fraction V) (HSA), bovine 
serum albumin (Fraction V) (BSA), sodium potassium (NaK) tartrate, sodium 
carbonate (NaCOg), sodium azide (NaNs), sodium hydroxide (NaOH), and sodium 
dodecyl (Lauryl) sulphate (SDS) were obtained from Sigma Chemical Company Ltd., 
(Poole, UK).
Diaminoethanetetra-acetic acid disodium sait (EDTA), disodium carbonate (NaiCOg), 
sodium chloride (NaCl), disodium hydrogen phosphate (Na2HP04), potassium chloride 
(KCl), potassium dihydrogen phosphate (KH2PO4), citric acid, hydrochloric acid 
(HCl), methanol and butan-l-ol were purchased from Fisher Scientific International 
Company, (Loughborough, UK).
Sodium bromide (NaBr), potassium bromide (KBr), sodium hydrogen carbonate 
(NaHCOs), sodium dihydrogen orthophosphate (anhydrous) (NaH2P04), hydrogen 
peroxide (H2O2), and trichloroacetic acid were manufactured from Fisons Scientific 
Equipment, (Loughborough, UK).
Cupric sulphate (CUSO4) was purchased from BDH Chemical Ltd., (Poole, England). 
Absolute alcohol was from Hayman Ltd., Eastways Park, Witham, Essex, England. 
All water was a reverse osmosis (R.O.) purified grade.
2.1.2 Antisera
Polyclonal rabbit anti-apo B-48 antiserum was produced by Nutritional Metabolism 
Research Group, School of Biological Sciences, University of Surrey, Guildford, 
Surrey. The production of this antibody was achieved by immunizing New Zealand 
white rabbits with a synthetic heptapeptide consisting of an N-terminal cysteine residue 
attached to the C-terminal hexapeptide equivalent to residues 2147-2152 of apo B-48. 
The heptapeptide was conjugated to HsN^-Cys-Leu-Gln-Thr-Tyr-Met-Ile-COO". The
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blood was collected after boosting the animal with the same peptide and thereafter 
antiserum was isolated. This antiserum was used for detection of apo B-48 in all 
related experiment.
2.2 METHODS
2.2.1 Blood collection
Blood was drawn by venous puncture into sterile plastic tube contaming anticoagulant 
0.15% (w/v) EDTA and immediately cooled in ice. Plasma was separated fi'om red 
blood cells by a low-speed centrifugation at 3,000 rpm for 10 min (1700 gmax-min) and 
aliquotted into separate tubes for different analysis. For analysis of apo B-48, 
preservative (Appendix I) was added to the sample to give a final concentration of 5% 
(v/v). All samples were stored at -80°C until further analysis.
2.2.2 TAGRL and TAGPL separation
TAGRL and TAGPL separation was performed as described by Grundy and Mok 
(1976). Plasma (3.5 ml) was over layered with 3.5 ml of buffered saline (d=1.006 g/ml 
NaCl) solution. The saline was prepared by dissolving 10.49 g of sodium chloride 
(NaCl) in one litre of R.O. water and the density was adjusted by hydrometer. Samples 
were then centrifuged at 4.83 x 10  ^gmax.min (45,000 rpm) for 30 minutes at 24°C in a 
Beckman 50.2 Ti rotor. This preparation allowed the flotation of larger TAGRL of 
density less than 1.006 g/ml. Following ultracentrifiigation, the TAGRL fraction was 
recovered by careful aspiration of the top 1.2 ml by glass Pasteur pipette from each 
tube. Occasionally, more than 1.2 ml of TAGRL was aspirated from the tubes and the 
volume removed was noted and the infranatant made up to 5.8 ml with NaCl solution. 
The afiquots for apo B-48 and RE analysis were treated as above. All the samples 
were kept frozen at -20°C until the assay.
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2.2.3 Protein determination
The protein content of the lipoproteins was quantified by a modified Lowry et al 
(1951) procedure, following clearing of turbidity due to lipids with SDS and using 
crystallise HSA as a standard.
2.2.3,1 Reagents
Stock Reagents
Solution A 
Solution B 
Solution C 
Solution D
2% (w/v) NaiCOg in 0.1 mol/1 NaOH 
2% (w/v) NaK Tartrate 
1% (w/v) CUSO4 
Folin Ciocalteu phenol reagent
Working Reagent
Biuret reagent:
Folin Ciocalteu 
reagent:
100 ml solution A, 1 ml solution B and 1 ml solution C 
were mixed together. 1 mg/ml of SDS was added to the 
sample if the sample to be analysed was turbid.
It was diluted with an equal volume of R.O. water.
2.2.S.2 Standard and quality control (QC)
Stock solution of HSA (1.0 mg/ml) was diluted with R.O. water to produce a standard 
curve ranging from 0-50 pg of HSA in a final volume of 400 pi. The BSA with two 
concentrations (0.15 mg/ml and 0.30 mg/ml) were used as QCs.
39
2 .2 33  Procedure
The samples were diluted with R.O. water, until they fell within the range of the 
standard curve. Biuret reagent (2 ml) was added to 400 pi of standard, QCs and 
samples. Then all tubes were vortexed and left for 10 minutes at room temperature. 
Then 200 pi of working Folin Ciocalteu was added, vortexed immediately and left for 
a ftirther 30 minutes at room temperature. After 30 minutes the absorbance was read 
with spectrophotometer at 750 nm within 2 hours.
2.2.4 Isolation of CM/CMR by column chromatography
2.2.4.1 Introduction
Several chromatography methods have been used to separate different types of 
lipoprotein. Gel permeation and affinity chromatography have been used for 
preparative purposes and to separate lipoprotein according to size and apolipoprotein 
content, respectively.
Gel permeation chromatography of plasma lipoproteins was initially performed on 
cross-linked dextran supports (Franzini, 1966) but the relatively small pore size of this 
gel yielded poor separations. Agarose gels, which have a larger pore size produced 
better lipoprotein separations (Sata et ah, 1970). The three major lipoprotein families 
VLDL, LDL, and HDL can be separated from whole plasma on 4% or 6% agarose gel 
using 0.9% NaCl containing 0.01% EDTA, pH 7.4 as the eluent (Rudel et al, 1986). 
An advantage of using gel permeation compared to ultracentrifiigation is that it is 
relatively gentle and non-destructive to lipoprotein particles. It can also be performed 
in most labs, because it does not require the purchase of expensive ultracentrifiigation 
equipment.
The ability of heparin-Sepharose gels to selectively bind apo B was demonstrated in 
1972 by Iverius. However the exact mechanisms of interaction between heparin and 
lipoproteins is not completely understand. It has been suggested that the interaction 
was between the positive groups of apolipoprotein and anionic groups of heparin
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(Tadey and Purdy, 1995). The lipoprotein binding capacity of heparin-Sepharose gels 
is generally increased by the presence of divalent anions, such as Mn^\ The 
lipoproteins that do not contain apo B or apo E do not bind to the column, whereas apo 
B and apo E-containmg lipoproteins are retained and can be eluted at high salt 
concentrations. Shelburne and Quarfordt (1977) separated VLDL into 2 fractions, one 
apo E-poor and the other apo E-rich. This method was also used by Huff and Telford 
(1984). They subfractionated VLDL into two distinct subfractions. The other 
researchers using heparin-Sepharose were Gomez-coronado et al. (1993) and Evan et 
al. (1989). The retained fraction has a higher TAG content, protein content, apo E/apo 
C ratio and smaller diameter. Heparin affinity chromatography has been used to sub- 
fractionate HDL particles according to apo E content (O’Brien et ah, 1993).
Affinity chromatography employs the specificity and avidity of the interaction between 
an antigen and its antibody to purify the antigen. The technique may employ either 
polyclonal or monoclonal antibodies. It provides the highest specificity for separations 
and isolation of lipoproteins on the basis of their apolipoprotein content. Among the 
advantages of immunoaffinity chromatography is its ability to produce virtually pure 
protein in a single step. Because of the high specificity and avidity of the adsorption 
stage, very dilute antigen solutions in the presence of large amount of extraneous 
protein may he processed successfully, since the sorbent will only bind the antigen of 
the immobilised antibodies.
2.2.4.2 Materials
Sodium thiocyanate (NaSCN) was obtained from SIGMA, Chemical Company, St 
Louis, USA. Hi-Trap heparin column and CNBr-activated Sepharose-4B (dried) were 
obtained from Pharmacia Biotech. The disposable columns with diameter 8 mm were 
purchased from Evergreen Scientific, Los Angeles, California. Protein A, activated 
solid glass matrix was obtained from Bioprocessing, No. 1 Industrial Est., (Consett, 
Durham, UK).
41
2.2,43 Procedures
(a) Hi-Trap Heparin Sepharose-4B chromatography
Sample was dialysed at 4°C in starting buffer (50 mmol/1 NaCl, 3 mmol/1 EDTA, pH
7.4) overnight. A pre-packed 5 ml column of Hi-Trap Heparin was equilibrated 
against the same buffer. The desalted lipoprotein from a PD-10 column was loaded 
onto the column and run at a flow rate of 0.1 ml/min at 4°C. The unbound proteins 
were washed out with 50 mmol/1 NaCl, 30 mol/1 EDTA, pH 7.4. The retained fractions 
were eluted in a stepwise manner with the same basic buffer containing 150, 200, 250 
and 300-700 mmol/1 NaCl. The fractions were collected (1 ml/tube) and elution 
profiles were obtained by monitored at a wavelength 280 nm. Aliquots were taken 
from the most concentrated fractions of each subfraction for analysis by SDS-PAGE. 
All the fractions were pooled for hpid and protein analysis.
(b) Immuno affinity column chromatography (lAC)
Step 1: Purification of an anti-apo B-48 on immobilised Prosep A adsorbents.
Principle
The use of Ig fraction rather than whole serum can avoid competitive binding and 
interference by the many other proteins present in serum and should give a more 
reproducible result. In this project, anti-apo B-48 was purified by Prosep A following 
the method of Godfrey et al. (1993). Prosep A is protein A immobilised onto silica 
gel. Protein A is a cell wall component of Staphylococcus aureus with size 4200 
Dalton of polypeptide. Protein A exhibits a strong affinity for the Fc domains of 
antibodies and has become a ligand of choice for the affinity purification of 
monoclonal antibodies.
Method
Prosep A and the citric/phosphate buffers were stabilized at room temperature. These 
buffers were filtered and degassed prior to use. The column with bottom outlet closed 
was clamped in a vertical position, and the 1 ml level at the column was marked. A 2
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ml slurry of suspended immunosorbent beads in their preserving buffer or in three 
volumes of PBS/NaNa Avas added to the column. The bottom cap was removed and the 
beads were allowed to pack by gravity. Further bead suspension was added drop wise 
to produced a settled bed volume of 1 ml. 5 ml of 0.1 mo FI citric acid, were applied 
slowly to the side of the lAC column to prevent disturbing the surface of 
immunosorbent.
The column was re-equilibrated by adding 5 ml of PBS, which was allowed to run 
through under gravity. 1 ml of anti-apo B-48, Avith a concentration 300 pg/ml, was 
loaded allowed to percolate through the column under gravity. 5 ml of washing buffer 
was then applied to the column and the eluate was collected to check the binding 
capacity of the lAC. The bound antibody was eluted by adding stepwise eluting buffer 
with different pH values, ranging from alkaline to more acidic; Na2HP04 (pH 8.88), 
citric/phosphate at 1:3 (pH 6.72), 1:1 (pH 4.91), 3:1 (pH 3.2) and citric acid solution 
(pH 2.06).
All the eluted fractions were collected into LP3 tubes (1 mFtube) which contained 10- 
fold concentrated PBS (pH 7.2). This step was to neutralise the acidic fractions that 
might contain the antibody of interest. The fractions were monitored 280 nm and then 
dialysed for 16 hour (overnight) at 4°C against PBS/NaNs with a change of buffer after 
4 hour. For short-term storage (not more than a year), the 0.01% (v/w) of sodium azide 
was added to the purified antibodies and stored at 4°C. For long term storage, 
antibodies are best aliquoted into small batches to prevent repeated freeze-thawing 
damage and stored frozen at below -20°C.
After purified the antibody, 5 ml of PBS/NaNs buffer were added to the column and 
the breakthrough was discarded. This column can be stores by adding 5 ml of 
PBS/NaNs containing methanol (5% v/v) replace the caps on the column and then 
stored at 4°C. Prior to a fiirther purification cycle, the column was washed by adding 5 
ml of citric acid, phosphate/methanol and PBS buffer.
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As the figure 2.1 shows, the bound anti-apo B-48 was eluted from the Prosep A 
column in fractions 22 and 23. These fractions were retained.
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Figure 2.1 The elution of anti-apo B-48 from the Prosep A column.
Step 2: ELISA screening assay
The well of a flat-bottomed flexible PVC microtitre plates were coated with 200 pi of 
a 1:1600 dilution of BSA-peptide conjugate in sodium carbonate/sodium bicarbonate 
buffer, pH 9.6 and incubated at 4°C overnight. The plate was washed three times with 
PBS, pH 7.4 containing 0.05% (v/v) Tween "^^  20 (PBST). 100 pi of rabbit serum 
serially diluted from 1:1000, 1:10000 and 1:100000 were added to a series of wells. 
The microtitre plate was then incubated at 37°C for 2 hours. Following further 
washing, 100 pi of HRP-labelled anti-rabbit IgG was added to the wells and incubated 
at 37°C for a further 2 hours. After washing, 100 pi of TMB (1 mg/ml) in DMSO was 
added to the wells, and incubated at 37°C until the absorbance was greater than 1.0, or 
after 2 hours, depending on which occurred first. The plates were read at 450nm with 
a Dynatech MR 600 plate reader.
Controls containing no coating conjugate, no rabbit anti-peptide antiserum, no enzyme 
label or no substrate were included on each plate. The plate was repeated if any of the 
control values were greater than 0.1 absorbance units since this would have indicated 
non-specific binding and produced artificially high values.
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Step 3: Assessment o f purified antisera
Principle
After being purified by Prosep A, the antisera was assessed. The assessment can be 
made in terms of their titre, avidity and specificity. An indirect assessment of avidity 
of an antiserum is provided from an antiserum displacement curve. This curve is 
obtained by incubating a set of tubes whose composition is identical to those used to 
derive the antiserum dilution curve except that an aliquot of the unlabelled antigen is 
added to each one. The second set of tubes will allow a similar sigmoid curve to be 
constructed whose linear portion is parallel to that of the antiserum dilution curve but 
displaced to the left of it. The degree of displacement horizontally is an indirect 
measure of the avidity of the antiserum: the greater the displacement the greater the 
avidity.
Method
The ELISA microtitre plate was coated with coating Ile-peptide-conjugate at 1:1600 
dilution. Bound antibody was detected with increasing dilution (1:25 to 1:128000 of 
rabbit anti-Ile antibody from rabbit 2005 (dated 22/3/93). This was co-incubated with 
either zero, 1 pg/ml, 50 pg/ml or 500 pg/ml of competing Ile-peptide. The Ile-peptide 
conjugate bound anti-Ile antibody was visualised with HRP-anti-rabbit IgG and TMB 
substrate as described as above.
The peptide used for displacement was solubilised in 5% (v/v) DMF before PBST 
diluent was added. The effect of DMF on the antiserum dilution curve was tested in a 
separate experiment. The ELISA format was identical to that just described above, 
except that a parallel set of wells were set up with the anti-Ile antiserum diluted in 5% 
DMF/95 % PBST. No effect of DMF was found.
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Figure 2.2 shows the results obtained. The purified antibody showed displacement in 
the presence of competing Ile-peptide, indicating that specificity and avidity had been 
retained during the purification process.
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Figure 2.2. Indirect assessment of purified anti-apo B-48 using displacement with 
a competing peptide
Step 4: Separation of lipoprotein by CNBr-activated Sepharose 4B chromatography 
and solid glass
a) CNBr-activated Sepharose-4B-anti apoB-48
Cynogen bromide (CNBr) is one of reagents most commonly used for coupling 
antibodies to matrices. It react with diol groups to form a stable imido carbonate group 
which will react with primary amine groups on antibodies to form iso-urea bonds.
Activated Sepharose-4B was prepared and coupled with purified antiserum following 
the method of the manufacturer. After coupling with purified anti-apo B-48, all 
materials were equilibrated to the temperature at which the chromatography was to be 
performed. A 1-ml lAC column was used and the column was washed extensively 
with 150 mmoFl NaCl containing 10 mmol/1 EDTA, pH 7.4 and (0.01% w/v) sodium 
azide. Samples were applied to the column and the unbound fraction was eluted with 
the same buffer. Bound fractions were then eluted (gravity flow) with 3 mol/1 NaSCN 
containing 3 mmol/1 EDTA, pH 7.4. Lipoproteins in the bound fraction were 
immediately dialyzed against PBS buffer containing 3 mmol/1 EDTA, 0.01% (w/v) 
sodium azide, pH 7.4 and the column was washed thoroughly with starting buffer.
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b) Solid Glass
The coupling of purified anti-apo B-48 with solid glass was slightly different from that 
to CNBr-Sepharose-4B due to their narrower pH stability range, which is around 5-8. 
The fine activated solid glass particles, were removed by decanting the supernatant. 8 
ml of solid glass was washed several times in 0.1 mol/1 glycine in PBS buffer, pH 7.4. 
Before the coupling process, the column was equilibrated with PBS buffer. Affinity- 
purified antibodies were dialysed prior to being added to the column, which was then 
roller-mixed at 4°C for overnight. After allowing the solid glass particles to settle, 2 
ml of antibodies solution buffers was added and collected. Unbound and loosely 
bound antibodies were washed from the column with five column volume of 0.1 mol/1 
glycine in PBS buffer, pH 7.4. Any remaining active groups on the glass were blocked 
by adding 0.1 mol/1 Tris-Cl, 0.5 mol/1 NaCl, pH 8.0 buffer, and was rotated for two 
hours at room temperature. Then the column was washed with three times 5 volumes 
of each of the following buffers; i) 0.1 mol/1 sodium acetate, 0.5 mol/1 NaCl, pH 5.0, ii) 
0.1 mol/1 Tris-Cl, 0.5 moPl NaCl, pH 8.0. Thereafter, the column was washed with 0.1 
mol/1 glycine, PBS buffer.
Column was equilibrated with column buffer (5 mmol/1 Na2HP04, 0.15 mol/1 NaCl, pH
7.4) before use. 200 pi of lymph was dialysed in the column buffer overnight at 4°C 
and was made up to 1.5 ml with the same buffer. Then it was applied to the column by 
gravity and was allowed to stand in the column for two hours at room temperature. 
Non-specifically bound proteins were removed with 25 mmol/1 Na2HP04, 0.5 mol/1 
NaCl, pH 7.4 until the absorbance at 280 nm returned to that of the column buffer. 
The bound lipoproteins were eluted with 3 mol/1 NaSCN, 3 mmol/1 EDTA, pH 7.4. 
Non-bound and bound lipoproteins were dialysed in PBS buffer. The column was 
thoroughly washed with column buffer, capped off and stored at 4°C in column buffer 
containing 0.01% (v/v) thimerosal.
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Step 5: Concentration o f samples
Samples were concentrated by using hydrogroscopic material, i.e. sucrose was placed 
outside a dialysis tubing membrane at 4°C. As reported by McConathy et a/. (1985), 
sucrose and polyethylene glycol (molecular weight 18,500) gave similar recoveries. 
Furthermore, when a large number of samples are to be concentrated, the use of 
dialysis tubing combined with sucrose is equally satisfactory. Sucrose also appears to 
have a better stabilizing effect on the structural integrity of lipoproteins than 
polyethylene glycol.
2,2.4.4 Discussion
The result showed that most of lipoprotein particles loaded on the column did not bind 
to the Hi-trap column. There is the possibility that this might be because of the size of 
particles loaded being too large to enter the pores of 6% cross-linked agarose. 
According to Sata et al. (1973), 6% agarose is more suitable for HDL whereas for 
TAGRL containing VLDL or CM needed 2% agarose.
Neither anti-apo B-48-solid glass or anti-apo B-48-Sepharose-4B activated columns 
retained CM. One possible reason for this is that lymph was used as a sample for these 
columns. Anti-apo B-48-solid glass column contains no pores at all and the anti-apo 
B-48-Sepharose-4B is composed of 4% agarose. So, the pores on the anti-apo B-48- 
Sepharose-4B column may not big enough for the CM to enter them and thus to be 
retained on the column. As far as the anti-apo B-48-solid glass column is concerned, 
eight times the volume of the matrix was used in order to increase the surface area for 
coupling of the anti-apo B-48 but still CM did not bind to the column.
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2.2.5 SDS-polyaciylamide gel electrophoresis (SDS-PAGE) and immunoblotting
2,2.5.1 Principle
Proteins carry a net charge at any pH other than their isoelectric point and therefore 
migrate when placed in an electric field. The migration of a charged particle under the 
influence of an electric field is described as electrophoresis. The rate of migration is 
dependent upon the charge density of the protein that is the ratio of overall charge to 
mass. The higher the ratio, the faster the protein will migrate. There are many choices 
of support media and polyacrylamide gel is one that has been widely used and 
frequently referred to as PAGE. It has a molecular sieving effect since the pore size is 
similar to the size of protein molecules.
In electrophoresis, protein samples are firstly denatured in sample buffer containing p- 
mercaptoethanol and an anionic detergent SDS. The mercaptoethanol reduces 
disulphide bridges in the proteins tertiary structure, and the SDS binds strongly to, and 
denatures, the protein. On average one SDS binds to every two amino acids residues. 
This high level of binding at a constant binding ratio overwhelms the native charge of 
the protein and produces a constant negative net charge per unit mass, causing all 
protein-SDS complexes to move towards the anode such that different sized proteins 
show different mobilities due to the sieving effect of the gel. The smaller the protein, 
the more easily it can pass through the pores of the gel whereas large proteins are 
successively retarded by fractional resistance due to the sieving effect of the gels. The 
molecular weight of a protein under investigation can be determined by comparing its 
mobility with those of a number of standard proteins of known molecular weight that 
are run on the same gel.
After electrophoresis, proteins separated on the polyacrylamide gel can either be 
visualised directly by staining with Coomassie Blue, or they can be transferred by 
electroblotting to a support matrix such as nitrocellulose membrane. Following 
electrotransfer, the protein of interest can be detected by incubation with specific 
antibody and then visualised by enhanced chemiluminescence (ECL) Western blotting. 
ECL Western blotting is a light emitting non-radioactive method, which can detect
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immobilised specific antigens, conjugated directly or indirectly with horseradish 
peroxidase (HRP)-labelled antibodies. It is achieved by performing the oxidation of 
luminol by HRP in the presence of chemical enhancers such as phenols. This has the 
effect of increasing the light output approximately 1000-fold and extending the time of 
light emission.
2,2.5.2 Materials
Ponceau Red S solution. Tween™ 20, ammonium persulphate (APS), Trizma-base (pH 
7-9), DL-dithiothreitol (DTT), 2-mercaptoethanol, N,N,N’,N’-tetramethyl 
ethylethylenediamine (TEMED), thiodiglycol. Brilliant Blue R concentrate were 
obtained from Sigma Chemical Company Ltd., (Poole, UK). Bromophenol blue was 
purchased from BDH Chemical Ltd., (Poole, England). Glycerol was from Fisher 
Scientific International Company, (Loughborough, England). Glycine was obtained 
from Fisons Scientific Equipment, (Loughborough, UK). Urea was from Lancaster 
Synthesis, (Eastgate, England). Sucrose was purchased from Rose Chemical Ltd., 
(UK). Protogel was supplied by National Diagnostics, (Aylesbury, Bucks, England). 
Marvel milk powder was from Tesco Stores Ltd., (Ware, Herts, England). The 
Saranwrap was manufactured by the Dow Chemical Company and supplied by gene 
Research Instrumentation Ltd., (Dunmow, Essex, England). ECL reagents, Hybond™ 
ECL™ nitrocellulose membrane, and ECL film were supplied by Amersham 
International Pic., (Little Chalfont, Bucks, England). The Rainbow coloured protein 
molecular weight markers which contains seven proteins, myosin (220 kDa), 
phosphorylase b (97.4 kDa), bovine serum albumin (66 kDa), ovalbumin (46 kDa), 
carbonic anhydrase (30 kDa), trypsin inhibitor (21.5 kDa) and lysozyme (14.3 kDa) 
was also purchased from the same company. X Ray developer (CD 18) and fixer (CF 
40) were supplied by Photosol Ltd., (Basildon, Essex, England).
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Stock solutions
Stock solutions were;
- 3 mol/1 Tris-buffer, pH 8.8, kept at 4°C,
- 0.5 mol/1 Tris-buffer, pH 6.8, kept at 4°C,
- urea/SDS/DTT solution [48% (w/v) urea,, 0.2% (w/v) SDS, 0.031% (w/v) DTT], 
prepared fresh,
-1.5% (w/v) APS, prepared fresh,
- electrode buffer [189 mmol/1 glycine, 25 mmol/1 Tris, 0.1% (w/v) SDS], 
prepared fresh,
- transfer buffer [192 mmol/1 glycine, 25 mmol/1 Tris], prepared fresh,
-10% (w/v) SDS, kept at room temperature,
- PBS [10-fold concentrated phosphate saline buffer (1.37 mol/1 NaCl, 81 mmol/1 
Na2HP04, 27 mmol/1 KCl, 14.7 mmol/1 KH2PO4, pH 7.4)], kept at
room temperature,
- PBS-MT [PBS-Marvel-Tween™ 20-buffer, (5% (w/v) Marvel milk powder,
0.1% (v/v) Tween™20, pH 7.4)], prepared fresh.
Antisera
HRP-labelled donkey anti-rabbit IgG was supplied from Guildhay Ltd., (Guildford, 
Surrey, England). Both polyclonal rabbit anti-apo B-48 antiserum and HRP-donkey 
anti-rabbit IgG were diluted in 1-fold PBS solution.
2.2.5.3 Procedure
Analytical gels (14 cm x 16 cm) consisted a 5-22% (w/v) linear gradient resolving gel 
coupled with a 3.8% (w/v) stacking gel, prepared as described by Isherwood (1996) 
originally by Laemmli (1970).
The mixtures of the gels were prepared as displayed in Table 2.1. Resolving portion of 
these gradient gels consisted of 10% (w/v) protogel, 370 mmol/1 Tris-HCl (pH 8.8), 
4.8% (w/v) urea, 0.0031% (w/v) DTT, 0.02% (w/v) SDS, 0.0035% (w/v) APS, 0.077%
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(v/v) TEMED as the upper gradient mixture and 53,3% (w/v) protogel, 370 mmol/1 
Tris-Cl (pH 8.8), 0.48% (w/v) urea, 0.00031% (w/v) DTT, 0.002% (w/v) SDS, 
0.0035% (w/v) APS, 0.077% (v/v) TEMED, as the lower gradient mixture. These gels 
were cast using a two-chamber gradient maker connected to a gel-casting cassette 
(Hoefer Scientific Instrument, San Francisco, CA) and then over layered with water 
saturated butan-l-ol or R.O. water to remove all air bubbles that might trapped in the 
gels mixture. After approximately 2 hours, water phase on the gel was removed and 
then the stacking gel which composed of 9.28% (w/v) protogel, 130 mmol/1 Tris-Cl 
(pH 6.8), 0.0041% (w/v) SDS, 0.012% (w/v) APS, 0.36% (v/v) TEMED was poured. 
Gels normally were left for 4 hours at room temperature to ensure complete and 
consistent polymerization.
Table 2.1. Gel mixtures for forming a 5-22% (w/v) gradient gel
Resolving gel Stacking gel
5% 22% 3.8%
Sucrose - 2.25 g -
Protogel 2.50 ml 10.00 ml 1.85 ml
Tris-buffer 1.85 ml 1.85 ml 3.75 ml
Urea/DTT/SDS 1.50 ml 0.15 ml 0.30 ml
1.5% (w/v) APS 0.35 ml 0.35 ml 1.15 ml
R.O. water 10.10 ml 1.35 ml 7.50 ml
Total volume 16.30 ml 13.70 ml 14.55 ml
TEMED 11.5 i^l 11.5 pi 25.0 pi
3 mol/1 Tris buffer, pH 8.8 was used for the resolving gels and 0.5 mol/1 Tris buffer, pH 6.8 was used for 
the stacking gel. Neat protogel is a mixture of 30% (w/v) acrylamide and 0.8% (w/v) N, N ’-bis- 
methylene acrylamide.
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Samples preparation
25 pi non-delipidated samples and lymph were dissolved in 100 pi of sample buffer 
[10.8% (v/v) glycerol, 2.16% (w/v) SDS, 67 mmol/1 Tris, 5.3% (v/v) 2- 
mercaptoethanol, 0.001% (w/v) bromophenol blue, pH 6.8] and subsequently 
denatured at 90°C for 4 minutes. After dénaturation, the mixtures were centrifuged at 
13,000 rpm for 2 minutes (2.1 x 10"^  gmax.min) in order to separate insoluble material 
just prior to loading. An aliquot of the Rainbow coloured protein molecular weight 
markers was diluted (1:1) with sample buffer and treated with the same condition. 
Samples were loaded, at 20-50 pl/lane, immediately after incubating and 
centrifugation. The outer and empty wells were filled with sample buffer.
Electrophoresis
Electrophoresis was first carried out at 30 mA (60 mA if two gels were run) until the 
sample reached the resolving gel (approximately an hour) and then increased to 60 mA 
(100 mA if two gels were run) for another about an hour until the dye front reached the 
bottom of the gel. After that, gels were removed from the apparatus and either stained 
for 30 minutes with Brilliant Blue R Concentrate or electrotransferred for 
immunoblotting. Destaining was in 7% (w/v) trichloroacetic acid with multiple 
changes of destainer during 24 hours.
Electrotransfer
This is based on the method first described by Towbin et al (1979). Following 
electrophoresis the gel was equilibrated in transfer buffer for 30 minutes with shaking, 
in order to remove SDS that might inhibit transferring of protein from gel to 
nitrocellulose membrane. The nitrocellulose membrane was floated and pre-wet in 
transfer buffer for half an hour before gel and membrane were assembled into the 
transfer cassette. Transfer took place in a Hoefer Scientific Instrument TE42 series 
transphor electrophoresis unit, with supercooling coil through which chilled water was 
pumped. Electrotransfer was carried out for at least 16 hours at a constant voltage of 
50 V.
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Immuno-detection of the nitrocellulose membrane
The transfer cassette was dismantled and the nitrocellulose membrane was placed in a 
clean tray with the protein side uppermost. The efficiency of transferring was checked 
by visualising the protein on the membrane with non-permanent Ponceau Red stain for 
a minute and then the excess stain was removed with R.O. water. Following staining, 
the membrane was placed inside a hybridisation tube. Incubation steps were carried 
out, by rotating the tube on a roller mixer. The unoccupied sites on the membrane, was 
blocked by incubation with 20 ml of PBS-MT solution for 1 hour with one change after 
30 minutes. The membrane was then incubated sequentially with 15 ml of rabbit anti- 
apo B-48 at the dilution of 1:10,000 in PBS buffer, followed by HRP-labelled donkey 
anti-rabbit IgG at the dilution of 1:1000. Each of the two incubations was for 1 hour 
and separated by 6 x 5 minutes washes with PBS-MT. After incubated with HRP- 
labelled donkey anti-rabbit IgG, the membrane was washed four times with PBS-MT 
and twice with PBS. Finally, the membrane was removed from the tube and immersed 
in PBS in a tray.
ECL detection
After the antibody incubations, detection using the ECL reagents was accomplished by 
mixing two solutions in a ratio of 1:1, following the manufacturer’s instruction 
(Amersham International Pic., Little Chalfont, Bucks, England). This mixture was 
applying to the membrane surface for precisely a minute. Excess reagent was drained 
off and the membrane was encased in Saranwrap to form a watertight seal and exposed 
to Hyperfilm ECL in a photographic film cassette. The time exposure depended on the 
strength of the band of interest. The film then was developed in X-ray developer 
solution for a few seconds, following a wash in tap water and lastly fixed in fixer.
Expression of results
Densitometric scanning was performed by ImageMaster ID Software, Amersham 
Pharmacia Biotech. Due to the limited number of wells on the gel, a standard curve 
was not run together with the samples. The band intensity of apo B-48 in each sample
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was expressed as a percentage of the band intensity of the internal standard (lymph 
1 A). Therefore apo B-48 levels were measured in a semi-quantitative way.
2.2.6 Quantitation of apo B-48 by enzyme-linked immunosorbent assay (ELISA)
2.2.6.1 Principle
The ELISA technique used for measuring apo B-48 was developed by Lovegrove et al.
(1996) and is a competitive system. In this method, a peptide used to raise the anti-apo 
B-48 antisera is conjugated to a large carrier protein (thyroglobulin) and adsorbed to 
the ELISA plate. A known amount of apo B-48 (Lymph 1 A) and an unknown amount 
of apo B-48 in the sample were allowed to react with the anti-apo B-48 antisera in a 
separate tube where the specific antibodies bind to any apo B-48 present in the 
mixture. The mixture is then added to the plate and incubated. Unbound antibodies 
bind to the peptide attached to the plate whereas all other material, including antibodies 
bound to apo B-48 are washed away with buffer. The secondary enzyme-labelled anti- 
IgG antibody was then added and bound to the primary antibody. Enzyme substrate 
was added and produced a colour from which the enzyme activity was measured. The 
amount of colour produced is inversely proportional to the amount of apo B-48 present 
in the sample. The principle of this procedure is illustrated in Figure 2.3.
2.2.6.2 Materials
Tween™ 20, and 3,3’,5,5’-tetramethylbenzidine (TMB) tablets were obtained from 
Sigma Chemical Company Ltd., (Poole, UK). Gelatin (biochemical grade) was from 
Fisons Scientific Equipment, (Loughborough, UK). Dimethyl formamide (DMF) and 
dimethyl sulfoxide (DMSO) were supplied by Fisher Scientific International Company, 
(Loughborough, UK). The maxisorp microtitre plates were from Nunc, Roskilde, 
Denmark supplied by Gibco Europe, (UK). The HRP-labelled donkey anti-rabbit IgG 
was obtained from Guildhay Ltd., (Guildford, Surrey, England). Human thoracic duct 
lymph sample (referred to as lymph lA) from a patient undergoing thoracic surgery 
were kindly gifted by Dr. J. Wright (Royal Surrey County Hospital, Guildford, UK) 
and was used for the analysis of apo B-48 in all chapters.
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Figure 2.3. Schematic representation of the competitive ELISA procedure for 
measuring apo B-48.
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Stock solution
Coating buffer
0.1 mol/1 bicarbonate/carbonate buffer (pH 9.6) contains 30 mmol/1 NaiCOg and 70 
mmol/1 NaHCOs.
Stock buffer
10-fold concentrated PBS buffer (pH 7.4) contains 1.37 mol/1 NaCl, 0.2 mol/1 
Na2HP04, 27 mmol/1 KCl and 14.7 mmol/1 KH2PO4.
Wash and diluent buffer
1-fold PBS buffer (pH 7.4) was added with 0.05% (v/v) Tween™ 20 and 0.1% (w/v) 
gelatin (PBS-GT). This buffer was made fresh daily.
Standard diluent
Human serum albumin (35 mg/ml) in 1-fold PBS was used as a diluent for the standard 
curve and prepared fresh each day.
Substrate buffer
It was prepared with 50 mmol/1 Na2HP04 and 24 mmol/1 citric acid (pH 5.0).
TMB stock solution
2 tablets (1 mg/each tablet) of 3,3%5,5% tetramethyl benzidine (TMB) were dissolved 
in 2 ml of DMSO by sonication.
TMB substrate
Substrate buffer (18 ml) and 4 pi of H2O2 were added to 2 ml of TMB stock solution. 
This was prepared within 15 minutes of usage.
Stop solution
1 mol/1 HCl was used to stop the reaction.
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Coating conjugate
Heptapeptide-SPDP-thyroglobulin conjugate consists of the carboxy terminal 6 amino 
acids (2147-2152) of apo B-48 bound to an amino terminal cysteine residue. This was 
custom synthesised by the National Institute of Medical Research (Mill Hill, London). 
The terminal iso leucine carboxy group was negatively charged to produce a peptide 
with the sequence:
HgN  ^-Cys-Leu-Gln-Thr-Tyr-Met-Ile-COO’
The heptapeptide was conjugated to thyroglobulin using SPDP as a conjugating agent 
as detailed previously (Peel, 1993). This conjugate was stored at -20°C and diluted in 
coating buffer (0.1 mol/1 bicarbonate/carbonate) before use.
Standard and QC
Lymph lA was used as a standard. This was aliquotted and stored at -20°C. To 
prepare the standard curve, lymph was double diluted in standard diluent (35 mg/ml 
HSA in PBS) to produce a nine point standard curve ranging from 1:1 to 1:128.
Antisera
Anti-apo B-48 and HRP-labelled donkey anti-rabbit IgG were diluted in PBS-GT prior 
to use.
2,2,6,3 Procedure
The day before the measurement, the 96 wells of NUNC maxisorp microtitre plate 
were coated with 100 pi per well of diluted coating conjugate (1:80,000) and incubated 
overnight under a humidified atmosphere at 4°C.
The next day, an eight point standard curve and zero was prepared by double dilution 
from 1-128 fold of lymph lA with HSA (35 mg/ml). The anti-apo B-48 (1:125,000) 
was added to the same volume of standard curve, zero, QCs and samples. These 
mixtures were then were vortexed thoroughly and pre-incubated at room temperature 
for 1 hour. Pre-coated microtitre plates were washed three times with 250 pi of PBS-
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GT per well. Following washing, 250 pi per well of PBS-GT were added to block the 
vacant sites and incubated at 37°C for 1 hour.
After 1 hour pre-incubation, the blocked plate was emptied and banged dry. 100 pi of 
lymph standard, QCs and samples, were pipetted in duplicate into the wells and 
incubated for 2 hour at 37°C. Thereafter, the plates were washed as above and banged 
dry. 100 pi of HRP-labelled donkey anti-rabbit IgG diluted with the same buffer, at 
the dilution of 1:9000, was added per well and incubated at 37°C. After 2 hours, the 
plates were washed again as above and incubated with 100 pi per well of TMB (1 
mg/ml), until the absorbance 620 nm was approximately 0.4 for the highest 
concentration of the standard. The reaction was stopped by addition of 50 pi per well,
1 mol/1 HCl and the developed colour of each well was read at 450 nm on an 
automated Genesis ELISA plate reader. A standard curve was plotted fi*om which the 
amount of apo B-48 in the QCs and samples was determined.
Figure 2.4. Apo B-48 ELISA plate layout
10 11 12
SI SI S7 S7 U1 U1 U7 U7 U13 U13
82 S2 S8 S8 U2 U2 U8 U8 U14 U14
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H
All Standard and samples run in duplicate 
S1-S9 : Standard (Lymph 1 A)
QC : Quality control (Low, medium and high)
U1 -U18 : Unknown samples
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2.2.7 Analysis of retinyl ester (RE)
2.2.7.1 Principle
An additional way to quantify intestinal lipoproteins is to use the specific metabolic 
route for absorption of vitamin A as retinyl palmitate (RP) and RE which is an indirect 
method. After the secretion of CM from the intestine mucosa, RE is carried in the 
lipoprotein core and is thought not to leave this lipoprotein particle until removal by 
the liver. Supplementation of a lipid-rich test meal with vitamin A has therefore often 
been used as a means of quantifying lipoproteins of intestinal origin in the postprandial 
state.
The method used to measure RE-labelled CMs and their remnants was normal phase 
HPLC procedure following the method of Jackson (1996) originally from Ruotolo et 
al (1992) with a few modification by Ah-Sing. Three peaks are observed following 
resolution which correspond to REs (predominantly RP along with retinyl stearate and 
oleate), RA (internal standard) and retinol.
2.2.7.2 Instrument
Equipment
Pump
Autosampler
Column
Detector
Injection volume 
Flow rate 
Detection
Description
Severn Analytical Model SA 6480 (Severn Analytical, 
UK)
Gynotek GINA Model 160 Precision Autosampler 
(Severn Analytical, UK)
Hichrom Spherisorb S5W (5 pm, 25 cm x 4.66 mm ID 
(Hichrom, UK).
RAPISCAN SA6508 multiple wavelength UVA/IS 
(Severn Analytical, UK)
50 pi 
1 ml/min 
UV330nm
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Integrator Model 160 Serial Chromatography Signal Interface
(Autochrom Incorporated, UK)
Computer software Apex Software model 625-1 (integration) and Quattro
Pro (spreadsheets)
Retention times RE = 2.55 (SD 0.08) minutes
RA = 3.47 (SD 0.09) minutes 
Retinol = 8.62 (SD 0.05) minutes
2.2.7.3 Material
Retinyl palmitate (RP) and retinyl acetate (RA) (all-trans, RP crystalline purity and RA 
synthetic) were supplied from Sigma Chemical Company Ltd., (Poole, UK). Hexane 
and 1-Chlorobutane were obtained from Sigma-Aldrich, (Dorset, UK). Methanol, and 
acetonitrile were purchased by Fison Scientific Equipment, (Loughborough, UK).
Reagent
Mobile phase buffer (MPB)
The constituents of the mobile phase buffer were hexane, 1-chlorobutane, acetonitrile 
in a ratio of 82:13:5. Before used, the mobile phase was sonicated under vacuum to 
remove the air. The MPB was made up fresh daily.
Standard solution
Stock solution (0.5 mg/ml) of RP and RA (internal standard) were prepared in MPB 
and kept at 4°C for two weeks. Standard solution was prepared daily in fresh MPB, 
from the stock solution. The standards used for TAGRL measurement were 25 pg/ml 
RP and 2.5 pg/ml RA and for plasma and TAGPL, 12.5 pg/ml RP and 1.25 pg/ml RA.
2.2.7.4 Procedure
The extraction procedure for the three fractions (plasma, TAGRL and TAGPL) was 
followed from the original method by Ruotolo and coworkers (1992). Briefly 100 ql 
of plasma /TAGRL or 300 pi of TAGPL were placed into a 2 ml glass tube with a
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push-on lid. 400 pi of saline was then added to plasma/TAGRL or 200 pi to TAGPL 
followed by the addition of 500 pi of methanol, 50 pi of RA (2.5 g/ml) for TAGRL or 
1.25 g/ml for plasma/TAGPL, RP and MPB with the volume indicated in the Appendix
I. The tubes were then mixed gently by placing on a rotary wheel for 10 minutes. The 
upper layer (200 pi) was carefiilly pipetted into individual autosampler vials. The 
autodetector was programmed to deliver 50 pi per injection onto the column.
A standard curve of spiked plasma, TAGRL or TAGPL (fasted samples) was extracted 
alongside the postprandial samples to enable determination of their concentrations. A 
data handling software package (Apex Chromatography) was used to integrate the 
chromatograms and to determine the peak area ratios of the RP and the RA peaks. This 
data was then transferred to Quattro Pro spread sheets to enable calculation of the RE 
concentrations of the test samples from the response factor which was determined from 
the slope of the standard curve. Internal standard calibration was used by the addition 
of a known amount of a reference sample (RA) to both standards and samples. Since 
the integrated amount of the internal standard was always the same, a change in the 
internal standard response indicates a change in the chromatogram. This is reflected in 
the calculation by taking the ratio of the RP concentration to the RA concentration 
(internal standard) and of the RP peak area response to the RA peak area response 
(internal standard). Since the spiked RP standard curve was directly proportional to 
the RP/RA ratio, a single level calibration can be used to determine the amounts of RE 
in postprandial samples.
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1
8
ak Ret, Time Area Height Area % Norm. Area/Hgt
0. (Min) (uV Sec) (uV) Area (Sec)
1 2.492 9207.7 1350.0 70.332 1.000 6.82
2 3.405 3807.9 487.3 29.086 0.414 7.81
3 7.342 76.1 10.8 0.581 0.008 7.03
Figure 2.3. Example of a typical HPLC chromatogram for the determination of RE in 
plasma, TAGRL and TAGPL samples.
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The following equation was used to calculate the response factor and hence the RE 
concentrations from the standard curve:
Response factor (Rf) = RA peak area x RP concentration
RP peak area RA concentration
Since the absorbance of REs is only determined by the retinyl content, the 
concentration of RE is given by:
Concentration (g/ml) = Rf(mean) x RA concentration x RE response
RA response
2.2.8 Insulin radioimmunoassay (RIA)
2.2.8.1 Principle
The RIA method was developed in the School of Biological Sciences by Dr. S.M. 
Hampton (1983). The method is based on the competition between a fixed amount of 
radiolabelled insulin and a standard or unknown quantity of unlabelled insulin for 
binding sites on a fixed and limiting number of antisera molecules to insulin. The 
quantity of antibody-bound radiolabelled insulin is inversely proportional to the 
quantity of unlabelled insulin present. A standard curve can be constructed using an 
unlabelled insulin preparation at a range of known concentration and from this curve 
the concentration in unknown samples is determined. The schematic representation of 
the RIA procedure for measuring insulin is shown in Figure 2.6.
2.2.5.2 Material 
Reagent
Stock Buffer IpH 7.41
5 1 of 0.04 mo FI stock buffer was prepared from 32.4 mmoFl Na2HP04 anhydrous salt 
and 7.65 mmoFl NaH2P04.2H20. The pH was adjusted to 7.4. For assay buffer, 0.5% 
(w/v) of BSA was added and used for the dilution of all reagent.
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Figure 2.6. Schematic representation of the radioimmunoassay (RIA) procedure 
for measuring insulin.
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Insulin antiserum
Insulin antiserum was raised in a guinea pig injected with porcine insulin conjugated to 
egg albumin. The conjugate was prepared using a gluteraldehyde reaction. The 
antiserum used in the assay is MF/GP/6 VIIA. The antiserum was stored, aliquoted at - 
20°C and was diluted to 1:10 000.
Insulin Standard
Insulin standard which was purchased from Dr S.M. Hampton, was originally supplied 
by the National Institute of Biological Standards and Controls. The standard is diluted 
in assay buffer and aliquotted in 0.1 ml amounts and these working standards are 
stored at -20°C. 0.9 ml of assay buffer was added to each 0.1 ml aliquot, which 
produces a top standard of 200 mU/1. To produce standards containing 1500, 750, 
375, 188, 94, 47 and 23 mU/1 of insulin, the top standard was double diluted with assay 
buffer (200 mU/l=1500 pmoFl).
Charcoal stripped serum (CSS)
To prepare CSS, the serum pool was collected from fasted volunteers. 20 g of Norit 
OL charcoal was added per 100 ml of serum and roller-mixed overnight at 4°C. The 
charcoal was allowed to settle and then the supernatant was centrifuged at 3,000 rpm 
for half an hour. The supernatant was then filtered through a Seitz filter until all 
charcoal was removed. Aliquots (10 ml) were stored at -20°C.
^^ I^ radiolabelled
^^ I^ radiolabels were produced in-house. It involved separation of the iodinated peptide 
from free ^^ I^ by gel filtration.
Secondarv antibodies
Two secondary antibody, normal guinea pig serum (NGPS) and donkey anti-guinea- 
pig (DAGP) were diluted to 1:200 and 1:16 respectively with assay buffer and were 
stored at 4°C.
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Polyethylene glycol (TEGV6000
4% (w/v) solution of polyethylene glycol (PEG) was made up in stock buffer (pH 7.4) 
and kept in 4°C.
QÇ
Low, medium and high quality control (QC) were prepared from fasting, medium and 
high meal plasma respectively.
2.2.83 Procedure
Samples were assayed for non-specific binding (NSB) as well as specific binding (one 
NSB tube, for each subject if multiple samples was taken from one subject). On the 
first day, assay buffer, insulin standards, CSS, QC (low, medium and high), samples 
were placed in the tubes (see Table 2.2) followed by incubation with primary 
antiserum (insulin antiserum) for 24 hours at 4°C. labelled insulin (100 pi) was 
added on the second day and incubated at 4°C for a fiirther 24 hours. Finally on the 
third day, 100 pi of NGPS (1:200) and DAGP (1:16) each, together with 700 pi of 4% 
(w/v) PEG were added to the tubes following by vortex mixing and incubated for 2 
hours at 4°C. Addition of antiserum to guinea pig IgG, which binds to the primary 
antibody can remove the unbound radiolabelled insulin and causes the precipitation of 
the antibody-antigen complexes in the presence of polyethylene glycol (PEG)-6000. 
Following incubation, the antibody-antigen complexes were pelleted by centrifiigation 
in a Beckman J-6B at 2500 rpm for 30 minutes (4°C). The resulting supernatant was 
aspirated off and the pellets in the tubes counted on a gamma counter. Multigamma 
1260, program A-20.
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2.2.9 Automated analyses on the Cobas Mira Plus
Analysis of paracetamol, TAG, cholesterol, NET A, glucose and apo B were carried out 
using an automated analyser - the COBAS MIRA plus (Roche Diagnostics Ltd., 
Welwyn Garden City, Herts, UK). TAG, glucose, paracetamol, cholesterol, and 
NEFA, were measured by sequential enzymatic analysis and apo B was measured by 
immunoturbidometry. All analytes were measured in fasting and postprandial plasma 
samples. In addition, TAG measurements were made in the TAGRL and infranatant 
(TAGPL) fractions obtained by ultracentrifugation of plasma during the postprandial 
studies.
For each analyte, all samples from one subject were measured in the same run. 
External QC samples with assigned values were measured at regular intervals within 
each run to ensure identical assay conditions for each run.
2.2.9.1 Analysis o f paracetamol
The working reagent and calibrator were supplied in kit form from Cambridge Life 
Sciences Pic, (Cambridge Science Park, Cambridge, UK).
Working reagent: Acetaminaphen assay kit (lyophilised enzyme, enzyme diluent,
colour reagent A and colour reagent B)
Calibrator: aqueous paracetamol standard
Quality controls: postprandial plasma sample and paracetamol standard
Principle
The analysis is an enzymatic colorimetric method based on an enzyme specific for the 
amide bond of acylated aromatic amines (aryl-acyl-amide aminohydrolase). The 
enzyme cleaves the paracetamol molecule to produce acetate and p-aminophenol. The 
p-aminophenol reacts with o-cresol in the presence of ammonia and copper ions to
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produce a blue indophenol dye colour. The intensity of colour is measured at 615 nm 
and is proportional to the concentration of paracetamol.
2.2,9.2 Analysis o f TAG
The working reagent and calibrator were supplied in kit form from Roche Diagnostics 
Ltd., (Welwyn Garden City, Herts, UK). The QC was supphed by Nycomed, 
(Birmingham, UK).
Working reagent: Unimate 5 TRIG reagent kit
Cahbrator: Lipid control serum
Quality control: Seronorm lipid
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
LPL
Triacylglycerol ------------------------------ ^  glycerol + 3x fatty acids
Glycerol + ATP Glycerol Unase______ ^  glycerol-3-P + ADP
Glycerol-3-P + O2 Phosphate oxidase ^ dihydroxyacetone phosphate +
H 2 O 2
H2O2 + 4-chlorophenol +aminophenazone
Peroxidase
-► quinoneimine derivative
The first step is catalysed by LPL, the second by glycerol kinase, the third by glycerol 
phosphate oxidase and the fourth by peroxidase. The red-coloured quinoneimine 
derivative absorbs at 500 nm. The intensity of the colour formed is proportional to the 
TAG concentration. Any samples with concentration greater than this were diluted 
with saline.
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2.2.9.3 Analylsîs o f total cholesterol
The working reagent and cahbrator were supphed in kit form from Roche Diagnostics 
Ltd., (Welwyn Garden City, Herts, UK). The QC was supphed by Nycomed, 
(Birmingham, UK).
Working reagent: Unimate 5 CHOL reagent kit
Cahbrator: Lipid control serum
Quahty control: Seronorm hpid
Principle
The analysis is an enzymatic colorimetric method based on the fohowing reactions:
Cholesterol esterase
Cholesterol ester + H2O -------------------------► cholesterol + fatty acids
Cholesterol oxidase
Cholesterol + O2 ---------------------------► cholest-4-en-3-one + H2O2
H2O2 + 4-chlorophenol + 4-aminophenazone
Peroxidase quinoneimine derivative
The red-coloured quinoneimine derivative absorbs at 500 nm. The intensity of the 
colour formed is proportional to the cholesterol concentration.
2.2.9.4 Analysis o f HDL-cholesterol (HDL-C)
The reagents, QC and calibrator were supphed by Randox Laboratories Ltd., (Diamond 
Road, Crumlin, Co. Antrim, UK).
Direct HDL-C Reagent: Enzyme Reagent R1
Enzyme Reagent R2 
Cahbrator: Randox Direct HDL-C/LDL-C Cahbrator, CH2673
Quahty control: Randox Lipid Control Sera, Level 1, Level 2 and Level 3
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Principle
The assay consists of 2 distinct reaction steps:
1. Elimination of chylomicron, VLDL-Cho lesterol and LDL-Cholesterol by 
cholesterol esterase, cholesterol oxidase and subsequently catalase.
Cholesterol esterase
Cholesterol ester ---------------------------- ► cholesterol + fatty acid
Cholesterol oxidase
Cholesterol + 0%  ► Cholestenone + H2O2
Catalase
2H2O2  ^  2H2O + O2
2. Specific measurement of HDL-cholesterol after release of HDL-Cholesterol by 
detergents in Reagent 2.
Cholesterol esterase
Cholesterol ester ------------------------------ ► cholesterol + fatty acid
Cholesterol oxidase
Cholesterol + O2 ------------------------------ ► Cholestenone + H2O
2H2O2 + 4-Aminoantipyrine + N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline
Peroxidase _ . . ^____________________^  Qumone pigment + 4H2O
The intensity of the quinoneimine dye produced is directly proportional to the 
cholesterol concentration when measured at 600 nm. In the second reaction catalase is 
inhibited by sodium azide in reagent 2.
2.2.9.5 Analysis o f LDL-cholesterol
Principle
After measurement of total and HDL-cholesterol, the LDL-cholesterol level can be 
determined from the Friedewald formula (Friedewald et al., 1972) in the following 
equation:
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Equation
LDL-cholesterol = total cholesterol -  tHDL-cholesterol + total TAG)
2.2
The formula relies on the assumption that, when the level of TAG in plasma is below
4.5 mmoFl, the level of VLDL-cholesterol bears a constant relationship to the level of 
TAG in the plasma. This assumption is not valid if the TAG concentration in the 
plasma is greater than 4.5 mmoFl.
2.2.9.6Analysis o f non-esterifiedfatty acids (NEFA)
The working reagent, QC and cahbrator were supphed as a kit manufactured by Waco 
and supphed by Alpha Laboratories, (Eastleigh, Hants, ETC).
Working reagent: Wako NEFA C test kit
Cahbrator: NEFA C standard
Quahty control: NEFA C kit
Principle
The analysis is an enzymatic colorimetric method based on the following reactions:
NEFA + ATP+ CoA ,  acyl CoA + AMP + PPi
Acyl CoA + O2 Acyl CoA oxidase ^ 2,3-trans-enoyl-CoA + H2O2
H2O2 + 3-methyl-N-ethyl-(p-hydroxyethyl)-aniline + 4-amino-antipyrene
Peroxidase
-------------------------► Purple coloured adduct
The first step is catalysed by Acyl CoA synthetase in the presence of magnesium ions, 
t^e second by acyl CoA oxidase and the third by peroxidase. The purple-coloured 
abduct absorbs at 550 nm. The intensity of the colour formed is proportional to the 
NElpA concentration.
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2.2.9.7 Analysis o f glucose
The working reagent and cahbrator were supphed in kit form from Randox 
Laboratories Ltd., (Diamond Road, Crumlin, Co. Antrim, UK).
Principle
Glucose is determined after enzymatic oxidation in the presence of glucose oxidase. 
The hydrogen peroxide formed reacts with phenol and 4-aminophnazone, catalysed by 
peroxidase, to form a re-violet quinoneimine dye as indicator. The reactions involved 
in the determination of plasma glucose are summarised below:
Glucose oxidase
Glucose + O2 + H2O -----------------------------^  gluconic acid + H2O2
Peroxidase
2H2O + 4-aminophenazone + phenol _______________ ^  quinoneimine + 4H2O
2.2.9.8 Analysis o f total apo B
The working reagent and cahbrator were supphed in kit form from Randox 
Laboratories Ltd., (Diamond Road, Crumlin, Co. Antrim, UK).
Assay Buffer: Polyethylene glycol (PEG), Tris/HCl, NaCl buffer
Antibody Reagent: Anti-human-apo B
Cahbrator: Randox Apo lipoprotein Cahbrator Kit
Quahty control: Specific Protein Control Low PS 1657 and Elevated PS 1658
Principle
This method is based on the reaction of a sample containing human apo B and a 
specific antiserum to form an insoluble complex, which can be measured 
turbidimetrically at 340 nm. By constructing a standard curve from the absorbances of 
standards the concentration of apo B can be measured.
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Another investigator determined all the analysis by Cobas Mira Plus except analysis of 
total apo B and TAG.
2.2.10 Analysis of lipase
Continuous Fluorometric Lipase Test (Confluolip™) was purchase from Progen 
Imuno-Diagnostika, Progen Biotechnik GMBH, (MaaPstrafe 30, D-69123 Heidelberg, 
Germany).
Principle
PROGEN’s lipase substrate is l-trinitrophenyl-amino-dodecanoyl-2-pyrendecanoyl-3- 
0-hexadecyl-sn-glycerol (12-TA-10-P-H6), a TAG in which the pyrene fluorescence is 
intramolecularly quenched by the trinitrophenyl group (Hermetter and colleagues. 
Upon addition of active lipase the quenching group is hydrolysed and the pyrene 
fluorescence can be detected. The kinetic increase in fluorescence intensity at 37°C is 
proportional to lipase activity. Fluorescence intensity is measured at 342 nm excitation 
and 400 nm emission wavelength. The analysis of lipase was conducted by another 
investigator.
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CHAPTER THREE
OPTIMISATION OF IMMUNO DETECTION 
AND SEMI-QUANTITATION OF APO B
3.1 INTRODUCTION
Interest in the role of apo B-containing lipoproteins in atherosclerosis has led to the 
development of numerous techniques for studying their metabolism. The observation 
by Phillips et a l (1997) that only one apo B-48 molecule is present per CM particle 
and it is retained within the particle until its removal from plasma, makes apo B-48 
the ideal marker for distinguishing between plasma lipoproteins of hepatic and 
intestinal origin. In addition, the quantitation of apo B-48 serves as a basis for the 
estimation of the number of apo B-48-containing-lipoprotein particles in plasma.
One of the most popular and widely used approaches for monitoring and detecting 
apo B-48-containing particles is the densitometric scanning of the stained apo B bands 
after separation of the delipidated and redissolved proteins using SDS-PAGE. The 
SDS-PAGE can be done using either tube (Poapst et a l, 1987; Karpe et a l, 1993) or a 
slab gels (Zilversmit and Shea, 1989; Scheeman et a l, 1993; Karpe and Hamsten, 
1994). Thereafter, apo B-48 can be quantified by various methods including; 
expression of apo B-48 as a percentage of the fasting or peak level, expression of the 
level of apo B-48 in arbitrary units (peak areas), expression of apo B-48 as its ratio to 
apo B-lOO, or by direct quantitation from an apo B-lOO standard curve. However, 
results given by these procedures are inconsistent. Whilst tube gel electrophoresis of 
apo B-48 and apo B-lOO, shows different chromogenicities (Poapst et a l, 1987), apo 
B data obtained by slab gel electrophoresis, shows equal chromogenicities (Kotite et 
al, 1995). The former observation has been explained by only a rim of dye 
penetrating into the gel (Kahn and Rubin, 1975).
The measurement of apo B-48 by SDS-PAGE has several shortcomings. Besides 
being labour intensive and time consuming, the concentration of CM/CMR in plasma 
is very low, due to their rapid clearance compared with apo B-lOO-containing 
particles, particularly in fasted, normolipidaemic individuals. The last point makes it 
difficult to study their metabolism by the standard technique of SDS-PAGE. In 
addition, unlike LDL-apo B-lOO, apo B-48 forms only about 5% of the entire protein 
mass of CM (Thompson, 1990). Usually ultracentrifiigally concentrated low density 
lipoproteins had to be used in SDS-PAGE in order to remove the majority of plasma
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proteins, other than apolipoproteins in the sample. Furthermore, samples need to be 
delipidated due to their high TAG content before being loaded on the gel and this 
process might cause greater losses of apo B-48, which is more soluble compared to 
apo B-lOO (Lee, 1996).
After separation of the sample by electrophoresis, proteins can be transferred from 
polyacrylamide gels to nitrocellulose or polyvinylidene difluoride (PVDF) 
membranes (Western Blotting) by electroblotting. This was first described by Towbin 
et al. (1979) and has been widely used in the field of protein research. Western 
blotting offers advantages when compared to the original gel (SDS-PAGE). Samples 
with low concentrations are more easily detected since they are not spread throughout 
the thickness of the gel, but are ‘concentrated’ on the surface of the membrane 
(Amersham’s booklet).
Several attempts have been made to increase the sensitivity of detection of a small 
amount of protein of interest in the sample. Immuno-detection is far more sensitive 
for the quantitation of proteins than dye binding and it is more specific because it 
utilises the recognition and strong binding affinity between an antigen and specific 
antibody. A specific primary antibody is used to locate the target protein. The 
position of the primary antibody-antigen complex can be located by adding a second 
labelled antibody against the species in which the primary antibody was raised. 
However, antibodies specific for apo B-48 are not as readily available as are 
antibodies to apo B-100. Most of the polyclonal and monoclonal antibodies produced 
against apo B-48 have cross-reacted with apo B-100, whereas antibodies produced 
against synthetic peptides of the carboxyl-terminal half of apo B-100 do not react with 
apo B-48. These include monoclonal antibodies MB47 (Young et al., 1986). So, 
theoretically, these antibodies can be used for the quantitation of apo B-100 and the 
more general polyclonal antibodies against apo B-100 can be used to quantitate the 
sum of apo B-100 and apo B-48. In theory, the difference between the two would be 
the value for apo B-48. However, this approach is suitable only if the relative content 
of apo B-48 is not small (Lee, 1996). This technique has been used by Myserth et al. 
(1989) to quantify apo B-100 and apo B-48 but the resolution of the apo B-48 band 
was no better than that detected by a Coomassie-stained gel. Quite recently Smith et 
al. (1997) have applied anti-apo B antiserum (DAKO A/S Denmark) to quantify
77
serum apo B-48 by using an ECL detection method to improve the sensitivity of the 
immuno-detection after SDS-PAGE. This method ehminated the need for pre- 
delipidation of samples and was approximately 10 times more sensitive than 
Coomassie staining.
3.1.1 AIMS
A novel antibody to apo B-48, which recognises the C-terminal end of apo B-48 (Peel 
et ah, 1993) and has been proven to be very specific to apo B-48 (Lovegrove et ah, 
1997) was used to optimise the SDS-PAGE separation and immuno-detection system 
to render it suitable for:
i) Separation of total plasma protein in the milligram range
ii) The detection of very dilute apo B-48 samples.
iii) To develop an immuno-detection system for the quantitation of apo B-48 and
apo B-100 in the same blot.
iv) To modify the established ELISA for apo B-48 so as to use it for quantitation
of apo B-48 in plasma.
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3.2 MATERIALS
A blood sample was collected from a healthy volunteer into EDTA tubes (final 
concentration of 0.1% (w/v) EDTA). Human thoracic duct lymph, obtained from a 
patient undergoing thoracic surgery, was kindly supplied by Dr. J. Wright at the Royal 
Surrey County Hospital, Guildford and was used as the standard. The quantitation of 
the absolute amount of apo B-48 in the lymph samples (lymph 1 A) was carried out by 
Dr Frederik Karpe at the Karolinska Institute, Sweden using their published method 
(Karpe and Hamsten, 1994). The value was 10.87 pg/ml of apo B-48. Goat anti rabbit 
IgG-HRP conjugated to a dextran backbone was purchased from AMDEX A/S, 
Denmark supplied by Amersham International Pic., (Little Chalfont, Bucks, England). 
Extravidin-peroxidase conjugated to monoclonal anti-rabbit IgG, monoclonal mouse 
anti-rabbit IgG-HRP, and biotin conjugated to goat anti-rabbit IgG (whole molecule) 
were from Sigma Chemical Company Ltd., (Poole, UK). Biotinylated swine anti­
rabbit IgG and ABComplex were obtained from DAKO Ltd., (Denmark House, Angel 
drove, Ely, Cambridgeshire, UK). Polyclonal sheep anti-apo B antiserum was 
purchased from Boehringer, (Mannheim, Lewes, Sussex, UK). The donkey anti-sheep 
IgG-HRP was from Guildhay Ltd., (Guildford, Surrey, UK). The general materials 
for apo B-48 and apo B-lOO immunoblotting are hsted in Section 2.1.
3.3 METHODS AND RESULTS
3.3.1 Preparation of TAGRL, TAGPL
Plasma was separated from red blood cells by centrifugation at 3000 rpm for 10 min 
(1700 gmax-inin) as described in Section 2.2.1. The plasma was removed and 
ahquotted into separate tubes. The TAGRL, consisting of CM and VLDL, were 
isolated from the plasma as described in Section 2.2.2 by overlayering 3.5 ml plasma 
with 3.5 ml NaCl solution (d=1.006 g/ml) and then centrifuging at 4.83 x 10^  gmax.min 
(45,000 rpm for 30 minutes at 24°C). The TAGRL fraction was recovered by careful 
aspiration of the top 1.2 ml. The diluted plasma remaining after TAGRL had been 
removed is called TAGPL or infranatant. Both samples were aliquoted, and 5% (v/v) 
preservative was added. The samples were stored frozen at -20°C until time of 
analysis.
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3.3.2 Preparation of TAGRL subclasses
TAGRL subclasses were prepared by another worker followed the method as 
described by Graham et al. (1996) with some modification. Briefly 2.5 ml of CM- 
free plasma was adjusted to 10% (v/v) iodixanol by added with 0.5 ml Optiprep' '^  ^ (5 
volume of plasma + 1 volume of Optiprep^* )^ and layered under the 9 ml of 0-6% 
(v/v) iodixanol gradient. After centrifugation in a SW 40Ti rotor at 35,000 rpm 
(115,000 gmaxmin, 16°C) for 76 minutes, the contents of each tube were eluted by 
upward displacement and collected into 150 pi fractions. The fractions were pooled 
into 4:
- Pool 1, CMR, Sf 100-400, collected from fraction 1-5
- Pool 2, intermediate between pool 1 and pool 3, collected from fraction 6-15
- Pool 3, VLDL 1, Sf 60-100, collected from fraction 16-35, and
- Pool 4, VLDL 2, Sf 20-60, collected from fraction 36-55.
3.3.3 Modification of SDS-PAGE
The original SDS-PAGE method by Isherwood (1996) used 3.8% (w/v) for stacking 
gel and 5-22% (w/v) of separating gel. Since the main purpose of this work was to 
measure low concentrations of apo B-48 in samples with a very high protein 
concentration other than apo B, such as whole plasma and TAGPL, the concentration 
of the gel was changed to a lower percentage, 2.8% (w/v) of stacking gel and 3-16% 
(w/v) of separating gel. The procedure was the same as that described in section 2.2.4 
with minor modifications. The preparation of the gel is shown in Table 3.1. To 
reduce the potential oxidative damage of apo B by residual ammonium persulphate, 
the sample was electrophoresed in fresh buffer containing anti-oxidant, 0.02% (v/v) of 
thiodiglycol (Sparks and Marsh, 1981). Instead of PBS buffer, Tris-Cl buffer (50 
mmol/1 Tris, 150 mmol/1 NaCl, pH 7.4) was used in all the dilution and washing steps 
in Western blotting following the method by Fairbanks et al (1971). This change is 
due to the high content of iron and other heavy metals in Na2HP04/NaH2P04, which 
could cause oxidation of apo B during electrophoresis (Sparks and Marsh, 1981).
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By changing the concentration of the gel to a lower percentage of acrylamide gradient 
gel, material in the sample was no longer left at the origin (well) and the separation of 
apo B-48 and apo B-lOO was improved (results not shown).
Table 3.1 Gel mixtures for forming a 3-16% (w/v) gradient gel
Resolving gel Stacking gel
3% (w/v) 16% (w/v) 2.8% (w/v)
Sucrose 2.25 g
Protogel 1.50 ml 8.00 ml 0.64 ml
Tris-Cl buffer 1.85 ml 1.85 ml 1.80 ml
Urea/DTT/SDS 1.50 ml 0.15 ml 0.14 ml
1.5% (w/v) APS 0.35 ml 0.35 ml 0.55 ml
R.O. water 9.80 ml 4.65 ml 3.77 ml
Total volume 15.00 ml 15.00 ml 6.90 ml
TEMED 11.50 pi 11.50 pi 25.00 pi
3 mold Tris-Cl buffer, pH 8.8 was used for the resolving gels and 0.5mol/l Tris-Cl buffer, pH 6.8 was 
used for the stacking gel. Neat Protogel is a mixture of 30% (w/v) acrylamide and 0,8% (w/v) N, N ’- 
bis-methylene acrylamide.
3.3.4 Optimisation of apo B-48 immuno detection and semi-quantitation
The protocol for immunoblotting was carried out as described in Section 2.4. After 
separation of the proteins by SDS-PAGE modified as above, electrotransfer to a 
nitrocellulose sheet and blocking with PBS-MT, the bands were immuno-detected 
with four different immuno-detection procedures as shown in Figure 3.1. After 
preliminary work, the dilution of reagents for each step was established (Table 3.2). 
The apo B bands were visualised by ECL as described in Section 2.4. The film was 
pre-flashed by sensitizer for 3 seconds prior to exposure of the membrane in order to 
increase sensitivity. A rainbow coloured molecular size marker was also included on 
each gel to help identify the apo B-lOO and apo B-48 bands.
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Separate protein sample by SDS-PAGE (3-16% w/v) 
Transfer to the membrane 
Block non-specific sites
i
Incubate with rabbit anti-human apo B-48
Mouse anti-rabbit IgG- Goat anti-rabbit IgG- 
HRP biotin ^
ExtrAvidin-HRPECL reagent 
Exposed to film ECL reagent
i
Expose to film
Swine anti-rabbit IgG- 
biotin
ABComplex-HRP
i
ECL reagent
i
Expose to film
Goat anti-rabbit IgG- 
HRP (AMDEX)
i
ECL reagent 
Exposed to film
(A) (B) (C) (D)
Figure 3.1 Outline of four different methods for immuno-detection of apo B-48
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Table 3.2 The dilutions of reagents for each step in four different immuno-detection 
procedures.
NO IMMUNO-DETECTION
(A) (B) (C) (D)
1 Rabbit anti- 
apo B-48 
(1:10,000)
Rabbit anti-apo 
B-48 
(1:3,000)
Rabbit anti-apo B- 
48 
(1:6,000)
Rabbit anti-apo 
B-48 
(1:10,000)
2 Mouse anti- 
rabbit-HRP 
(1:40,000)
Goat anti-rabbit 
-biotin 
(1:3,000)
Swine anti-rabbit- 
biotin 
(1:800)
AMDEX 
(Goat anti-rabbit- 
HRP) 
(1:10,000)
3 ECL ExtrAvidin-
peroxidase
(1:3,000)
ABComplex-HRP
(1:50)
ECL
4 ECL ECL
The immuno-detection results for each protocol are shown in Figure 3.2. Method A 
showed that immuno-detection by secondary antibody-HRP is very specific for apo 
B-48. It detected apo B-48 in lymph but not in plasma even after 5 minutes exposure. 
For Method B. immuno-detection by ExtrAvidin-peroxidase can detect apo B-48 in 
lymph and plasma after 30 seconds, but the results showed a very high background 
due to the secondary antisera used. Method C- Immuno-detection of ABComplex- 
HRP as a secondary antibody-HRP, gave a very clear background, but it could not 
detect apo B-48 in plasma even after 5 minutes. Furthermore, this technique required 
three steps and hence longer to complete. Lastly, Method D. immuno-detection by 
AMDEX, specifically detected apo B-48 in both lymph and plasma in 1.5 minutes 
with a very low background.
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iApo B-48
(a) Method A: Film was pre-flashed 
and exposed to the membrane 
for 5 minutes.
(c) Method C; Film was pre-flashed 
and exposed to the membrane 
for 5 minutes.
t
7 1
(b) Method B: Film was not pre­
flashed and exposed to the 
membrane for 30 seconds.
Apo B-48
Unknown
protein
(d) Method D: Film was not pre­
flashed and exposed to the 
membrane for 1.5 minutes.
Figure 3.2. A comparison of immuno-detection by four different methods. Each 
picture shows the results obtained after SDS-PAGE followed by Western Blotting and 
ECL detection. In each case: lane 1 is a molecular weight standard, lane 2, 3, 4 are 
different quantities of lymph which contained 0.04, 0.02 and 0.01 pg of apo B-48 
respectively, and lane 5, 6, 7 are decreasing quantities of plasma which contained 
0.02, 0.008 and 0.004 pg of apo B-48 respectively.
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A standard curve for apo B-48 in lymph and plasma was determined based on 
densitometric scanning of increasing quantities of purified apo B-48 separated by 
SDS-PAGE and quantitated by immunoblotting and ECL (Figure 3.3). The AMDEX 
immuno-detection was able to detect apo B-48 in lymph and plasma. Figure 3.4 and
3.5 show the results of standard curves of apo B-48 in lymph and plasma
1 2 3 4 5 6 10 11
Apo B-48
Figure 3.3. Quantitation of different amount of apo B-48 in lymph and plasma by SDS- 
PAGE followed by immuno-detection using method D (AMDEX). Lane 1 is rainbow 
coloured molecular size marker, lane 2 to 6 are serial dilutions of lymph samples 
which contained 0.08, 0.07, 0.04, 0.02, and 0.01 pg of apo B-48 respectively, and lane 
7 to 11 are serial dilutions of plasma samples which contained 0.032, 0.02, 0.016, 
0.008, and 0.004 pg of apo B-48 respectively.
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Figure 3.4. Standard curve of lymph
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Figure 3.5. Standard curve of plasma
There were several bands visualised in the lower region of the blot (Figure 3.2b, d). 
To eheek whether the baekground was due to the seeondary antibody, several 
dilutions of lymph and plasma samples were run on a gel and immunoblotted with the 
seeondary antibody (AMDEX) only using TBS buffer without primary antibody. The 
results in figure 3.6 show that all the bands except the apo B-48 were visible on an 
immunoblot incubated with the primary anti-apo B-48 and the AMDEX (see Figure 
3.2d and 3.3), were present on the immunoblot incubated with only the AMDEX. It 
can be concluded that these unknown bands resulted from eross-reaetivity or non­
specific binding of other smaller proteins in the blot with the secondary antibody 
(AMDEX).
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Figure 3.6. Bands visualised in lymph and plasma samples after immunoblotting with 
the secondary antibody (AMDEX) only. Lane 1 to 3 are decreasing quantities of lymph 
sample diluted in TBS buffer, lane 4 to 6 are decreasing quantities of plasma sample 
diluted in TBS buffer.
Various conditions and dilutions of antibodies for each step were carried out in an 
attempt to reduce the baekground produced after immuno-detection by AMDEX. 
These variations included increasing the washing time and volume of washing buffer, 
increasing the concentration of Tween™ 20 in blocking solution from 0.1% to 0.5% 
(v/v) and changing the type of blocking agents such as Super-Bloek’^'^  Blocking 
Buffers (Pierce, Pierce and Warriner Ltd., Chester, UK), 3% (w/v) BSA (Amersham 
International Pic., Little Chalfort, Bucks, England) in Tris-Cl buffer (TBS). None of 
these blocking agents produced better results than the non-fat milk solution (TBS- 
MT).
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3.3.5 Application of immuno-detection and semi-quantitation using AMDEX 
Sample preparation
The optimised method for the immuno-deteetion and semi-quantitation of apo B-48 
using AMDEX method was applied to samples taken from the ethanol study (Chapter 
5.0). These samples included whole plasma, TAGRL and TAGPL (infranatant) 
fractions, all of which contained a high concentration of other proteins. It was also 
used to detect the presence of apo B-48 in very dilute samples derived from an 
iodixanol gradient used to separate the TAGRL subclasses by another investigator. 
Before these experimental samples were analysed, lymph diluted with various 
volumes of Optiprep^^  ^solution (iodixanol) were compared with lymph diluted in TBS 
buffer on SDS-PAGE, followed by immuno-detection in order to check whether 
Optiprep^"  ^solution would interfere with the immuno-detection of apo B-48.
A standard volume of each test material (25 pi) of lymph, plasma and TAGPL 
samples was added to 100 pi of sample buffer, whereas 25 pi of each pool from the 
iodixanol gradient (TAGRL subclasses) were added to the same volume of sample 
buffer. After heating at 95°C for 4 minute and centrifugation at 13,000 rpm for 3 
minutes (2.1 x 10"^  gmax.min), the mixtures were electrophoresed using 20 pi for 
lymph, 30 pi for whole plasma and TAGPL, and 40 pi for each TAGRL pool.
Comparison o f apo B-48 postprandial pattern in whole plasma and TAGRL fraction 
measured by immunoblotting
Figure 3.7 and 3.8 show the postprandial patterns for whole plasma and the TAGRL 
fractions respectively obtained from a healthy subject after the consumption of a meal 
containing 44 g fat without ethanol. The apo B-48 postprandial profile obtained from 
TAGRL fraction was higher than whole plasma. The time to reach peak levels was 
also earlier in the whole plasma compared to TAGRL fraction (Figure 3.9).
8 9 10 11 12
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Figure 3.7. Apo B-48 bands in whole plasma samples obtained from subject 1 (ethanol 
study) after a meal containing 44 g of fat. Lane 1 and 2 are fasting samples, lane 3 is a 
sample taken 30 minutes after the meal, lane 4 to 11 are samples taken at hourly 
intervals after the meal and lane 12 is a standard (lymph) enriched with apo B-48.
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Figure 3.8. Apo B-48 bands in TAGRL fractions obtained from subject 1 (ethanol 
study) after a meal containing 44 g of fat. Lane 1 is a standard (lymph) enriched with 
apo B-48, lane 2 and 3 are fasting samples, lane 4 is a sample taken 30 minutes after 
the meal, and lane 5 to 12 are samples taken at hourly intervals after the meal.
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Figure 3.9. Comparison of apo B-48 postprandial response in whole plasma and the 
TAGRL fraction obtained from subject 1 (ethanol study) after a meal containing 44 g of 
fat measured after immunoblotting.
Using AMDEX immuno-detection, apo B-48 was detected and measured at all time 
points in postprandial TAGPL fractions (Figures 3.10 and 3.11). The results also 
showed that there was no interference by Optiprep^^ solution in SDS-PAGE and 
Western Blotting (Figure 3.12) and that apo B-48 was present in all pools of TAGRL 
subclasses (Figure 3.13).
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Figure 3.10. Apo B-48 bands in TAGPL fractions obtained from subject 4 (ethanol 
study). Lane 1 to 5 are samples at 0, 60, 180, 360, and 480 minutes respectively 
before and after a meal containing 44 g of fat without ethanol (control). Lane 6 to 10 
are samples at 0, 60, 180, 240, 360, and 480 minutes respectively before and after a 
meal containing 44 g of fat together with ethanol. Lane 11 is a standard (lymph) 
enriched with apo B-48
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Figure 3.11. Comparison of apo B-48 postprandial pattern in the TAGPL fraction 
obtained from subject 4 (ethanol study) after a meal containing 44 g of fat with or 
without ethanol measured by AMDEX immuno-detection.
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Figure 3.12. Apo B-48 bands in a serial dilution of lymph diluted in PBS or Optiprep™.
Lane 1 and 7 are Rainbow coloured marker, lane 2 and 8 are neat lymph, lane 3 to 6 
are lymph diluted in PBS with the ratio 2:1, 4:1, 5:1 and 10:1 respectively, and lane 9 
to 12 are lymph diluted in Optiprep™, with the ratio 2:1, 4:1, 5:1 and 10:1 
respectively.
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Figure 3.13. Apo B-48 bands in samples obtained from TAGRL subclasses. Lane 1 is a 
standard (lymph) enriched with apo B-48, lane 2 to 5 are pool 1, pool 2, pool 3 and 
pool 4 respectively from control, lane 6 to 9 are pool 1, pool 2, pool 3, and pool 4 
respectively from ethanol study.
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3.3.6 Specific immuno-detection and semi-quantitation of apo B-48 and apo B 
100 on the same blot
Using the immuno-detection technique developed for apo B-48 the immuno-detection 
of apo B-lOO was investigated using several dilutions of a polyclonal antiserum 
against apo B which could easily detect apo B-48 and apo B-100 in the same sample 
by SDS-PAGE and immunoblotting. The method was similar to that used for apo B- 
48 as shown in the simplified flow chart (Figure 3.14).
Western Blot
I
i) Rabbit anti-apo B-48 
(1:10,000)
ii) Goat anti-rabbit IgG 
-HRP (AMDEX) 
(1:10,000)
T
15 ml TBS
Polyclonal sheep anti-apo B 
(1:1,500)
Donkey anti-sheep IgG 
-HRP
(1:5,000)
15 ml TBS
I
ECL
Figure 3.14. Outline for immuno-detection of apo B-48 and apo B-lOO on the same 
sample after Western blotting.
This technique was applied to measure apo B-48 and apo B-lOO levels in TAGRL 
fractions from one subject who participated in the ethanol study. The apo B-48 and 
apo B-lOO bands were distinctly separated and easily identified using AMDEX 
immuno-detection with a very clear background (Figure 3.15).
The level of apo B-48-containing lipoproteins and apo B-lOO-containing lipoproteins 
in the TAGRL fraction were increased after the subject ate the test meal containing 44 
g of fat with (A) or without (C) ethanol consumption (Figure 3.16). The
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concentrations were also generally higher when ethanol was consumed (A) with the 
test meal, compared to control (C). Furthermore, the level of apo B-48-containing 
lipoproteins remained higher at 8 hours after ethanol intake together with meal. In 
contrast, apo B-lOO-containing lipoproteins had returned to baseline levels after 8 
hours.
1 2 3 4 5 6 7 8 9 10 11 12 13
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Figure 3.15. Immuno-detection of apo B-48 and apo B-lOO in TAGRL fractions 
obtained from subject 4 (ethanol study). Lane 1 was loaded with 20 pi of a standard 
(lymph) enriched with apo B-48. Lanes 2 to 7 were loaded with 30 pi of the TAGRL 
samples taken at 0, 60, 180, 240, 360 and 480 minutes respectively before and after a 
meal containing 44 g of fat without ethanol (control). Lane 8 to 13 were the samples 
at 0, 60, 180, 240, 360, and 480 minutes respectively before and after a meal 
containing 44 g of fat together with ethanol.
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Figure 3.16. Apo B-48 (CM) and apo B-lOO (VLDL) in the TAGRL fraction obtained 
from subject 4 (ethanol study) after a meal containing 44 g of fat either with (A) or 
without (C) ethanol measured by AMDEX immuno-detection.
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3.4 DISCUSSION
Despite substantial clinical evidence to suggest a causal role of postprandial 
dyslipidaemia in CHD, studies of CM and CM remnants metabolism in vivo have 
been hampered by the very low concentration of apo B-48, particularly in the 
postabsorptive state. Because sensitivity has been an important limitation of the 
existing procedures used in quantifying apolipoprotein B-48, the main objective of 
this section was to optimise a procedure that permits quantification of apo B-48 in a 
very dilute solution.
Most methods available for the quantitation of apo B-48 are indirect methods, which 
depend on separation of apo B-48 from apo B-lOO and simultaneous measurement of 
both apolipoproteins. As reviewed by Lee (1996), amino acid compositions show that 
the average aromatic amino acid content of apo B-48 is 12% lower than that of apo B- 
100. If all aromatic amino acids have equal dye binding capacity and if no oxidation 
occurs during SDS-PAGE, one would expect the chromogenicity of apo B-48 to be 
12% lower than that of apo B-100. If the oxidizing agent, ammonium persulfate, is 
not removed from the polyacrylamide gel, the chromogenicity of apo B-48 would 
further decrease after electrophoresis. Because apo B-48 moves faster than apo B-100 
in the electrophoretic field, the former is exposed to oxidants first. This may have 
resulted in an underestimation of apo B-48 when the apo B-48/apo B-100 ratio is 
calculated directly from the areas under the peaks of the protein bands after gel 
scanning.
This study compared several immuno-detection protocols that are in ^videspread use 
for their ability to quantitate protein transferred from a polyacrylamide gradient gel to 
a nitrocellulose sheet. Compared with the other techniques, visualisation of proteins 
by method D (AMDEX) was the best method with high sensitivity and without a 
significant increase in the background and a reduced assay time. The ExtrAvidin- 
peroxidase method (Method B) had as high a sensitivity for apo B-48 as AMDEX, but 
the background produced was too high. Furthermore, it took an additional step to 
detect the labelled proteins. The ABComplex-HRP (Method C) produced a clear 
background but the sensitivity was low and it too needed an extra step. The 
secondary antiserum-HRP (Method A) had the poorest sensitivity in detection of apo
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B-48 even though, as with AMDEX, only two steps were required. The ability to 
detect apo B-48 even in very small quantities with AMDEX down to 0.004 pg is 
because this conjugate utilises a hydrophilic straight chain dextran back bone to which 
hundreds of HRP molecules are covalently coupled, and which is linked directly to a 
specific goat anti-rabbit IgG.
Apo B-48 in the whole plasma and TAGPL (infranatant) could not be measured 
reliably by ELISA. This was explained by interference m the ELISA by some 
unknown components in the plasma reacting vdth the secondary antibody as the entire 
plasma sample is placed in each well without prior separation of the plasma proteins 
from the apo B-48. This could produce artificially high apo B-48 results in the 
plasma and infranatant if these components were able to bind to the ELISA plate and 
were recognised by the secondary antibody. An attempt to use the anti-apo B-48 
directly conjugated to an HRP label in the ELISA developed by Isherwood (1996) to 
remove the need for a secondary antibody to IgG were unsuccessful. The antisera had 
to be affinity purified before it could be conjugated to the HRP and this diluted the 
antisera, hence the standard curve for ELISA was very shallow. Immuno-detection 
using the AMDEX product as shown in this study was very sensitive with a very low 
background. It might give the possibility of using the AMDEX product as the 
secondary antibody in the ELISA with reduced interference.
Method B which used the Extra-Avidin peroxidase system, instead of AMDEX, 
produced a high background although the intensity of the apo B-48 band was very 
clear and distinct from other bands and more diffuse. This technique, together with 
the AMDEX based method, could be used to detect the presence of apo B-48 in very 
dilute samples such as TAGRL pools taken from an iodixanol gradient of TAGRL 
subclasses, which could not be detected by ELISA. These methods also avoid the 
need to delipidate samples for quantitation when using SDS-PAGE. Delipidation 
could cause differential losses of apolipoprotein particularly apo B-48 because apo B- 
48 has a slightly higher solubility than apo B-100. There is also a risk of exposure of 
the samples to organic solvents containing oxidants or contaminants (Lee, 1996).
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By most methods, apo B-48 is usually not detected in the fasting plasma of a normal 
subject. The finding of apo B-48 in fasting plasma is interpreted as a result of a defect 
in CMR removal (Nestel et al., 1983). How^ever, in these studies apo B-48 has been 
shown to be present in the plasma and TRL fraction of healthy subjects, after an 
overnight fast. This result supports those of Cohn et al (1988) and Smith et ah 
(1997) but contrasts with the observations by Kane et al (1980). Since the clearance 
of CM from the circulation appears to be a very rapid process and since there is now 
good evidence to suggest the human liver does not synthesis apo B-48 (Edge et al, 
1985), it is probable that a low basal rate of apo B-48 secretion from the intestine 
accounts for the small amount of this apolipoprotein in the plasma TAGRL fraction 
during fasting (Cohn et a l, 1988).
Peel et al. (1993) demonstrated that there was no cross-reactivity of anti-apo B-48 
with apo B-100 in a denatured, linear form. This indicates that the antiserum reacts 
with the negatively charged carboxyl group on the amino acid ile-2152 in apo B-48. 
On the apo B-100 molecule the carboxyl group on ile-2152 is bound in a peptide 
bond. The sequence of amino acids in the carboxyl-terminal of apo B-100 is different 
from the heptapeptide used to raise the apo B-48 antiserum and therefore there is no 
cross-reactivity in the immunoblot system (Isherwood, 1996). The present study 
further supports this finding.
The postprandial increase in TAGRL apo B after a fat containing meal was due to a 
rise in the concentration of both TAGRL-apo B-100, and apo B-48. In addition, this 
experiment showed that compared to VLDL, CM appears to make a significant 
contribution to postprandial triacylglyceridaemia.
The present technique of immuno-detection and quantitation needs ftuther 
improvements such as development of a proper standard curve for apo B-100 and apo 
B-48 using purified samples in which the apo B-100 and apo B-48 concentrations are 
already known.
In conclusion, the sensitivity of this immuno-detection enabled quantitation of fasting 
plasma and TAGRL apo B-48 samples that could not be achieved by SDS-PAGE and 
Coomassie staining. The sensitivity of the system was also superior (25-50 fold) to
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that previously reported by Karpe and Hamsten, (1994) (0.2 p,g) and Kotite et al. 
(1995) (0.1 pg). This technique could also be applied to measure apo B-48 in 
different groups of subjects including hyperlipidaemic or dyslipidaemic diabetic 
subjects who have a higher risk of CAD.
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CHAPTER FOUR
IMMUNO-LOCALISATION OF 
APO B-48 AND APO B-100 IN HUMAN
TISSUES
4.1 INTRODUCTION
4.1.1 Atherosclerosis
The walls of an arterial vessel generally consist of three layers: an inner (intima) layer 
which is normally narrow but become thickened by a fibrous cushion; the media 
(middle) layer which is composed of elastic fibres and smooth muscle cells (SMC), 
and: an outer layer, the adventitia, a loose network of collagen and elastic fibres 
containing lymphatics, nerve fibres and nutrient vessels (vasa vosarum) (Figure 4.1).
E lastica  __
interna
Intima
* M edia
-.T.:.:;-
Vasa vasorum
Adventitia
Figure 4.1 Segment of a cross-sectioned human aorta
(Sobotta and Hammersen, 1976)
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Atherosclerosis is the scientific term given to the process whereby a blood vessel 
becomes narrower due to the deposition of lipids and other substances. It gradually 
affects the fimctioning of heart, brain, kidney or more rarely intestine and spinal cord. 
The hallmark of the atherosclerotic process and the characteristic that distinguishes it 
fi-om other inflammatory processes is the presence of both intra- and extra-cellular 
lipid deposits (Guyton and Klemp, 1989).
4.1.2 Atherogenic potential of CM to contribute to atherosclerosis
Elevated plasma levels of TAGRL, including VLDL, CM and their remnants are now 
established as atherogenic (Gianturco and Bradley, 1991). The importance of these 
lipoproteins as predisposing factors in atherosclerosis are either through indirect 
mechanisms, such as by influencing compositional changes in other cholesterol- 
containing lipoproteins such as LDL and HDL (Miesenbock and Patsch, 1992) as 
explained in section 1.5, and/or directly through the delivery of their cholesterol and 
lipid to the arterial wall which could then convert macrophages into foam cells and 
cause endothelial dysfunction (Zilversmit, 1979; Mamo and Wheeler, 1994; Gianturco 
and Bradley, 1992). However, the processes that lead to their accumulation in the 
artery wall are still unclear.
4.1.3 The direct role of CM in atherosclerosis
Zilversmit (1979) described atherosclerosis as a ‘postprandial phenomenon’ and 
proposed that atherogenesis involved the binding of CM to the arterial surface, the 
hydrolysis of TAG by arterial LPL and the subsequent internalisation of cholesterol- 
enriched CMR by arterial SMC.
This proposal was consistent with a number of studies that demonstrated a possible 
direct relationship between CM/CMR and CHD. In m vitro studies by Goldstein et ah 
(1980) cholesterol-enriched CMR were shown to be the most potent of all lipoprotein 
species in inducing the transformation of cultured human macrophages to foam cells. 
This was confirmed in an investigation done by Ellsworth et al (1986), who showed 
that TAGRL, especially CMR, which are found in abundance in the postprandial 
phase, promote the rapid accumulation of cholesterol within arterial cells in culture.
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Proctor and Mamo (1998) using rabbit fiirther demonstrated that fluorescently- 
labelled CMR rapidly penetrate arterial tissue, but the efflux is not complete and as a 
consequence, focal accumulation of CMR occurs within the sub-endothelial space. 
The degree of remnant entrapment within the sub-endothelial space is also thought to 
influence the susceptibility to atherogenesis in arteries of patients with chronic 
hyperglycaemia (Proctor et al., 2000).
Even though CM contain only ~5% cholesterol compared to LDL (-50%), their half- 
life in the circulation is shorter at less than 5 minutes (Redgrave, 1983) compared to 
that of LDL, which have a mean residency time of up to 24 hours (Soutar et a l, 
1977). This indicates that more cholesterol is metabolised via CM over a day than via 
LDL (Proctor and Mamo, 1996). Furthermore, the data from Shen et al. (1977) as 
summarised in Table 4.1 clearly shows that on a per particle basis, a TAGRL particle 
carries many more molecules of cholesterol than an LDL particle. Hence if a TAGRL 
or its cholesterol entered the intima and was taken up by a macrophage, it would 
deliver a very significant amount of cholesterol to the macrophage which could 
accumulate to produce a fatty lesion (Ooi and Goi, 1998).
Table 4.1 Number of molecules of components per lipoprotein particle and percentage 
of particle dried weight (in parenthesis) (Shen et a l, 1977)
LIPOPROTEIN TAG CE EC
HDL 8.3-19 8-90 1.2-50
(4.1-4.6) (3-16) (0.3-5.4)
LDL 298 1,310 475
(11) (37) (8)
VLDL 11,500 3,600 3,539
(50) (12) (7)
CM 507,000 27,000 25,840
(84) (5) (2)
Abbreviation; TAG: triacylglyceride, CE: cholesterol ester, PC: free cholesterol
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4.1.4 Postulated mechanisms by which CM might be involved in the early 
stages of atherosclerosis
The potential mechanisms by which CM/CMR could be involved in the early stages 
of atherosclerosis are depicted in Figure 4.2.
In theory, lipoproteins can pass between the cells lining of the arteries and accumulate 
beneath this epithelial layer. The only exceptions are CM, which are too large to 
penetrate the pores between intact adjacent arterial endothelial cells. CM need to be 
reduced in size by hydrolysis before they can be delivered to the sub-endothelial cells. 
However, their size can vary depending on diet and stage of catabolism and it is 
possible that CM might gain access to arterial tissue after sufficient conversion to 
smaller particles (CMR) by LPL activity on the vessel wall (Mamo et ah, 1997). 
Furthermore, CMR with a diameter of 40-45 nm are sufficiently small for delivery via 
transeytosis vesicles (about 70 nm diameter) which form on the intimai surface of 
endothelial cells (Simionescu and Simionescu, 1991). Transeytosis is thought to be 
the primary route of lipoprotein delivery to the arterial cell. However, this route is 
dependent on plasma lipoprotein concentration, access of lipoprotein to vesicle and 
the rate of vesicle formation. In addition, large arterial vessels also possess a 
significant vasa vasorum (capillary-like network) which represent an alternative route 
by which hpoproteins might be delivered to the intima (Heistad and Marcus, 1979). 
There is also evidence to suggest that FF A, generated during hydrolysis of TAGRL by 
LPL on the arterial endothelium are cytotoxic to endothelial cells in vitro (Chung and 
Segrest, 1991). Damaged endothelial cells allow the transfer of macromolecules such 
as cholesterol-rich remnant hpoproteins across the endothehal monolayer (Zilversmit, 
1973; Hennig et al., 1985; Chung et a l, 1995).
CMR that penetrate the arterial wall have been shown to be selectively retained when 
compared to several other types of lipoproteins (Mamo and Wheeler, 1994). Greater 
retention could reflect their inherent size, their tendency to bind with high affinity to 
extra-cellular connective tissue components such as collagen and their susceptibility 
to aggregation and fusion. Hurt-Camejo et al (1997) have suggested that heparin- 
binding regions of LDL that are predominantly found near the carboxyl terminal 
region of apo B are responsible for LDL retention within arteries. However, apo B-48
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lipoproteins that do not have this region are also atherogenic (Veniant et al, 1997). 
Studies by Goldberg et al. (1998) show that despite the lack of the carboxyl-terminal 
portion of apo B (52%), the apo B-48 LDL from mice have been shown to bind to 
heparin-affmity gels as well as apo B-IOO-LDL. They suggest that the NH2-terminal 
region of apo B (NTAB) is sufficient for the interaction of lipoproteins with 
glycoconjugates produced by endothehal and SMC. They have also shown that 
NTAB bind to heparin affinity gels with an affinity equal to or greater than apo B- 
100-containing LDL. This could explain why apo B-48 and apo B-lOO-containing 
hpoproteins are equally atherogenic. This NTAB region has also been shown to bind 
to LPL (Sivaram et al, 1994), to interact with the scavenger receptor (Ramprasad et 
al, 1995), and to bind to a TAGRL receptor on macrophages (Kreuzer et a l, 1997).
CMR might be a preferential substrate for macrophages compared to native LDL (not 
oxidized) (Proctor and Mamo, 1996). As shown by Whitman et al. (1998), native 
CMR can induce foam cell formation without any modification, in contrast to LDL- 
particles which must be modified (e.g. oxidised-LDL) before inducing transformation 
of monocyte/macrophage into foam cells.
Several receptor-mediated mechanisms, as explained in section 1.3, have been 
proposed for CMR uptake by macrophages and the arterial wall. Koo et al. (1988) 
and Bowler et al. (1991) suggested that the LDL (apo B-100/E) receptor is the main 
mechanism. This receptor could also be involved in 90% of CMR degradation in 
rabbit aortic SMC (Yu and Mamo, 1996). In possessing apo E, CMR share a common 
binding site with LDL for the LDL receptor (Windier et al, 1980; Chen and Reaven, 
1991) since the LDL receptor binds lipoproteins containing either apo B-lOO or apo E. 
The binding affinity of LDL-receptors for lipoproteins containing apo E is many times 
higher than that for lipoproteins containing apo B-lOO alone (Hui et a l, 1984; Brown 
et a l, 1989). This enables apo E-containmg lipoproteins to bind to LDL-receptors 
with 10-to 100-fold greater affinity than LDL, which have only apo B-lOO (Innerarity 
and Mahley, 1978). The higher affinity of apo E-containing lipoproteins is due to the 
interaction of four apo E molecules with four LDL-receptors. This was shown in 
studies by Mamo and Wheeler (1994) who demonstrated that CMR uptake in the 
thoracic aorta of conscious rabbits is approximately 10-fold more than LDL and 4- 
fold greater than CM. Fielding (1992) calculated that one CMR particle contains
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63,000 molecules of cholesterol, some 42-fold more than one LDL, so they can 
suppress LDL-receptor activity significantly more than LDL. Hence, CMR act more 
effectively than LDL in causing cholesterol uptake in arterial SMC (Floren et a l, 
1981). In addition to the LDL-receptor, Gianturco et al (1994) proposed another 
receptor in human macrophages, which is an apo E-independent receptor pathway. 
This receptor has been cloned recently and named as the apo B-48 receptor (apo B- 
48-r) and could bind to TAGRL through apo B-48 (Brown et al, 2000). The uptake of 
TAGRL by this receptor rapidly converts macrophages and apo B-48-receptor 
transfected Chinese hamster ovary cells in vitro into lipid-filled foam eells, as seen in 
atherosclerotic lesions. They suggested that the normal role of the apo B-48-r might 
be to provide essential lipids to reticulo-endothelial cells. However, if overwhelmed, 
foam cell formation, endothelial dysfunction and atherothrombogenesis may ensue, 
representing another mechanism for cardiovascular disease risk of elevated TAG.
Mamo and Wheeler (1994) also proposed another route of CMR uptake by 
macrophages. Pro-inflammatory properties possessed by CMR could trigger an 
inflammatory response, promoting macrophage recruitment and thereafter degradation 
via phagocytosis which is a natural property of macrophages in dealing with an 
inflammatory response (Mamo et a l, 1996). This mechanism is an actin-dependent 
pathway. It is not dependent on the intracellular cholesterol concentration and would 
be initiated after binding to a cell surface protein, which is distinct from the LDL- 
receptor, LRP or scavenger receptors, which all utilise an endocytotic mechanism.
Macrophage-derived monocytes, produced as a result of the inflammatory effect of 
CMR, can express a variety of factors, including growth factors and cytokines. One 
effect of cytokines is to stimulate endothelial cells to express adhesion molecules, 
which leads in turn to the adherence of more blood monocytes (Barter and Rye, 
1996). In addition, the production of superoxide free radicals by macrophages derived 
from cellular uptake of CMR might also contribute to plaque destabilisation as a 
consequence of cell death (Yu and Mamo, 2000).
The substantial quantities of LPL synthesised by macrophages as shown by Khoo and 
CO workers (1981), ftirther support a possible role of CM in arterial cholesterol 
accumulation. In vitro, LPL seem to metabolize CM avidly, irrespective of the
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intracellular cholesterol concentration, and the FFA thus generated have been shown 
to be toxic towards macrophages (Chung et a l, 1989; Yu and Mamo, 1996), This 
FFA may also serve as potential ligands for peroxisome proliferator-activated 
receptors (PPARy) which have recently been implicated in foam cell formation (Sattar 
et a l, 1998). Furthermore, it has been postulated that FFA generated by LPL may be 
transferred to the surface monolayer phospholipids of these lipoproteins, increasing 
the density of negative charge on the surface of TAGRL remnants. This in turn 
activates faetor VII through the intrinsic coagulation pathway and activates factor XII 
(Silveira et al, 1994; Kapur et al, 1996). The presence of LPL in the vessel wall has 
also been demonstrated to increase the retention of lipoproteins by proteoglycans of 
the subendothelial cell matrix (Saxena et al, 1992) and aortic segment, and also aids 
the uptake of lipoproteins by macrophages. A pro-atherogenic role for LPL in the 
vessel wall has been supported by other investigators (Clee et ah, 2000; Van Eck et 
al, 2000). However, the potential of macrophage-LPL expression in artery walls to 
promote atherogenesis may be limited to macrophage-rich lesions (Babaev et al, 
2000).
CMR might also stimulate endothehal expression of adhesion molecules and the pro- 
thrombotic factor, plasminogen activator inhibitor-1 (PAI-1) (Sattar et al, 1998). 
This group demonstrated impaired endothelium-dependent vascular relaxation 
(endothelium dysfunction) at a plasma concentration of between 500-2000 mja g TAG 
of remnant lipoprotein/ml in the patients with CHD (Doi et a l, 1998). These workers 
suggested that the impairment may be independent of receptors and that lipids in the 
remnants seem to contribute to the inhibitory effect. A study by Grieve et al (1998) 
on rat aorta observed similar results. Impaired endothelium function caused by CMR 
may promote the development of atherosclerosis through its effects on vasoregulation, 
platelet and monocyte adhesion, vascular SMC growth, and coagulation. In addition, 
recently Kawasaki et al. (2000) demonstrated the ability of CMR to induce apoptosis 
in vaseular endothelial cells.
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4.1.5 AIMS
As mentioned earlier, CM/CMR may be directly or indirectly atherogenic. Hence, the 
objective of this current study was to provide evidence to show that they contribute 
directly to the formation of atheroselerotic plaque in human. The principle aim was to 
localise apo B-48 containing lipoproteins (CM/CMR) within different stages of 
atherosclerotic lesions and to investigate the variations, if any, that may occur in their 
distribution pattern. To do this, anti-apo B-48 together with anti-apo B-lOO (MB-47) 
were used as specific markers of intestinal and hepatic lipoproteins respectively. The 
specificity of these antibodies was also investigated in human ileum and liver tissues.
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4.2 MATERIALS
ABComplex/HRP, biotinylated-swine monoclonal anti-rabbit IgG, biotinylated rabbit 
anti-mouse IgG, monoclonal mouse anti-human macrophage, HAM-56 and diamino 
benzidine tetrahydrochloride (DAB) chromogen tablets were obtained from DAKO 
Ltd., (Denmark House, Angel Drove, Ely, Cambridgeshire, UK). Sodium hydroxide 
(NaOH), Tris pH 7-9, Tween'^  ^20, 3-amino propyltriethoxysilane (APES), 3-amino- 
9-ethylearbazole (AEC), molecular sieve beads, pig serum, hematoxylin, glycerol 
jelly and microslides with finely ground edges, pre-cleaned were purchased were 
obtained from SIGMA Chemical Company Ltd., (Poole, UK). Disodium carbonate 
(NaiCOs), sodium chloride (NaCl), disodium hydrogen phosphate (Na2HP04), 
potassium chloride (KCl), potassium dihydrogen phosphate (KH2PO4), methanol, 
citric acid, acetone, hydrochloric acid (HCl), xylene and alcohol were supplied by 
Fisher Scientific International Company, (Loughborough, UK). Hydrogen peroxide 
(H2O2) and gelatin (biochemical grade), sodium hydrogen carbonate (NaHCOs), were 
from Fisons Scientific Equipment, (Loughborough, UK). Microscope coverslips were 
purchased from Chance Propper Ltd., (West Midlands, UK). Polyclonal rabbit anti- 
apo B-48 antiserum was produced by Nutritional MetaboHsm Research Group, School 
of Biological Sciences, University of Surrey Guildford, Surrey. Monoclonal mouse 
anti-apo B-lOO, MB-47 antiserum was gifted from L.K. Curtiss, Scripps Research 
Institute, California.
Tissue samples studied consisted of bloeks of fatty streaks and atherosclerotic lesions 
from human aorta and coronary. All these blocks were kindly given from Professor 
Mike J. Davies from Histopathology Department, Medieal School, St George’s 
Hospital. Tissues studied also included human ileum and liver which were obtained 
by Professor Roger King (University of Surrey).
4.3 METHODS
4.3.1 Preparation of the slides
The pre-eleaned glass slides were immersed in 2% (v/v) of APES in acetone for 5 
seconds, allowed to drain (but not dry), followed by washing in dry acetone (acetone
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added with molecular sieve), and lastly rinsed with running distilled water. APES is a 
strong adhesive reagent and functions to prevent detachment of tissue section from 
slides. These slides were allowed to air dry prior to use. Tissues in paraffin blocks 
were cut to give 5 pm thick sections on a microtome and mounted on APES coated 
thin glass slides. These slides were then air-dried and incubated at 37°C overnight 
before use.
4.3.2 Immunolabelling
Paraffin sections on the slides were routinely dewaxed in xylene (4 minutes), and 
dehydrated with graded alcohol, 100%, 80% and 50% (v/v) for 30 second each, 
followed by a rinse with distilled water for another 60 seconds and 10 mmol/1 
phosphate-buffered saline, pH 7.4 (PBS) prior to immunocytochemical treatment. All 
subsequent incubations were done in a moist atmosphere to prevent the tissue sections 
from drying out and to aid the staining process. After 30 minutes incubation with 
0.3% (v/v) H2O2 in absolute methanol to queneh the endogenous peroxidase activity, 
tissue sections were immersed in boiling citric acid buffer (10 mmol/1, pH 6.0) for 30 
minutes to expose the antigenic sites that might be hindered during the embedding 
process and to allow access of antibodies to the cell contents. The tissue sections 
were washed with PBS. Then 5% (v/v) of pig serum in PBS containing 1% (w/v) 
gelatin and 0.05% (v/v) Tween'^  ^20 (PBS-GT) was applied for 30 minutes to block 
non-specific binding. Removal of this normal serum was followed by incubation with 
the primary and then the biotin-labelled secondary antibody at the dilutions indicated 
in Table 4.2 in PBS-GT.
Table 4.2 The antibodies and dilutions used in immunocytochemical analysis
PRIMARY ANTIBODY WORKING
DILUTION
SECONDARY
ANTIBODY
WORKING
DILUTION
Polyclonal rabbit anti- 
apo B-48
1:1000 Biotinylated swine 
anti-rabbit IgG
1:200
Monoclonal MB-47 
mouse anti-apo B-lOO
1:500 Biotinylated rabbit 
anti-mouse IgG
1:200
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For negative control purposes, primary antibodies were substituted with normal serum 
or the other antibodies with irrelevant specificity. The tissue sections were incubated 
with primary antibodies for an hour at room temperature and then overnight at 4°C. 
After rinsing with PBS, secondary antibody was applied for another hour. Following 
the washing with PBS, avidin-biotinylated peroxidase complex (ABComplex), that 
was prepared at least 30 minutes prior to use in 1:1 ratio in PBS-GT buffer, was 
carefully layered onto all the tissue sections and incubated for a further 30 minutes. 
After washing with PBS, an AEC chromogen substrate was applied to all the sections 
for 10-15 minutes (Graham et a l, 1965). The addition of H2O2 to this substrate 
resulted in a red-brown colour product. The reaction was terminated by rinsing with 
distilled water. DAB chromogen substrate, to which 10 pi of absolute H2O2 has been 
added, was also used in some of the experiments. This yielded an insoluble brown- 
end product at the site of the target antigen after 5-10 minutes. The slides were rinsed 
gently with distilled water, and then counter-stained with haematoxylin, dehydrated in 
sequential alcohol, cleared in xylene followed by mounting in glycerol jelly and the 
application of cover-slips. A schematic of the immunocytochemical procedure is 
given in Figure 4.3.
In addition, macrophages were localised by using cell-specific monoclonal antibodies 
HAM-56, which recognize human macrophages (Gown et a l, 1986). HAM-56 was 
used at a titre of 1:200 and the slides were treated by the same procedure as described 
above.
Double staining for macrophage either with apo B-48 or with apo B-lOO was 
performed as follows. Slides were incubated with the first antibody against the 
macrophages, HAM-56, visualised by the addition of DAB (details as previously 
described) and then rinsed with PBS. Following renewed blocking with 5% (v/v) pig 
serum, slides were incubated with one of the two primary antibodies against apo B-48 
or apo B-lOO, respectively. Shdes were then incubated with biotin-conjugated anti­
rabbit or biotin-conjugated anti-mouse antibody, followed by avidin biotin peroxidase 
reagent, and the reaction products were visualised with AEC. Finally, the slides were 
counterstained with hematoxylin and mounted.
I l l
EITHER APO B-48 OR APO B-lOO
n
/ \
n
DAB/AEC
n
INCUBATE WITH 
SPECIFIC 
ANTIBODY
1
INCUBATE WITH 
BIOTINYLATED 
ANTI SPECIES 
IgG
INCUBATE WITH 
AVIDIN-BIOTIN 
PEROXIDASE 
COMPLEX
LOCATE WITH 
PEROXIDASE 
SUBSTRATE 
(DAB/AEC) DAB/AEC
Apo B-48 Anti apo B-48 Apo B-100
Peroxidase Biotinylated anti-species IgG
Figure 4.3 Immunolocalisation of apo B-48 and apo B-lOO
Anti apo B-100
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4.4 RESULTS
To illustrate the general histology of tissue at low power, hematoxylin and eosin- 
stained sections have been included with immunocytochemistry stained sections.
4.4.1 Ileum
The results with sections of ileum are shown in Figure 4.4 with the general histology 
in Figure 4.4 (a). The control sections (Figure 4.4b), are negatively stained as is the 
test for apo B-lOO (Figure 4.4d), whereas an intense brown stain is present in the 
section treated with anti-apo B-48 (Figure 4.4c) in enterocytes cells (e), indicating the 
presence of apo B-48 in these cells. However, apo B-48 was not detected in mucous 
(goblet) cells (G), which are also found in the villi of ileum (Figure 4.4c).
4.4.2 Liver
Strong staining was evident in the hepatocytes (H) of the hver sections tested for apo 
B-lOO (Figure 4.5d). However, incubation of this section with anti-apo B-48, yielded 
only a very pale colour reaction (Figure 4.5c) which indicated a low level of apo B-48 
in this tissue.
4.4.3 Fatty streak
The earliest development of an atheromatous lesion is the accumulation of lipid in the 
myointimal cells, which develops from early childhood onwards. These are termed 
foam cells. This stage is represented macroscopically by the fatty streak (Wheater et 
al, 1991). These are gray-white areas consisting of fat-filled cells, which are small in 
number and concentrated immediately under the endothelium or more deeply within 
the intima. As shown in Figure 4.6 (a), the intimai thickening is largely accounted for 
by foam cells aggregated immediately beneath the endothelium. An illustration of 
fatty streaks is also inserted in Appendix II. Immunostaining of this section with 
HAM-56 showed that macrophages were detectable as foam cells near to the 
superficial of the intima (Figure 4.6b). However, apo B-48 and apo B-lOO as detected 
immunocytochemically by anti-apo B-48 and anti-apo B-lOO respectively were absent 
in these sections (Figure 4.6c and Figure 4.6d).
113
1I s
o o0 p.
1XI T3
2 1?
i-i« oa  o>
i |
^  ’o
s g
oo -Tf-
l . s «
® 'g '
II
lî
II
lîéMVMMMW'
m m
Ê % A #
»
c3
X
î io o o  9 , 
o ^
II
I
I I
A  a
Xm<Nf l(U
S 'S ?
B3
m
o3 m
. %
- I
s i
11 
cS f  
% % 
H I" 
S i -
03 O
I  
I
o _
I I
O O
o
PQ
II
O  (U
Ph h  
S ' S '
f
I
i Xo
a
a
B3
\ô
3Dt
C/DO<U
I
I
o3
<§
00
3
I
H  =
S 3
4.4.4 Aorta
Figures 4.T-4.9 show the changes in the aorta during the development of 
atherosclerosis. In Figure 4.7 (a), a fibrous tissue, which contains SMC as the main 
component of the media, migrates into the intima when the internal elastic lamina is 
disrupted. This thickening of intima involves accumulation of lipid as shown by the 
presence of macrophage in this area (Figure 4.7b).
Immunoperoxidase staining of these aortic sections with antibody apo B-48 shows 
specific staining in the middle of the intima (Figure 4.7c). A similar location of apo 
B-lOO was observed in this section (Figure 4.7d).
The continuous migration of SMC fi"om the media together with their proliferation 
within the intima is seen in Figure 4.8 (a). The elaboration of extracellular connective 
tissue components of collagen and elastin produce dense fibrous tissue as shown in 
this figure. New elastic fibres are concentrated in the deeper half of the intima.
These sections show that as well as being in the middle of the intima, apo B-48 was 
also present in the surface layer of the media layer (Figure 4.8c). Apo B-lOO as 
detected by MB-47 antibody, was localised in the area surrounding the plaque and 
with less intensity in the SMC near the superficial region of the intima (Figure 4.8d).
As the lesion progresses (Figure 4.9a) by further accumulation of intracellular lipid, 
foam cells (F) break down and liberate fi-ee lipid (L) into the intima. The build-up of 
fi*ee lipid produces a cleft ( C ). This cleft contained crystals of cholesterol and fatty 
acids. In these aortic sections both apo B-48 and apo B-lOO were detected in the 
intima particularly at the section rich in foam cells for apo B-48 (Figure 4.9c, d).
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4.4.5 Coronary artery
The photomicrograph of a coronary artery (Figure 4.10a) shows that the formation of 
a large plaque of atheroma in the intima can greatly reduce the size of the lumen (LU). 
Also shown here is the media (M) (pink) which is markedly thinned, underlying the 
thick mass of atheroma. Macrophages as identified by HAM-56 were present in 
lesions rich with foam cell and lipid (Figure 4.10c and d)
The pale reddish-brown staining of apo B-48 was observed in the foamy area of 
coronary artery tissue incubated with anti-apo B-48 (Figure 4.11b) which indicated 
the presence of a small amount of apo B-48, which was also present in the fibrous 
tissue containing SMC (Figure 4.11c). Strong staining of apo B-lOO by MB-47 was 
observed in the SMC area (Figure 4.1 Id) which is different from the location of 
macrophages.
Double staining for macrophage and apo B-48 or apo B-lOO was also performed on a 
limited number of sections by combined AEC and DAB substrates (Figure 4.12). The 
result from these experiments corroborated the above findings. Moderate staining- 
(reddish brown) from MB-47 which identifies the location of apo B-lOO, co-localised 
with marker HAM-56 (macrophage) (brown) in the foamy area but was present 
predominantly in the SMC which are located primarily in the fibrous cap of the 
plaque.
However, the results show that the combination of these two substrates, AEC and 
DAB is not recommended since the colours produced are similar, red-brown and dark 
brown, making it difficult to differentiate between the two antigens in the same tissue, 
especially for antigens co-localised at the same site.
Overall, apo B-48 and apo B-lOO were found mainly in the intima and to a lesser 
extent deep in the artery wall. In the coronary artery, apo B-lOO was observed mainly 
in the SMC area which differs from the location of macrophages.
121
e03 Ü
X
ceO<U
1
X
<D
î
i
('S
s
Xi 13
b
t
CQ
I I2 .a
o  ce
il
s - s
II
E S
1
eu 13•5-
il
II
ü DJ
oo
à
oo
m
o
E. «
f lO 
OO o
r f  r—I
çh m
o o
bû D CD
C H  H
I
fsi
t ‘
îa
ota
2ou
a
93
Sa
X
00
m
1
4
00
s
1
<e
£a
&£
g E% H a
3 S 3
mCN
.-If "\
%
o
o
'm y
pq CQ
U (U ÛÛ ÙÛ
t t  § Ic3 cd
0> <DH H
4.5 DISCUSSION
In all control sections examined, the characteristic brown/reddish colour was 
completely absent indicating that the substrate (DAB/AEC) staining seen in the 
sections treated with immune rabbit Ig was due to an immunological reaction.
The positive reactions observed after treatment of the ileum section with anti-apo B- 
48 is consistent with the evidence that apo B-48 is synthesized in the rough 
endoplasmic reticulum of the enterocyte which are the main cells in the villus (V) or 
the ileum. The final modification of the lipoproteins occurs within the Golgi 
apparatus of this cell before release into the intestinal lymph.
Apo B-lOO was apparently absent fi-om these same cells. However, in previous 
studies by Lee and Singh, (1988) apo B-lOO was observed in human intestine Caco-2 
cells and in human plasma CM under well-preserved condition and also with CM 
analysed within a few hours of blood colleetion. This finding is consistent with 
observations by Hoeg et al. (1990) and Levy et ah (1990), who showed that both apo 
B-48 and apo B-lOO are synthesised and secreted by adult human intestine. The 
contrast between this evidence and our own results suggest that intestinal apo B-100 is 
very sensitive to proteolytic degradation and may be converted to a smaller molecular 
form resembling authentic apo B-48 (Lee, 1996). While this might give rise to a 
result with SDS-PAGE it is very unlikely to react with the anti-apo B-48 produced in 
our laboratory.
Hepatocytes (H), which are the main functional cell in the liver, were strongly stained 
for the presence of apo B-lOO, and there was also a low level of staining for apo B-48. 
Since hver is the site of synthesis of apo B-lOO and the main tissue where CMR are 
taken up, these results were as expected.
There are two predominant cell types in the atherosclerotic plaques, macrophages and 
SMC. Macrophages appear as isolated groups of round or spindle-shaped cells either 
within the intima or forming one or more layers next to the luminal surface. They 
were detected in the early lesion in the fatty streak in the superficial intima adjacent to
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the lumen. As the lesion progresses, macrophages start to accumulate around lipid 
cores of arteriosclerotic plaques in line with their function to mobilise extracellular 
cholesterol deposits through the uptake of lipoproteins, cholesterol crystals and other 
debris (Libby and Clinton, 1993). They are present in high concentrations within the 
‘foamy area’ and there are few at the necrotic core, which mostly consists of dead 
cells and free lipid. This supports the suggestion by Ross (1999) that macrophages 
have an important role in both the initiation and progression of the atherosclerotic 
lesion. Apo B-48 and apo B-lOO were detected in the intima, the same area as 
macrophages, rieh in lipid but they were not detected in fatty streak. The presence of 
apo B-48 and apo B-100 in the same area as macrophages might indicate a role for 
both apo B-48 and apo B-lOO-containing Hpoproteins in transporting lipid to 
macrophages. Co-localisation of apo B-48 in macrophage-rich areas of 
atherosclerotic lesion/plaque further suggests a potential role for CMR in the 
accumulation of cholesterol. Apo B-48 and apo B-lOO-containing particles were also 
detected in media, rich in SMC and fibrous tissue but not in the adventitia layer. SMC 
produce proteoglycans which could increase the accumulation of both apo B-48 and 
apo B-lOO containing lipoprotein through their NTAB region as described in section 
4.14 (Goldberg et aL, 1998).
Due to the absence of apo B-48 and apo B-lOO in the fatty streak, we do not know 
whether their presence in later stages of the atherosclerotic lesion was through their 
ability to penetrate the intima waU or through endothelial damaged. Autoradiographic 
analysis of the aortic distribution of lipoproteins by Mamo and Wheeler (1994) 
showed that CM/CMR and LDL had penetrated the intimai and medial tissues. The 
dehvery and retention of these lipoproteins in the intima and media were monitored 
by digital confocal microscopy (Proctor and Mamo, 1998). It is uncertain whether the 
apo B-48 localised in human tissues studied are from normal CM/CMR or from very 
small CMR which were identified by their apo B-48 content, by SDS-PAGE and 
Western Blotting by Isherwood et ah (1996) but were found in the low density 
lipoprotein (LDL) fractions. This is also supported by previous studies by Meng et al. 
(1983) that apo B-48 was detected not only in CM but also in much denser lipoprotein 
in IDL and LDL fractions in type III hyperlipoproteinemic subjects with apo E 
deficiency.
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This study fiirtheraiore does not provide information on whether the apo B-lOO 
detected was derived from VLDL, IDL or LDL. Shaikh et al. (1991) showed that 
small VLDL and IDL particles could enter the arterial wall of humans. However, 
VLDL isolated from plaque is larger in size and contains more apo E than VLDL 
isolated from plasma (Rapp et ah, 1994). In another study by Carew et al (1984) 
LDL-derived radioactivity was observed in the intima. Quite recently Boren et al. 
(1998) and Nielsen et al (1998) demonstrated that not just hver and intestine, but 
human heart also secretes apo B-containing lipoproteins. The level of human apo B- 
expression in the heart of human apo B transgenic mice is 3-4% of that produced by 
the hver (Nielsen et a l, 1998), predominantly as LDL but occasionally small amount 
of VLDL and IDL (Boren et a l, 1998). Apo B serves as a structural protein in the 
assembly of TAGRL, so they speculated that the lipoprotein secretion by the heart 
represents a mechanism for removing excess lipids from the heart. VLDL-TAG could 
also serve as an important metabohc substrate for the working heart (Evans et a l, 
2000). Hence, it is not clear whether apo B-lOO detected in the coronary arteries was 
synthesised locally or represented hepatogeneous hpoproteins that were merely within 
the extra-cehular spaces of the myocardial tissue.
In the postprandial state, the majority of the apo B-containing TAGRL is in apo B-lOO 
containing lipoproteins, whereas CM and CMR account for only 10-20% of the total 
increase in TAGRL particles after fat intake. This might explain the reason why the 
amount of apo B-48 detected by immunocytochemistry is less when compared to apo 
B-100 in coronary atherosclerosis sections. There are other reasons that might explain 
the relatively low levels of apo B-48 and apo B-lOO in the tissue shces. Since they 
occurred in the lipid-rich regions, during the dewaxing process, lipid was solubilised. 
Any apo B-48 and apo B-lOO-containing hpoprotein present in this hpid would be 
removed. As the anti-apo B-48 only recognised the negatively charged carboxyl 
terminal end of apo B-48, the process of cutting the blocked tissues into shces might 
affect this region so that it could not be recognised by anti-apo B-48. Another reason 
of low intensity of apo B-48 and apo B-lOO detected in tissue tested might also 
because apo B-48 and apo B-lOO was degraded or hydrolysed within macrophages.
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Hamsten and Karpe (1996) have claimed that plasma contains apo B-48, whereas the 
plaque does not. They suggested that CMR were not directly implicated in 
atherogenesis. These CM and large CMR are removed from plasma long before they 
attain a particle size small enough to allow them to penetrate the vascular endothelium 
(Karpe et ah, 1995). Previous studies by Guyton and Klemp (1989) however, have 
visualised in situ the lipid particles that make up the lipid core by electron 
microscopy. They found that the size of most lipid particles in the core of the lesion 
is approximately 30-40 nm in diameter. This average size is about twice the size of 
plasma LDL (~22 nm) which was considered the major source of lesion cholesterol. 
CMR are larger than LDL and are similar in size and density to the lipid particles 
found in the lipid core of lesions, so they might be one of lipoproteins involved in the 
accumulation of the lipid. The direct visualisation of apo B-48 in the present study 
provides strong evidence for the direct involvement of CM-derived particles in the 
development of these lesions.
4.6 CONCLUSION
The application of immunocytochemical techniques in the study of the distribution of 
lipoproteins within the arterial intima shows that apo B-48 derived from CM is 
present in a variety of patterns of localisation in atherosclerosis. The results support 
the body of evidence that this lipoprotein, in addition to LDL, may contribute directly 
to the development of atherosclerotic plaque in aorta and coronary arteries.
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CHAPTER FIVE
EFFECT OF ETHANOL ON POSTPRANDIAL 
LIPID METABOLISM IN MAN
5.1 INTRODUCTION
5.1.1 Ethanol metabolism
Alcohol or more precisely ethanol constitutes approximately 4-6% of the energy 
intake in the Western diet (Mitchell and Herlong, 1986) in the form of beer, wme and 
spirits. It has a higher caloric value than carbohydrate, liberating 30 kJ/g (7 kcal/g) 
when oxidised (Rissanen et a l, 1989) and is readily absorbed from the gastrointestmal 
tract, where it is absorbed into the bloodstream.
Since only 2-10% of the ethanol absorbed is eliminated through lung and kidneys, the 
rest must be oxidised and about 90% of its oxidation take places in the liver. Ethanol 
is oxidised in the liver by three enzyme systems: The first primary system, alcohol 
dehydrogenase (ADH) in the cytosol, catalyses the oxidation of ethanol to 
acetaldehyde, requiring NAD^ as an electron acceptor. Secondly, ethanol can also be 
oxidised to acetaldehyde by an accessory pathway, microsomal ethanol-oxidising 
system (MEOS) that requires NADPH as a cofactor and is localised in the smooth 
endoplasmic reticulum. Unlike ADH, MEOS increases in activity during chronic 
ethanol consumption and does not appear to be the normal route of ethanol 
metabolism when it is consumed moderately (Lieber, 1991). In addition, a third 
system, peroxisomal oxidation, also has been proposed which uses hydrogen peroxide 
to oxidise ethanol to the corresponding aldehyde. Acetaldehyde produced from these 
three systems must enter the mitochondrion for further oxidation by acetaldehyde 
dehydrogenase (ALDH), also an NAD^ dependent reaction, to form acetate. Finally 
this acetate could, theoretically be activated to acetyl-CoA for oxidation by Krebs 
Cycle to yield energy, H2O and CO2 as the ultimate end products of ethanol. 
However, in liver, Krebs Cycle is unable to oxidise this acetyl-CoA, because of the 
prevailing high ratio of NADH + H"/NAD+ in the mitochondrial matrix. 
Consequently, the acetate will probably leave the liver for oxidation by the 
extrahepatic tissues (Salway, 1996).
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5.1.2 Ethanol and postprandial lipaemia
The excessive consumption of ethanol is an independent risk factor for CAD 
(Gruchow et al, 1982) and also has been associated with a variety of health problems 
such as cirrhosis of the liver, fetal alcoholic syndrome, pancreatitis, breast and 
digestive tract cancers, hypertension and stroke (Doll et a l, 1993). It is also 
frequently accompanied by poor diet and micronutrient (vitamin and minerals) 
deficiency (Thompson, 1978).
Numerous epidemiological studies however have shown that the light to moderate 
consumption of ethanol, the equivalent of a glass or two or 10 to 30 g of wine a day 
can decrease the risk of CHD (Rayo and Marin, 1998). Half of the observed 
protective effect of ethanol against CHD may be mediated by an increase in HDL- 
cholesterol (Valimaki and Taskinen, 1992) and an additional 18% of this protection is 
attributable to a decrease in LDL-cholesterol (Criqui et a l, 1987). Furthermore, a few 
studies also showed that low to moderate amount of daily ethanol consumption can 
improve insulin sensitivity (Mayer et a l, 1993; Facchini et a l, 1994) and may also 
decrease the concentration of lipoprotein (a) (Frohlich, 1996).
Compared to fatty acids, ethanol yields energy more rapidly and is a preferred 
substrate for energy generation in the liver. The change in the NAD /NADH ratio 
from oxidation of ethanol as described as above results in the accumulation of fatty 
acid and TAG in the liver through a variety of mechanisms; reduced p-oxidation of 
fatty acids in the liver, enhanced incorporation of acetate into hepatic fatty acids, 
enhanced estérification of fatty acid to TAG, and increased uptake of unesterified 
fatty acid by the liver.
The effects of ethanol consumption on lipoproteins as reported from several studies 
are variable and inconsistent. It might depend on several factors. These include the 
amount of ethanol consumed, pattern of drinking (regular daily doses or binge 
drinking), administration with or without food, period of study (short term or long 
term) and also a number of genetic and environmental interactions such as body 
composition of the drinkers, fitness and individual susceptibility (Frohlich, 1996). In
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addition, the type of beverage (beer, whisky, white or red wine) also influences the 
effect of ethanol on lipoproteins. For instance flavonoids and polyphenols found in 
red wines have been shown to inhibit the oxidation of human LDL, a process now 
generally believed to play an important role in the formation of atherosclerotic lesions 
(Steinberg et a l, 1989). They also have the potency to inhibit blood platelet 
aggregation, another component of the atherosclerotic process (Pace Aciak et a l, 
1995) which is considered to be an additional benefit of red wine consumption rather 
than ethanol in general.
Schneider et al. (1985), have compared various lipoprotein fractions, LPL and HL 
during short-term and long-term uptake of ethanol in healthy subjects. In a short-term 
experiment, fasting subjects were given a basic dose of 0.5 kg ethanol/kg body 
weight, followed by hourly maintenance doses of 0.15 g of ethanol/kg body weight. 
They found that VLDL, LDL, and HDL increased significantly particularly VLDL 
from 42 mg/dl to 92 mg/dl after 10 hours. In subject who consumed food (45% 
carbohydrate, 35% fat and 20% protein) together with ethanol, all lipoprotein 
fractions were again raised significantly. The CM-TAG increased from 9.3 to 35.5 
mg/dl, whereas VLDL from 29.8 to 54.5 mg/dl. Furthermore, there was no significant 
change in postheparin HL but postheparin LPL decreased. In a long-term experiment 
(4 weeks), plasma-TAG increased especially VLDL from 50 to 82 mg/dl. The CM- 
TAG in the plasma of fasting subjects was elevated to a value of 29.3 mg/100ml. 
HDL-cholesterol increased and LDL-cholesterol decreased. Postheparin LPL also 
increased in adipose tissue but not in postheparin HL. The effect of ethanol on 
lipolytic activity has also been shown to be influenced by individual fitness. 
Compared to untrained subjects, trained subjects had higher LPL activity but lower 
HL activity after acute or moderate ethanol consumption (Hartnung et a l, 1990; 
Hartnung et a l, 1993).
In a study conducted by Fraceschini et al (1988), healthy volunteers (male and 
female) were given 40 g ethanol together with a test meal containing 70 g of fat or a 
test meal alone. The TAG level increased by 180% at 4-6 hours after fat plus ethanol. 
Serum-apo B and HDL-TAG were increased by 8% and 57% respectively, whereas 
HDL-cholesterol was decreased by 10%. When ethanol was omitted, TAG increased
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by only 70% with HDL-cholesterol rising progressively to 15% after 12 hours. They 
suggested that the changes in HDL properties were evident when ethanol was given 
concomitantly with fat. This is supported by Valomiki et al. (1988), who showed that 
the effect of ethanol on HDL is dose-dependent. In this study HDLi increased when 
men consumed two drinks (12 g ethanol) per day, and both HDL2 and HDL3 increased 
when ethanol consumption was increased to five drinks per day. There was also the 
suggestion that women may be more sensitive to the effect of ethanol on HDL.
In another study by Rumpler et al. (1999), when women consumed a high fat (38%) 
diet together with ethanol, they had 6% lower cholesterol, 11% lower LDL- 
cholesterol, 3% higher HDL-cholesterol (21% greater is in HDL2 fraction) compared 
with a high fat diet together with carbohydrate, after 6 weeks. However, no 
significant differences existed in plasma lipids in women who consume a low fat 
(18%) diet between the periods in which they had ethanol or carbohydrate added to 
their diet. These researchers suggested that the decrease in CHD risk factors typically 
seen in moderate ethanol consumption may not be evident in individuals consuming a 
diet low in fat. This observation is consistent with the view of Srivastava et al. (1994), 
who suggested that some of the inconsistency seen in the response of cholesterol to 
ethanol consumption might be related to the fat level in the diet. They observed that 
individuals consuming a high-fat diet might be more sensitive to the effects of ethanol 
on blood lipids. In addition, gender differences may also have contributed to the 
variation in the responsiveness of blood lipids to ethanol consumption. Taylor et al. 
(1981) showed that TAG levels are only higher in male drinkers and not in female 
drinkers as compared to non-drinkers of the same sex.
More recently. Fielding et al. (2000), demonstrated that plasma-TAG concentration 
increased after healthy males were given ethanol (47.5 g) together with a mixed meal 
containing 50.9 g fat, 82 g carbohydrate and 16.2 g protein. The elevation in serum 
TAG was mainly due to increasing in TAGRL in the flotation range Sf 60-400 
(VLDLi), whereas those in the range of Sf 20-60 (VLDL2) and Sf >400 (CM) were not 
significantly affected.
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However, in the study by Mishra et ah (1991), no changes in HDL-cholesterol, LDL- 
cholesterol or apo A-I were shown after 4 hours when normal subjects were 
administered with ethanol intravenously in a dose of 0.6 g/kg body weight. Apo B 
decreased and there was a delayed increase in lipolytic activity. This discrepancy in 
results is most likely related to a difference in the route of administration of ethanol 
and times of blood sampling.
5.1.3 AIMS
Even though many epidemiological studies have shown a positive effect of moderate 
intake of ethanol on blood lipids, none of the studies to our knowledge have 
investigated the ethanol effect on CM-apo B-48 metabolism which might have the 
potential to initiate CHD either directly or indirectly (Zilversmit, 1979). Therefore 
the purpose of this study was to investigate whether the increased postprandial 
lipaemia caused by drinking ethanol is derived fi*om an increase in the number of 
chylomicrons or an increase the number of VLDL particles by using a novel 
antiserum to apo B-48 and the RP loading methods. In addition we measured changes 
that occur in glucose, insulin, NEFA, CETP, LPL, HL, LDL, and HDL to examine 
potential metabolic determinant of these effects.
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5.2 METHOD
5.2.1 Subject recruitment
Eight healthy, non-smoking male subjects (students and staff of the University of 
Surrey), aged 32.8 ± 12.7 (SD) years with body mass index (BMI) 23.0 ± 2.9 (kg/m^), 
with a fasting concentration of TAG < 2.5 mmol/1 participated in this study. They 
were hilly informed about the experimental nature of the study, which was approved 
by the local ethical committee. None of the volunteers had a history of liver disease 
or ethanol abuse, took medication or suffered illness known to affect glucose or 
triacylglycerol metabolism. Other exclusion parameters were an ethanol intake of > 
30 units/week. A blood specimen was also taken for routine haematology and 
biochemistry; any abnormality detected was notified to the volunteer and to his 
general practitioner.
5.2.2 Study protocol
The study was a single blind cross-over design with volunteers attending twice as 
either tests or controls. They were asked to refrain from consuming ethanol and from 
vigorous exercise for the 12 hours proceeding a study day. They were fasted for 12- 
14 hours. The study was carried out in the Clinical Investigation Unit, University of 
Surrey. Informed written consent was obtained from all volunteers.
The subjects were given 0.6 g ethanol/kg body weight (test study) or an identical 
volume of water (control study). These together with paracetamol and the test meal 
was consumed within 20 minutes, provided 4.4 MJ of energy, 44% as fat, 50% as 
carbohydrate and 6% as protein. The constituents are as indicated in Table 5.1. Each 
meal contained 170 000 I.U. of vitamin A (Water-Miscible Type 100) purchased from 
Roche Products Ltd., (Derbyshire, UK). On the morning of a study, each subject was 
fitted with an intravenous cannula under local anaesthetic, from which 17-25 ml of 
blood was collected periodically. The first collection was carried out immediately 
before the test meal was consumed; additional collections were at 0.5 hour, 1 hour, 
and every hour thereafter up to 8 hours after meal consumption. In addition, ethanol
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was measured in the breath using a Lion Alcolmeter™ 400 (Lion Lab Ltd., Barry, 
South Glamorgan, UK). During the 8 hours of the study, the subjects remained in the 
investigation unit and continued with their normal sedentary daily activities. They 
consumed no food and were only allowed decaffeinated and non-caloric drinks during 
this period. After 8 hours the subjects were given an intravenous bolus of 7500 U of 
heparin at a site distant from the cannula, which causes the release of LPL. Two 5-ml 
blood samples were taken at 5 and 15 minutes after the injection of heparin. These 
samples were used to analyze HL and total lipase.
5.2.3 Preparation of plasma samples
At each time point after the meal, the blood was collected into 0.1% (w/v) EDTA 
tubes, immediately centrifiiged at room temperature at 1700 gmax.min (3000 rpm for 
10 minute) to separate the plasma fi*om red blood cell. The plasma was divided into 
0.5 ml aliquots in LP3 tubes for different analyses: paracetamol, TAG, NEFA, insulin, 
glucose, cholesterol, total apo B, apo B-48, retinyl palmitate (RP); and 3.5 ml for 
TAGRL/TAGPL separation. Plasma was also aliquotted at time 0, 360 and 480 
minute for HDL measurement and at 0, 4, 6, and 8 hours for CETP analysis. 
Preservative (Appendix I) was added at a volume of 5% (v/v) of the total samples 
volume to the sample for apo B-48 analysis to prevent proteolysis. Samples for RP 
analysis were protected from light by wrapping them with aluminum foil. Samples 
aliquots were stored at either -20°C or -80°C before analysis, but fresh plasma 
samples were used for the separation of TAGRL/TAGPL.
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Table 5.1 Composition of the test meal
FOOD QUANTTTY
1
FAT
(g )
PROTEIN
(g)
CARBOHYDRATE
(g)
ENERGY
(kJ)
Orange juice 250 ml 0.3 0.3 22.0 385
White bread 135 g 1.9 10.5 63.0 1302
Butter lOg 8.1 0.1 0.1 307
Strawberry jam 36 g 0 0.1 23.4 393
Nesquick 15 g 0.1 0 14.5 246
Full fat milk 120 g 4.7 3.8 5.8 338
Double cream 75 g 36.0 1.3 2.0 1411
TOTAL 51.1 16.1 130.8 4382
% Energy 44 6 50
The orange juice contains 1 ml of RP (170 000 LU.) together with either vodka to 
provide 0.6 g ethanol/kg body weight or an equivalent volume of water.
5.2.4 Preparation of TAGRL/TAGPL
TAGRL/TAGPL fractions were prepared by ultracentrifugation as described in 
Section 2.2.2 from plasma for each time point.
5.2.5 Analysis of samples
Plasma paracetamol, TAG, total cholesterol, HDL-cholesterol, NEFA, total apo B 
were measured on an automated analyser, the COBAS Mira Plus as described in 
Section 2.2.8 utilising commercial assay kits. In addition, TAG was also measured in 
TAGRL/TAGPL fraction. These analyses, except total apo B and TAG were carried 
out by a research coworker. The Friedewald formula as explained in Section 2.2.8.5 
was used to estimate the LDL-cholesterol level in the plasma.
Analysis of apo B-48 content in plasma-TAGRL was undertaken by two methods, 
competitive ELISA developed by Lovegrove et al. (1996) as explained in Section
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2.2.5 and SDS-PAGE followed by optimised immuno-detection as described in 
Section 3. Apo B-48 was also measured in TAGPL fraction by competitive ELISA.
Total lipase activity in post-heparin plasma from each subject was determined using 
Continuous Fluorometric Lipase Test (Confluolip) as described in Section 2.2.9 by 
another worker. Plasma-CETP was measured by sandwich ELISA at the Institute of 
Diagnostic Research, USA.
Analysis of retinyl ester in plasma, TAGRL and TAGPL were determined by normal 
phase HPLC as described in Section 2.2.6, originally from Ruotolo et ah (1992) and 
plasma-insulin followed the RIA method developed by Hampton (1983) as explained 
in Section 2.2.7.
In an attempt to minimise systematic bias due to assay variability, all samples from 
one subject were assayed on the same day and within the same assay run.
5.2.6 Analysis of results
The results for each individual and each analyte were entered in Excel Spreadsheets. 
The data is presented as time response curves for each variable with values at each 
time-point plotted as mean with standard deviation (SD) or standard error of the mean 
(SEM). The postprandial lipaemic response was analysed by statistical analysis of the 
total area under the 480 minutes time response curve (AUG) for each parameter. The 
incremental AUG (lAUG), which reflected changes occurring after the meal, was also 
calculated for the plasma-TAG, insulin, apo B-48 and RE. Differences in AUG 
between control and ethanol studies were analysed using a paired Student’s t-test. 
Differences in the pattern of responses after the two studies within the subjects were 
also assessed by repeated measures ANOVA. The differences between the two 
studies (control and ethanol) for each time point was identified using the post-hoc 
Duncan test. Galculations were done in with STATISTIGA Version 5.0, 1997. The 
correlation between the changes of the TAG concentration and LPL activity was 
determined using Instat package. The mean data for all parameters are presented in 
Appendix IV.
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5.3 RESULTS
5.3.1 PLASMA ETHANOL
Plasma ethanol concentration was calculated from breath ethanol concentration. The 
concentration was increased immediately from an undetectable level in the fasting 
state to a peak of 9.35 mmol/1 at 30 minutes then declined steadily to zero by 
approximately 5 hours. During the control experiments, plasma ethanol concentration 
was not measured under the assumption that plasma concentration of ethanol would 
be undetectable (Figure 5.1).
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Figure 5.1. Breath (a) and plasma (b) ethanol concentrations before and after ingestion 
of a test meal with ethanol.
Values are given as mean ± (SD) for 8 subjects.
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5.3.2 PLASMA PARACETAMOL
Paracetamol was given to the subjects in order to measure the absorption rate of the 
meal (gastric emptying), as paracetamol is not normally present in the circulation. 
The rate of appearance of paracetamol in the plasma gives an indication of the rate of 
entry of the component of the meal into the plasma. No significant difference in the 
concentration of paracetamol between ethanol and control groups (Figure 5.2).
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Figure 5.2. Paracetamol level for 8 hours after ingestion of the test meal with (□) or 
without (0) ethanol.
Values are given as mean ± (SD) for 8 subjects.
5.3.3 PLASMA INSULIN, GLUCOSE
Insulin and glucose demonstrated similar patterns for the control and ethanol studies, 
they increased early in the study and peaked at 1 hour (Figure 5.3a, b). Consuming 
ethanol together with test meal increased glucose levels slightly but not significantly. 
However, the postprandial response of insulin was significantly increased by the 
presence of ethanol, as measured by I AUG (P=0.037) and was of borderline 
significance by TAUC (Table 5.2).
5.3.4 PLASMA NEFA
The mean concentration of NEFA in the plasma decreased rapidly after the ingestion 
of the test meal in both studies, to a minimum value between 2 and 3 hours but 
increased thereafter (Figure 5.3c). However, this increase was suppressed after the 
meal with ethanol, such that the TAUC was significantly decreased (P=0.001, Table 
5.2).
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Figure 5.3. Plasma concentrations of insulin (a), glucose (b), and NEFA (c) at baseline 
and for 8 hours after the ingestion of the test meal with ( □ ) or without ( ® ) ethanol.
All values are given as mean ± (SD) except for insulin ± (SEM) for 8 subjects. 
Significantly different from control, *(P<0.05), **(/><0.01), ***(/><0.001)
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Table 5.2. Total and incremental area under the paracetamol, insulin, glucose and 
NEFA curve.
ANALYSIS TAUC (min.mmol.r^) lAUC (min.mmoLl'^)
Control Ethanol Control Ethanol
Paracetamol 41.83 ±19.16 
(SD) 
P=QM1
46.62 ±20.32 
(SD)
40.63 ±20.1 
(SD) 
iM).09
45.12 ±21.44 
(SD)
Insulin
113747.8 ± 
23849.0 (SEM) 
P=0.059
130360.9 ± 
19977.2 
(SEM)
89904.0 ± 
21603.6 (SEM) 
P=0.037
107655.2 ± 
17869.7 (SEM)
Glucose
2840.2 ±260.1 
(SD)
NS
2984.3 ± 173.7 
(SD)
149.2 ±281.3 
(SD)
NS
164.3 ±424.7 
(SD)
NEFA
196.7 ±39.3 
(SD) 
iMl.OOl
135.8 ±30.3 
(SD)
2.7 ± 63.43 
(SD)
NS
-47.1 ±59.14 
(SD)
NS* Non significant
All values are given as means ± (SD) except insulin ± (SEM) for 8 subjects.
5.3.5 TAG IN PLASMA, TAGRL AND TAGPL
The effect of ethanol intake on TAG in whole plasma, TAGRL and TAGPL fractions 
can be seen in Figure 5.4 and Table 5.3. After test meal alone, TAG levels in plasma 
and TRL fraction increased in all subjects (Figure 5.4a and b). Plasma-TAG and 
TAGRL-TAG level reached their maximum value at 4 hours and 5 hours respectively 
then returned to baseline level after 8 hours. Consumption of ethanol with the test 
meal delayed the peaks significantly, which were 6 hours for both plasma-TAG 
(P=0.013) and TAGRL-TAG (P=0.046). Furthermore, plasma and TAGRL-TAG 
were still higher, compared with the basal level at 8 hours (P<0.05). The total and 
incremental area under TAG curve in these plasma and TAGRL fractions were 
significantly elevated in ethanol compared to control, particularly between 5 to 8 
hours (Table 5.3). In contrast, mean TAGPL-TAG concentration did not change 
significantly during the course of the studies (Figure 5.4c, Table 5.3).
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Figure 5.4. Postprandial response of TAG in whole plasma (a), TAGRL fraction
(b) and TAGPL fraction (c) after ingestion of the test meal with ( □ ) or without ( @ )
ethanol.
All values are given as mean ± (SD) for 8 subjects. Significantly different from 
control * (P<0.05), **(P<0.01), ***(P<0.001)
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Table 5.3. Total and incremental area under TAG curve for whole plasma, TAGRL and 
TAGPL fractions.
TAG TAUC (min.mmol.1^) LAUC (min.mmol.1^)
Control Ethanol Control Ethanol
Plasma
(5 to 8 hrs) 
316.24 ±139.94 
(SD) 
P=0.006
(5 to 8 hrs) 
447.86 ±156.85 
(SD)
(0 to 8 hrs) 
295.6 ± 89.71 
(SD) 
P=0.001
(0 to 8 hrs) 
489.9 ± 109.02 
(SD)
TAGRL (5 to 8 hrs) 
149.20 ± 88.61 
(SD) 
P=0.011
(5 to 8 hrs) 
261.18 ±140.66 
(SD)
(0 to 8 hrs)
252.36 ±81.58 
(SD) 
P=0.004
(0 to 8 hrs)
347.66 ±180.11 
(SD)
TAGPL (0 to 8 hrs)
372.83 ±104.19 
(SD)
NS
(0 to 8 hrs)
389.12 ±62.79 
(SD)
(0 to 8 hrs) 
-17.51 ±77.9 
(SD)
NS
(0 to 8 hrs) 
2.98 ±73.31 
(SD)
N S * Non significant
All values are given as means ± (SD) for 8 subjects.
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5.3.6 CM IN PLASMA BY APO B-48 AND RE
Apo B-48 in plasma measured by ELISA did not show any significant different 
between the control and ethanol studies (Figure 5.5a). The level of apo B-48 as 
determined by SDS-PAGE and RE was higher by ethanol intake compared to control 
at 4 hour of postprandial phase. They remained high up to 8 hours when ethanol was 
added to test meal, whereas after the control study it started to decline steadily after 3 
hours (Figure 5.5b).
Although the CM did not differ significantly between the control and ethanol studies, 
as measured by SDS-PAGE for apo B-48 and RE, their concentration in the plasma 
still remained higher after ethanol intake in the latter part of the postprandial phase 
and the TAUC nearly reached significance between 5-8 hours after the meal (Table 
5.4). The pattern of plasma-apo B-48 induced by ethanol a measured by SDS-PAGE 
was significantly higher than control (P<0.05) after analysis by repeated measure 
ANOVA.
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Figure 5.5. Postprandial response in whole plasma to the test meal, with ( □ ) 
or without ( ® ) ethanol, measured as apo B-48 by ELISA (a) and SDS-PAGE (b), 
and by RE (c).
All values are given as the mean ± (SEM) for 8 subjects.
Significantly different from control, *(P<0.05)
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Table 5.4. Total and incremental area under the apo B-48 and RE curves in whole
plasma measured by ELISA (apo B-48), SDS-PAGE (apo B-48) and HPLC (RE).
ANALYSIS TAUC lAUC
(PLASMA) Control Ethanol Control Ethanol
Apo B-48 
(min.|xg.ml'^) 
(ELISA)
1385.57 ± 
190.1 (SEM) 
NS
1244.08 ± 
201.17 (SEM)
136.1 ±76.14 
(SEM)
NS
231.6 ±63.5 
(SEM)
Apo B-48 as 
% of internal 
standard 
(SDS-PAGE)
(0 to 8 hrs)
7979.78 ± 
1502.24 
(SEM)
NS
(5 to 8 hrs)
1908.03 ± 
654.23 (SEM) 
P=0.0645
(0 to 8 hrs)
8909.85 ± 
1354.23 
(SEM)
(5 to 8 hrs)
3380.3 ± 
463.20 (SEM)
(0 to 8 hrs)
2553.08 ± 
1511.5 
(SEM) 
NS
(0 to 8 hrs)
3874.86 ± 
1562.12 
(SEM)
Retinyl ester
(min.pg.ml'^)
(HPLC)
(0 to 8 hrs)
427.69 ±61.95 
(SEM)
NS
(5 to 8 hrs)
121.52 ±22.46 
(SEM) 
P=0.054
(0 to 8 hrs) 
542.79 ± 38.54 
(SEM)
(5 to 8 hrs) 
193.89 ±23.63 
(SEM)
(0 to 8 hrs)
366.28 ± 54.57 
(SEM)
NS
(0 to 8 hrs)
491.14 ± 
39.40 (SEM)
NS* Non significant
Data are means ± (SEM) for 8 subjects.
146
5.3.7 CM IN TAGRL BY APO B-48 AND RE
As expected, the apo B-48 levels in the TAGRL fractions as measured by ELISA were 
elevated after the test meal. These changes paralleled those observed for TAG level in 
plasma and TAGRL. In the control study, the apo B-48 peaked at 5 hours and 
returned to the baseline level within 8 hours whereas when ethanol was consumed 
with the meal, the level of apo B-48 remained elevated after 8 hours (Figure 5.6a) 
compared to baseline (P=0.013). The TAUC and lAUC for apo B-48 measured by 
ELISA were significantly greater after ethanol intake as shown in Table 5.5 (P<0.05). 
When apo B-48 was measured after SDS-PAGE there was no significant difference 
between the TAUC or lAUC (Table 5.5). It is apparent that the mean response curves 
in Figure 5.6 (a) and (b) are very similar. Furthermore, apo B-48 levels determined by 
SDS-PAGE, still remained significantly raised above baseline (P=0.002). However, 
CM as measured by RE was only significantly increased after ethanol between 5 to 8 
hours (P<0.05).
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Figure 5.6. Postprandial response in TAGRL fraction to the test meal, with ( □ ) or 
without ( O ) ethanol, measured as apo B-48 by ELISA (a) and SDS-PAGE (b), and 
byRE(c).
All values are given as mean ± (SEM) for 8 subjects. Significantly different from 
control, * (P<0.05), ** (P<0.01)
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Table 5.5. Total and incremental area nnder the apo B-48 and RE curves in the TAGRL
fraction measured by ELISA (apo B-48), SDS-PAGE (apo B-48), and HPLC (RE).
ANALYSIS TAUC lAUC
(TAGRL) Control Ethanol Control Ethanol
Apo B-48
(min.pg.ml'^)
(ELISA)
(0 to 8 hrs) 
82.46 ± 5.68 
(SEM) 
P=0.017
(5 to 8 hrs)
30.12 ±2.70 
(SEM) 
P=0.011
(0 to 8 hrs)
95.52 ±8.16 
(SEM)
(5 to 8 hrs) 
41.92 ±4.37 
(SEM)
(0 to 8 hrs)
43.35 ±3.98 
(SEM) 
P=0.039
(0 to 8 hrs) 
57.83 ±7.10 
(SEM)
Apo B-48 as 
% of internal 
standard 
(SDS-PAGE)
24646.6 ± 
1981.96 
(SEM) 
NS
26052.6 ± 
1479.39 
(SEM)
18024.96 ± 
2514.28 
(SEM) 
NS
19400.46 ± 
2450.39 
(SEM)
Retinyl ester
(min.pg.ml'^)
(HPLC)
(0 to 8 hrs)
374.66 ± 46.43 
(SEM) 
P=0.087
(5 to 8 hrs) 
80.55 ± 18.09 
(SEM) 
P=0.038
(0 to 8 hrs)
466.82 ± 
42.73 (SEM)
(5 to 8 hrs)
155.30 ±22.88 
(SEM)
(0 to 8 hrs)
361.60 ± 
44.99 (SEM) 
P=0.076
(0 to 8 hrs)
454.49 ±41.54 
(SEM)
AS* Non significant
Data are means ± (SEM) for 8 subject.
5.3.8 CMR IN TAGPL BY APO B-48 AND RE
The TAUC for apo B-48 in the TAGPL fraction as measured by ELISA (Figure 5.7a) 
was significantly reduced (P=0.005) after ethanol compared to the control study 
(Table 5.6), but there was no significant change in RE values (Figure 5.7b).
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Figure 5.7. Postprandial response in TAGPL fraction to the test meal, with ( □ ) or 
without ( O ) ethanol, measured as apo B-48 by ELISA (a), and by RE (b).
All values are given as means ± (SEM) for 8 subjects.
Table 5.6. Total and incremental area under the apo B-48 and RE curves in the TAGPL 
fraction measured by ELISA (apo B-48) and HPLC (RE).
ANALYSIS TAUC lAUC
(TAGPL) Control Ethanol Control Ethanol
Apo B-48
(min.pg.mr*)
(ELISA)
1684.23 ± 
131.18 (SEM) 
P^O.0046
1474.81 ± 
115.31 (SEM)
46.03 ± 47.6 
(SEM) 
NS
-21.78 ±41.06 
(SEM)
Retinyl ester
(min.pg.mf')
(HPLC)
91.13 ±17.34 
(SEM)
NS
104.36 ± 10.45 
(SEM)
39.50+ 10.9 
(SEM)
NS
56.86 ± 12.08
(SEM)
NS* Non significant.
Data are means ± (SEM) for 8 subjects.
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5.3.9 TOTAL CHOLESTEROL, PROTEIN AND APO B
No changes of total cholesterol, total protein and total apo B were observed with time 
after the test meal either with or without ethanol (Figure 5.8).
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Figure 5.8. Postprandial response of total protein (a), total cholesterol (b) and total 
apo B (c) in plasma after ingestion of the test meal with ( □ ) or without ( O ) ethanol.
All values are given as means ± (SD) for 8 subjects.
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5.3.10 TOTAL LIPASE, HL AND LPL
The activities of total lipase, HL and LPL (calculated) in post-heparin plasma, though 
consistently reduced, showed no significant response to ethanol overall (Figure 5.9).
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Figure 5.9. Post heparin total lipase activity (a), hepatic lipase activity (b), and 
lipoprotein lipase activity (c) at 8 hours after ingestion of the test meal with ( □ ) or 
without(O ) ethanol.
All values are given as means ± (SD) for 8 subjects.
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5.3.11 HDL, CETP AND LDL
After ethanol was consumed together with the test meal, a very small, non-significant 
increase of HDL-cholesterol (HDL-C) was observed. Similarly, the CETP 
concentration was slightly lower in the early part of the study (0-4 hours), but 
increased at the end of the study between 6 to 8 hours. In addition, the LDL- 
eho le sterol (LDL-C) level was decreased but the decrease was not statistically 
significant.
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00
L A l a
360 
Time (m in)
480
Figure 5.10. HDL-C concentration in plasma at baseline, and at 6 and 8 hours after 
ingestion of the test meal with ( □ ) or without ( □ ) ethanol.
All values are given as mean ± (SD) for 8 subjects.
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Figure 5.11. CETP concentration in plasma at baseline, and at 4,6 and 8 hours after 
ingestion of the test meal with ( □ ) or without ( ■ ) ethanol.
All values are given as mean ± (SD) for 8 subjects.
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Figure 5.12. LDL-C concentration in plasma at baseline, and 6 and 8 hours after 
ingestion of the test meal with ( □ ) or without ( 0  ) ethanol.
All values are given as mean ± (SD) for 8 subjects.
5.3.12 RELATIONSHIP BETWEEN LPL ACTIVITY AND PLASMA TAG 
CONCENTRATION
Figure 5.13 showed that there was an inverse relationship between the changes in LPL 
activity and serum TAG (r = 0.881) (P< 0.005), which the greatest increasing in TAG 
been associated with the greatest falls in LPL activity (and vice versa).
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Figure 5.13. The correlation of A LPL activity (5min) with A TAG (360 min) after 
ingestion of the test meal with or without ethanol (control).
154
5.4 DISCUSSION
Hyperlipaemia induced by ethanol can, in theory, be produced either by an excessive 
production and release of lipids into circulation or by defective removal from the 
blood or by a combination of these mechanisms. One of the possibilities is due to 
alterations in the rate of gastric emptying and/or fat absorption. Previous evidence 
demonstrated that ethanol consumption increased the supply of lipids from the small 
intestine into the blood by increasing both the splanchnic and the mesenteric blood 
flow. However, this effect is concentration dependent. Concentrations of ethanol of 
about 8-10 g/100 ml are needed to exhibit significant changes in gastric emptying. 
At these concentrations, ethanol has been reported to accelerate as well as to delay 
gastric emptying whereas at higher concentrations the effect of ethanol on gastric 
emptying is inhibitory (Review by Baraona and Liber, 1979). Paracetamol has been 
used to measure the absorption rate of the meal in several studies such as Medhus et 
al. (1999). This is according to the observation by Heading et al (1973) that 
paracetamol absorption is related to the rate of gastric emptying. Rapid gastric 
emptying was associated "with the early appearance and high peak concentration of 
paracetamol in plasma, whereas peak concentration was lower and occurred later 
when gastric emptying was slow. The observation from our study showed that the 
maximum plasma-paracetamol concentration varied widely for each individual from 
0.07 to 0.24 mmol/1 (control) and 0.08 to 0.36 mmol/1 (ethanol). The time taken to 
reach peak concentration ranged from 30 minutes to 5 hour after ingestion of the test 
meal. Even though the area under the paracetamol curve was higher after ethanol, the 
difference was not statistically significant. However, the reliability of this result in the 
present study is questionable because the test meal used was not totally liquid, 
whereas in the previous studied by other researchers, the meal given was in the liquid 
form.
The administration of ethanol to man may result in either hyperglycemia or 
hypoglycemia (Yki Jarvinen et a l, 1988). In this study however, we found no 
significant changes in glucose concentrations with ethanol. As observed by Siler et 
al (1999), the oxidation of acetate produced from ethanol hydrolysis only replaced 
lipid but not carbohydrate as body fuel. As a consequence of the increase in plasma
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glucose after the meal, insulin level was also enhanced. The intake of ethanol 
together with the test meal resulted in a significantly greater incremental area under 
the insulin curve (P<0.05) than the test meal alone, a finding consistent with a 
previous study by Koivisto et al (1993). The effects of ethanol on insulin are variable 
in different studies and have been reported to either lower (Manolio et a l, 1990) or 
have no effect on fasting insulin (Ostrander et al, 1974; Mayer et al, 1993). These 
different findings might depend on simultaneous food intake as explained by 
Christiansen et al (1993, 1996) in NIDDM patients. The ability of ethanol to 
augment insulin levels in the presence of food has also been reported by Friedenberg 
e ta l{ \9 1 \).
In the postabsorptive state, NEFA, also known as free fatty acids (FFA), are produced 
by the hydrolysis of the TAG stored in adipose tissues and transported to the site 
where it is needed as an important source of energy. The release of NEFA from 
adipose tissue will be almost completely suppressed after a meal by the action of 
insulin on hormone sensitive lipase (HSL). Therefore the NEFA concentration in 
plasma falls markedly as shown in the early postprandial phase for both control and 
ethanol studies. Compared to the control, ethanol intake together with the test meal 
further reduced the TAUC for NEFA (P<0.005). This was most apparent during the 
later part of postprandial phase. Fielding et al (2000) suggested that the reduction of 
NEFA after ethanol ingestion with a mixed meal is due to the enhanced uptake of 
plasma-NEFA into tissues or organs, which, in part, is accounted for by increased 
incorporation into hepatic-TAG. This view is based on their observation that ethanol 
has no effect on 3-hydroxybutyrate level, which implies that the fatty acids were 
directed towards estérification rather than oxidation. It might also be due to a shift in 
the ratio of NADHiNAD caused by ethanol oxidation. This inhibits the tricarboxylic 
acid cycle and oxidation of fatty acids in the liver and peripheral tissue (Lieber et a l, 
1984). In addition. Fielding et al (2000) also found no changes in the plasma 
concentration of palmitoleic (a component of the test meal) after ethanol intake which 
indicated that the decrease of plasma-NEFA was not due to reduced action of LPL, as 
shown by Pownall (1994) when ethanol was given with a pure fat load and Frayn et 
al (1990) when ethanol was given without a meal. Furthermore, Crouse et al (1968) 
suggested that the inhibition of fatty acids oxidation is due to a direct effect of acetate
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and not of ethanol itself. It has been shown that acetate could also inhibit lipolysis in 
vivo (Yki-Jarvinen et al., 1988) and in vitro (Nilsson and Belfrage, 1978).
As expected, the postprandial response curve of plasma-TAG increased and peaked 
between 4 to 5 hours. The increase of plasma-TAG was due to the enhancement of 
the TAG concentration in TRL fraction as shown by Figure 6.4 (b). The pattern of 
TRL-TAG response was very similar to that of plasma-TAG for the two studies. Both 
figures displayed the prolonged elevation of the TAG level after the consumption of 
the test meal together with ethanol. In contrast, in the TAGPL fraction which might 
contain CMR, the TAG level was not significantly changed by the ingestion of 
ethanol. Consequently, the TAGPL-TAG concentration was almost constant 
throughout both studies. The data obtained in this study showed that the total area 
under the TAG curve in the TAGRL fraction was only significantly elevated due to 
ethanol ingestion, during the second half of the study, between 5 to 8 hours. After 8 
hours, plasma-TAG still exceeded the baseline level (P<0.05). The 
hypertriglyceridemia produced after ethanol intake was also observed recently by 
Fielding and colleagues (2000). They demonstrated an even greater difference in 
plasma-TAG levels even though the amount of ethanol was similar. This might be 
due to the different percentage of fat given in the meal. Compared to their meal (54% 
fat), our meal contained only 44% of fat from the total calories. As shovm by Pownall 
(1994), increasing the fat load from 33 to 50% with ethanol resulted in a small 
increase in the magnitude of the lipemia, whereas doubling the load from 50 to 100% 
increased the plasma-TAG by more than a factor of 5.
The postprandial response of apo B-48 in plasma after separation by SDS-PAGE and 
in the TAGRL fraction measured by both techniques is similar to the postprandial 
response of TAG in plasma and the TAGRL fraction. These results indicate that 
increased numbers of CM/CMR are involved in the elevated TAG levels seen when 
ethanol was ingested with the test meal. As demonstrated by Cohn et al. (1993), CM 
and CMR account for 80% of the postprandial increase in plasma-TAG concentration. 
Although the total area under the TAGRL-apo B-48 curve for 8 hours was 
significantly elevated after ethanol ingestion (P=0.02), most of this increase in apo B- 
48 was seen towards the end of the study (5-8 hours, P=0.01). Due to the fact that one 
particle of CM contains 500,000 molecules of TAG (Gianturco and Bradley, 1992),
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the increasing number of CM could enhance the concentration of TAG in the plasma 
several fold. The result of increased CM after ethanol consumption with a test meal is 
in contrast with that of Fielding et al (2000). This might have resulted from the 
different methods of isolation for CM from the plasma. In our study, TAGRL- 
containing CM was separated from the plasma by ultracentrifiigation for 30 minutes, 
45,000 rpm at 24°C, whereas the other investigators including Fielding et al (2000) 
defined CM as the fraction with Sf >400 that was prepared by ultracentrifugation with 
speed 40, 000 rpm, 15°C for 32 minutes, and Schneider et al (1985), 195, 000 x g, for 
30 minutes.
The results with RE support the findings with apo B-48. In both plasma and the 
TAGRL fraction, the TAUC over the whole study period were not significantly 
different. However, there was a significant increased in RE, in both plasma and the 
TAGRL fraction between 5-8 hours after the meal when ethanol was consumed. The 
much lower concentrations of RE in the TAGPL fraction were not affected by the 
ingestion of ethanol. This study on the other hand showed the disadvantages of the 
ELISA technique in quantifying apo B-48 in the samples with a high protein 
concentration such as plasma. Apo B-48 measured by SDS-PAGE showed no 
significant differences between two study, probably due to the greater inter-individual 
variation with this method.
VLDL-TAG could also contribute to the hyperlipidaemia after the test meal together 
with or without ethanol. Even though the secretion of VLDL-TAG from the liver is 
normally suppressed by insulin in the postprandial period in order to conserve fat 
stores (Durrington et al, 1982), this situation could be altered by the present of 
ethanol and would maintain VLDLi(Sf 60-400)-TAG secretion (Fielding et a l, 2000). 
It has also been suggested that the inhibition of HL following ethanol ingestion 
(Goldberg et al, 1984) may explain the increased concentration of VLDL-TAG. If 
more VLDL particles are secreted after ethanol consumption, then total apo B in 
plasma should increase. The data from our results however, did not show any 
significant increased in total apo B in plasma after ethanol intake compared to the 
control. The level of apo B in plasma did not change with time during the 
postprandial study. This is in accordance with evidence from Chan (1992) that the
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generation of the apo B-lOO seems to be constant, whereas the secretion rate of VLDL 
is partly determined by the availability of TAG. Even though the number of apo B- 
48-containing particles was shown to increase with ethanol, this would not effect the 
level of total apo B in the plasma because they are present in such low levels relative 
to apo B-100. Karpe et al (1993) and Cohn et al (1993) also reported that food 
intake did not effect the total serum apo B-100 levels but caused a change in apo B 
distribution. The limited availability of NEFA in the plasma could decrease the 
formation of VLDL particles. Acetate derived from ethanol oxidation might also be 
converted into fatty acids through acetyl-CoA and become a substrate for VLDL 
synthesis. However Siler et a l (1998, 1999) have demonstrated that acetate produced 
from ethanol oxidation in the liver is mostly (70-80%) released into the circulation, 
and only a small portion (<5%) was activated via acetyl-CoA, to fatty acids for 
incorporation into VLDL-TAG. Furthermore stable isotope measurements showed 
that compared to dietary fat intake, endogenous synthesis of fatty acids makes a 
relatively minor contribution to VLDL (Faix et a l, 1993 and Hellerstein et a l, 1991). 
The enhanced lipeamia could also be due to the hepatic utilisation of fatty acids of 
dietary origin for VLDL-TAG synthesis and secretion, an effect reported for fat loads 
administered without ethanol (Scheeman et a l, 1993). If this were the case, the 
composition of VLDL-TAG would include those fatty acids derived from the fat load. 
However, studies by Pownall (1994) shows that ethanol reduces the amount of fatty 
acids given from the meal in VLDL-TAG.
There were no obvious changes in plasma cholesterol throughout the study and also 
no significant difference between control and ethanol studies. CM contains only a 
small percentage of cholesterol compared to VLDL, which account for 90% of the 
cholesterol increase in the TRL fraction (Scheeman et a l, 1993). Hence the increased 
number of CM/CMR during the late postprandial phase is unlikely to affect the level 
of cholesterol in plasma.
There have been inconsistent results for the effects of ethanol on LPL activity from 
different investigators. LPL activity showed no change effects (Mishra et a l, 1991), 
been decreased (Schneider et a l, 1985; Povmall, 1994), or increased (Taskinen et a l, 
1982; Hartnung, 1993; Nishiwaki et a l, 1995) by ethanol. Results from our study 
indicated a general decrease in lipase activities (HL and LPL) after ethanol
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consumption. The primary fate of ethanol involves its release as acetate into the 
circulation (>70% of ethanol administration). The dramatic increase of acetate has 
important metabolic consequences because it inhibits lipolysis in vitro and in vivo as 
mentioned in the previous paragraph. There is also some evidence that the plasma of 
individuals that are susceptible to ethanolic lipeamia contains a factor that inhibits 
LPL (Kessler et a l, 1963). It is possible that the activation or release of this or 
another inhibitory factor into plasma might be elicited by acetate, Avhich in turn would 
explain the increased residence time of CM particle in plasma. A decrease in LPL 
activity after ethanol ingestion and a corresponding delay in CM removal at the end of 
this period was also reported by Pownall (1994) whose demonstrated that ethanol 
inhibited LPL activity against intestinally derived lipoprotein. The reduced hydrolysis 
of CM could augment the decline in plasma-NEFA as suggested by Griffiths et al 
(1994). Another possibility is that LPL activity may be insufficient to clear CM. Even 
though HL can hydrolysis CM, since hepatic receptors recognise CMR rather than 
CM, hydrolysis of CM-TAG by LPL is potentially a rate-limiting step in the removal 
of TAGRL from plasma.
The metabolism of HDL is clearly linked to the catabolism of TAGRL (CM and 
VLDL). Hence changes in HDL after lipidaemia due to fat plus ethanol intake, is of 
interest especially when considering that HDL levels are inversely correlated with 
heart disease, through its role in transporting cholesterol from extrahepatic tissues to 
the liver for excretion. Several studies have shown an increase in HDL-cholesterol 
after ethanol consumption (Mayer et a l, 1993; Hendriks et al, 1998) which is 
consistent vvdth our result and also the long term studies by Schneider et al. (1985), 
but in contrast to the studies by Franceschini et al (1988). The mechanism is not ftilly 
understood but might be due to several factors. Firstly, ethanol might increase the 
synthesis or secretion, or both of apolipoproteins, lipids and lipoprotein particles. 
Secondly, ethanol possibly enhances the lipolysis of TAGRL particles and thus the 
supply of lipoprotein surface components to immature HDL particles. This possibility 
is unlikely in our case because we predicted that the hydrolysis of TAGRL notably 
CM was delayed when ethanol was consumed together with a meal due to a low 
activity of LPL. Another possibility for the increasing HDL-cholesterol in response to 
ethanol, is the clearance of the whole HDL particle or its lipid components by HL, an 
enzyme which catalyses the degradation of HDL, the activity of which may be
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delayed or decreased by ethanol (Hojnacki et a l, 1992). This is in accordance with 
our observation of a decrease in HL activity after ethanol intake and also from other 
researchers (Taskinen et a l, 1985; Goldberg et a l, 1984; Baraona and Liber, 1979).
Several authors suggest that the effect of alcohol in increasing the level of HDL- 
cholesterol might be caused by the low activity of CETP and thus the net mass 
transfer of cholesteryl ester from HDL to VLDL and LDL decrease (Savolainen et a l, 
1990, Hannuksela et a l, 1992, Ritsch et a l, 1997). However, CETP activity in our 
study was slightly but not significantly higher at time 6 and 8 hours after ethanol 
intake (the times at which TAG and apo B-48 were delayed). Even though CETP 
activity was higher after ethanol intake due to the elevated level of TAG, the binding 
of this enzyme to lipoproteins might differ after ethanol oxidation. As observed by 
Liinamaa et al (1998), CETP was sensitive to changes in the concentration, chemical 
composition and qualitative in lipoprotein and lipids induced by ethanol. This 
suggests that the high level of HDL-cholesterol in this study might be due to the 
decreased HL and LPL activity. In addition, alterations in the protein components of 
HDL following ethanol consumption may also decrease the ability of HDL particles 
to bind to hepatic membrane receptors (Bisson et a l, 1995).
In contrast to HDL, LDL cholesterol was lower in response to ethanol compared to 
the control. There are several explanations for this effect as reviewed by Savolainen 
and Kesaniemi, (1995). Firstly, ethanol may stimulate the LDL (B/E) receptors in the 
liver as shown in experimental animals and enhanced the fractional catabolic rate of 
LDL. LDL might also be modified by ethanol or its chemically active metabolites 
which could cause a rapid clearance from the circulation. Savolainen et al (1986) 
postulated that aeetaldehyde even in low concentrations can effect LDL catabolism by 
masking the free amino groups of lysine in apo B. Furthermore the metabolism of 
LDL precursor (i.e. VLDL and IDL) may differ after ethanol ingestion, so that fewer 
of these precursors may be converted to LDL. This possibility might explain our 
observation of decreased HL activity with ethanol and an apparent delay in the 
metabolism of VLDL.
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5.5 CONCLUSION
Our results show that the consumption of ethanol with a fat load leads to an increase 
in the magnitude and duration of lipemia above and beyond that seen with a fat load 
alone and mainly due to an increase in TAGRL. The greatest differences between the 
control and the ethanol supplemented fat loads became apparent at the later time 
points. CM particles as measured by apo B-48 were clearly involved in this ethanol- 
indueed hypertriglyceridaemia. The consumption of ethanol might interfere with the 
lipolysis of CM-TAG due to a decrease in the activities of LPL and HL. Whether 
ethanol stimulates synthesis of hepatic VLDL-TAG is unknown though it apparently 
does not enhance production of VLDL-apo B. This present study also confirmed that 
plasma NEFA was reduced after the ingestion of ethanol particularly in the late 
postprandial phase. While total plasma protein, cholesterol and glucose were not 
affected, insulin levels showed a non-significant increase after ethanol intake. The 
impact of ethanol on post-heparin plasma lipases, may also play a crucial role in the 
metabolism of HDL and LDL through its effect on postprandial TAG or 
independently. HDL-cholesterol was increased (not significant) whereas LDL- 
cholesterol was non-significantly reduced by ethanol.
Some of the data observed may seem to be inconsistent or even opposite to that of 
other previous studies. This discrepancy most likely arises from; individual 
susceptibility, amount and mode of intake (pure ethanol, wine, beer), study duration, 
diet, and experimental designs, especially the addition or omittance of fat.
From this study, it can be concluded that the late postprandial elevation of plasma- 
TAG after excessive ethanol intake together with a fatty meal is explained at least in 
part by the accumulation of intestinal TAGRL.
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CHAPTER SIX
GENERAL DISCUSSION AND 
CONCLUSION
6.0 GENERAL DISCUSSION AND CONCLUSION
In recent years the pathogenesis of atherosclerosis has focused on the role of plasma 
total cholesterol and especially LDL-cholesterol. Hence, cholesterol screening is 
routinely conducted in the patients at high risk of atherosclerosis where an increase 
plasma total LDL-cholesterol level and a low HDL-cholesterol level are associated as 
major risk factors. Analysis of plasma-TAG was usually ignored until 1970 when 
Zilversmit proposed that CHD is a postprandial phenomenon. According to his 
original hypothesis, the TAGRL-remnants that were generated after LPL hydrolysis 
contributed directly to the atherogenic process. However, Patsch et al. (1992) 
proposed an alternative role for postprandial lipoproteins in atherosclerosis. They 
found that postprandial lipaemia was indirectly associated with atherogenesis and 
influenced the metabolism of other lipoproteins through the CETP-mediated 
reactions. There have been numerous studies confirming the correlation between 
fasting TAG levels and CHD (Hokanson and Martin, 1996) and now TAGRL is 
recognised as being closely related to the progression of CHD (Phillips et ah, 1993; 
Alaupovic et al., 1997) whereas serum cholesterol is only a weak predictor of CHD 
risk within populations (Fruchart and Packard, 1997).
One of the objectives in this study was to develop and optimise some of our current 
methods in the laboratory for the immuno-deteetion and quantitation of apo B-48 and 
apo B-lOO-containing lipoproteins. In Chapter 3, we tried to optimise the immuno­
detection of apo B-48, which was hampered by normal Coomassie Brilliant staining. 
Anti-apo B-48, produced by our group, has been shown to be highly specific for apo 
B-48. The first step of this attempt was to reduce the gel concentration for SDS- 
PAGE from 5-20% (w/v) to 3-16% (w/v). Hence, samples containing a high protein 
concentration could be resolved without proteins being trapped in the stacking gel. 
Immuno-deteetion with anti-apo B-48 and anti-apo B showed that both types of apo B 
were separated more effectively in this gel concentration without material left in the 
origin (stacking gel). However, due to the lower percentage of the gel, it needed 
increased time to polymerise. Normally at least 2 hours were needed to prepare the 
separating gel and another 2 hours for stacking gel. The second step was to increase 
the sensitivity of apo B-48 immuno-deteetion. Four techniques of immuno-deteetion
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were employed and the sensitivities for each technique were compared using serial 
dilutions of lymph and plasma. From the results, immuno-deteetion by AMDEX gave 
the best result. This method reduced the assay time whilst maintaining the same 
detection limit as in the case of ExtrAvidin-peroxidase. The AMDEX immuno­
detection method based on the use of goat anti-rabbit conjugated with chemically 
activated dextran to which hundreds of molecules of HRP have been attached. Even 
when only a small amount of apo B-48 was present in the sample, the formation of the 
apo B-48-AMDEX complex caused a greatly increased HRP signal after incubation 
with the ECL substrate. According to the manufacturer’s instructions, AMDEX is for 
use in ELISAs, but this study revealed that AMDEX could also be used successfully 
with immunoblotting. While AMDEX also increased the background staining of the 
blot, the background produced was shown to be due to the non-specific binding of the 
AMDEX conjugate with proteins other than apo B-48. Furthermore, the band of non­
specific binding was well separated from the apo B-48 and apo B-100 bands. At 
present, the non-fat dried milk (Marvel) is still the most effective blocking agent when 
compared to 0.3% (w/v) BSA (Amersham) and Super-block (Pierce). The sensitivity 
of the AMDEX immuno-deteetion enabled the detection of apo B-48 in very dilute 
samples such as those from TAGRL subclasses, which could not be detected by the 
ELISA procedure. It was noted above that the presence of apo B-100 in very high 
amounts compared to apo B-48 makes the quantification of apo B-48 difficult. The 
enhanced signal produced by apo B-48 when using the AMDEX-conjugate was 
comparable to that produced by apo B-100. It can be concluded that immuno- 
deteetion by the AMDEX-conjugate technique in combination with ECL has greatly 
improved the SDS-PAGE method for the quantification of apo B-48-eontaining 
lipoprotein particles. Although this technique is not ideal for the analysis of many 
samples and is time consuming, it still provides a powerftil tool to follow CM 
metabolism, especially in subjects with a high risk of CHD. By combining the 
AMDEX-immuno-detection and semi-quantitation with other technique of lipoprotein 
subfractionation (TAGRL and LDL), the metabolism of CM and their remnants, 
which are heterogeneous in size and composition, could be followed. In view of the 
earlier observation of Isherwood (1996) of the existence of small, dense CMR, these 
methodological developments will allow the fiirther exploration of the direct role of 
CM and their remnant in atherogenesis. The low background produced by AMDEX 
immuno-deteetion indicated that the non-specific binding with this antibody
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preparation and with components other than apo B was less when compared to other 
four immuno-deteetion techniques. The possibility of using this antibody as a 
secondary antibody for apo B-48 quantitation by ELISA in plasma and infranatant 
fraction needs to be tested.
An initial event in atherosclerosis is the retention of lipoproteins within the intima of 
the vessel wall. The work by Rapp et al. (1994) which demonstrated the deposition of 
apo B-lOO-containing VLDL and IDL in the human arterial wall has stimulated 
interest in this area of immunohistology. However, as to whether CMR actually 
infiltrate the endothelium of blood vessels and play a direct role in the atherosclerotic 
process is still open to question. To address this. Chapter 4 aimed to address whether 
CM or their remnants could contribute directly to this process. Human tissue slices 
from intestine, liver, fatty streak, aorta and coronary artery were used for this purpose. 
Furthermore, the immunolocalisation of apo B-lOO-containing lipoproteins was also 
studied in these tissues. The result showed that apo B-48 but not apo B-100 was 
localised in intestine slices and this supports the evidence that only apo B-48 is 
synthesised in human intestine. In contrast to intestine, apo B-100 was clearly present 
in liver tissue as expected. Apo B-48 was also detected in human liver. We could not 
confirm whether this was CM or CMR. We assume that the small amount of apo B- 
48 detected in the liver was from CMR taken up by the liver in which the apo B-48 
had not been completely hydrolysed.
It has been proposed that circulating CMR can be taken up by macrophages to form 
foam cells leading to atherogenesis. Hence, immunolocalisation of macrophages in 
tissue slices should provide further evidence for the relationship between CMR with 
macrophages in initiating atherogenesis. The results showed that, macrophages were 
present in the fatty streak, which is consistent Avith the important role of these cells in 
this early stage of atherosclerosis. They were also detected at all stages of 
development of the atherogenic lesion at superficial of intima. As the atherogenesis 
spread, they were located 'within the thickening intima layer, particularly around the 
area rich in lipid at the foamy area. Apo B-48 was in the main present in the same 
areas as macrophages, which suggests that these apo B-48-containing lipoproteins 
might be involved in the accumulation of cholesterol in the macrophage. It is possible 
that apo B-48 may be degraded or hydrolysed by macrophages so that anti-apo B-48
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cannot recognise the modified apo B-48. Henee, the amount of apo B-48 detected 
was small in all tissues examined. In contrast to apo B-48, apo B-100 was present in 
greater amounts within the media layer, which consists of elastic fibres and SMC. 
Even though this study provides evidence for the presence of apo B-48 and apo B- 
100-containing lipoprotein in slices of human aorta and coronary artery, it is unclear 
to what extent these lipoproteins contribute to the formation of atherosclerotic lesions. 
The presence of CM/CMR in the tissue slices of human aorta has implications for the 
Zilversmit Hypothesis, which proposed a direct role of CMR in atherogenesis. The 
co-loealisation of both apo B-48 and apo B-100, together with macrophages in the 
same tissue by using different labels and visualising them by confocal microscopy, 
would provide a clearer picture of the interactions of these lipoproteins within 
macrophages. In addition, in view of the accumulating evidence that LPL in the 
vessel wall is pro-atherogenic, it might also be interesting to locate the presence of 
LPL in these tissues.
Hyperlipidaemia associated with ethanol consumption is relevant to the problem of 
atherosclerosis and heart disease in the drinking population. Some preliminary 
evidence has shown that very limited consumption of ethanol may raise the levels of 
HDL in blood, reducing the tendency of cholesterol plaque to deposit in plaque in 
coronary arteries. Chapter 5 was designed to examine whether CM contribute to the 
hyperlipaemia that is known to occur when ethanol is consumed with a fat-containing 
meal. In an attempt to examine the metabolic basis of this ethanol-induced 
hyperlipidaemia, a range of parameters were measured including; plasma NEFA, 
glucose, LDL, HDL, insulin, LPL, HL, CETP activities. This was a cross-over study 
design whereby 8 healthy male subjects were given ethanol on one occasion together 
with a meal containing 44 g of fat, and then on another occasion they only consumed 
the meal without ethanol. Meal intake caused an increase postprandial plasma-TAG 
and a parallel increase of CM both with and without ethanol. However, the clearance 
of TAG and CM were significantly delayed after ethanol intake with the meal. This 
study also demonstrated statistically significant increases of insulin and a reduction in 
NEFA associated with ethanol, which confirms the finding of previous research in 
this field. However, ethanol had no significant effect on plasma glucose, total protein, 
total apo B, and total cholesterol. The delayed clearance of CM after ethanol intake
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was most probably due to reduced LPL activity caused by ethanol intake compared to 
the control.
The results from this study support the evidence that limited consumption of ethanol 
raises HDL-cholesterol levels in the blood but decreases the LDL-cholesterol level. 
Hence ethanol might reduce the tendency of cholesterol plaque to accumulate in 
arteries. However, no beneficial effects of ethanol intake have been shown even in 
moderate amounts, for healthy individuals and in the general population, in particular 
the elderly, people with coronary risk factors and patients with previous coronary 
events. Ethanol increases mortality through other causes, especially injury, cirrhosis 
of the liver and some forms of cancer, thereby outweighing the benefits for CHD. In 
addition, the effects of ethanol vary and depend on the amount ingested, the type of 
drinking (binge or moderate regular ethanol consumption), body composition of the 
drinkers and a number of gene/environment interactions (Frohlich, 1996). Another 
confounding factor is the time at which the effect of ethanol on lipoprotein and TAG 
is evaluated as short- and long-term experiments may lead to different conclusions. 
As concluded by Renaud et al. (1993) the increase in HDL-cholesterol does not 
account for the full effect of ethanol in reducing the risk of CHD. A more definitive 
recommendation will also depend on additional studies in a larger population that 
includes hypertriaeylglyceridaemia subjects as indicated previously. On the other 
hand, guidelines regarding ethanol intake should always be linked to pertinent 
recommendations about other atherosclerotic risk factors (PovmaU, 1994).
This study also showed the presence of CM/CMR in the fasting plasma of normal and 
healthy subjects, providing further evidence of the high sensitivity of immuno­
detection that has been optimised for use with plasma. The presence of intestinal 
TAGRL was detected by measuring plasma-RE and TAGRL-RE. Results showed a 
similar peak for apo B-48 and RE, in contrast to several previous publications that 
reported apo B-48 and RE as being unequal markers for CM. As mentioned in 
Chapter 1, the type of RP used might influence the response. In this study we used a 
vitamin A water-miseible Type 100 and its absorption might be faster than oil based 
RP. The immuno-deteetion and semi-quantitation technique using the AMDEX- 
conjugate, as explained in Chapter 3, was also applied in this study to the CMR- 
containing TAGPL fraction. Additionally, the ability to detect of apo B-48 and apo
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B-100 in the same blot was examined as a means of investigating the relationship 
between different TAGRL (CM/CMRA^LDL) in a shorter time and with more 
reliability.
One of the earlier aims of this research was to purify CM from TAGRL. Due to the 
problem of isolating CM/CMR from endogenous TAGRL, as pointed out earlier, an 
attempt was made to construct immunoaffinity columns to separate CM from VLDL. 
The first step in this effort was to purify polyclonal anti-apo B-48 Ig fraction from the 
other proteins following the method of Godfrey et al. (1993). Anti-apo B-48 Ig was 
separated from other proteins by elution from the column with citric-phosphate buffer. 
An optimisation displacement experiment was conducted to check the reactivity of 
purified anti-apo B-48. The results showed that the activity of purified anti-apo B-48 
was preserved. Purified anti-apo B-48 thereafter was conjugated with activated 4B- 
sepharose matrix (Amersham) following the manufacturers instructions. However, 
due to the larger size of CM, they could not interact with anti-apo B-48, which were 
bound in the relatively small pores of the sepharose gel. An alternative matrix was 
used, which was solid glass without pores with bead size of 70 microns. It had low 
binding capacity, which was less than a milligram protein/g of solid glass. Due to the 
small area available on the surface of solid glass, only small amounts of anti-apo B-48 
were successfully conjugated. As a result, anti-apo B-48 conjugated to the column 
was not sufficient to interact with apo B-48-containing lipoproteins, even though the 
length of the column was doubled. In addition, a commercial Hi-Trap Heparin 
column was used in an attempt to purify CM from VLDL. Unfortunately, in our 
hands, this method also failed to separate CM/CMR from TAGRL.
There might be several reasons to explain the lack of success of these experiments. 
The source of CM used might be one of the causes. The size of CM from lymph is 
larger than CM in the plasma because CM from lymph undergoes continuous changes 
while circulating in the blood stream. This will affect the size and composition of CM, 
for instance the apo E content, and thus influencing the capacity of the lipoprotein 
particles to interact with the immunoaffinity column. The presence of small amounts 
of apo B-48-containing particles in the sample could be fiirther diluted during the 
eluting process. At the time of these experiments, immuno-deteetion by AMDEX- 
conjugate had not been developed. So, there is also the possibility of using this
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enhanced immuno-deteetion technique for screening apo B-48 from immunoaffinity 
columns. The successfiil development of this method would be very useful in order to 
determine the structure and fimction of CMR in relation to their possible direct role in 
atherogenesis. Following the metabolism of CM by monitoring apo B-48 is 
informative but it is still not possible to examine the composition of CM through the 
different stages of their metabolism without developing a method for their physical 
separation.
The results from each chapter clearly shown that the anti-apo B-48 synthesised in our 
laboratory has a very high specificity towards apo B-48. This research has also 
developed a valuable immuno-deteetion and semi-quantitation technique for apo B-48 
with high sensitivity. Furthermore, it was possible to show the direct visualisation of 
apo B-48 and apo B-lOO-containing lipoprotein in human tissues, which has 
implications for the Zilversmit Hypothesis, in supporting a direct role of TAGRL, 
particularly CMR, in atherogenesis.
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APPENDICES
APPENDIX I
Table I. Apo B-48 preservative preparation
Stock solutions Final concentration 
in sample
Amount/50 ml stock
EDTA (0.2 M, pH 7.4) T2gd 1.2 g
Chloramphenicol (200 mg/ml) 80.0 mg/1 80.0 mg
Sodium azide (2.5% v/v) 0.1 gA 0.1 g
Gentamicin sulphate (10 mg/ml) 80.0 mg/1 80.0 mg
Kallikrein inactivator 10,000 U/1 10,000 U
(Aprotinin - 4 TIU/mg) (2.75 mg)
NaCl (0.3 M, pH 7.4) 0.15 M 8.8 g
Benzamidine (IM) 0.16 g/1 0.16 g
To prepare:
Weight out 8.8 g NaCl in 100 ml beaker and add 1.2 g EDTA. Add 40 ml of distilled 
water while stirring. Add 3M NaOH drop wise to adjust the pH to 7.4 until solid 
dissolves. Weigh out and add all other solids to solution while stirring. Make volume 
up to 50 ml with distilled water. Do not put chloromphenicol last because it cannot 
get dissolved. The preservative should be added to the appropriate tubes before the 
addition of the sample in order to have a final concentration of 5% (v/v). The 
preservative cocktail is very toxic and the use of gloves, mask, and safety spectacles is 
absolutely necessary during preparation and handling. Sodium chloride (NaCl) 
ensures salt molarity. Sodium azide prevents bacterial growth. Gentamicin sulphate 
and chloramphenicol are used to inhibit strict and facultative anaerobes. EDTA 
prevents lipid oxidation (cleavage of polypeptide chains caused by sodium azide) has 
anticoagulant properties (avoids osmotic effects that shift water from erythrocytes to 
plasma), inhibits the action of bacterial phospholipase C, and chelates heavy metals. 
Benzamidine inhibits trypsin proteolysis. Aprotinin (Kallikrein inactivator) prevents 
trypsin proteolysis.
(Edelstein and Scanu, 1986).
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Figure 1. A typical 9-point standard curve produced by double dilution of a lymph 
standard (Lymph 1A was used).
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Table 2. Standard curve preparation for RE analysis
(a) TAGRL fraction
RP
Standard
(ng)
TAGRL
(fasting)
(Fl)
Saline
(pl)
Methanol
(pl)
RA
(2.5pg/ml)
(pl)
RP
(25pg/ml)
(pl)
MPB
(pl)
Blank 100 400 500 - - 500
Blank + RA 100 400 500 50 - 450
0.125 RP 100 400 500 50 5 445
0.25 RP 100 400 500 50 10 440
0.50 RP 100 400 500 50 20 430
1.0 RP 100 400 500 50 40 410
Unknown 100 400 500 50 - 450
(b) Plasma
RP
Standard
(Pg)
Plasma
(fasting)
(pl)
Saline
(pl)
Methanol
(pl)
RA
(1.25pg/ml)
(pl)
RP
(12.5pg/ml)
(pl)
MPB
(pl)
Blank 100 400 500 - - 500
Blank + RA 100 400 500 50 - 450
0.125 RP 100 400 500 50 5 445
0.25 RP 100 400 500 50 10 440
0.50 RP 100 400 500 50 20 430
1.0 RP 100 400 500 50 40 410
Unknown 100 400 500 50 450
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(c) TAGPL fraction
RP
Standard
w
TAGPL
(fasting)
(pl)
Saline
(pl)
Methanol
(pl)
RA
(1.25pg/ml)
(pl)
RP
(12.5|xg/ml)
(pl)
MPB
(pl)
Blank 300 200 500 - - 500
Blank + RA 300 200 500 50 - 450
0.065 RP 300 200 500 50 5 445
0.125 RP 300 200 500 50 10 440
0.250 RP 300 200 500 50 20 430
0.50 RP 300 200 500 50 40 410
Unknown 300 200 500 50 - 450
* Saline is 0.9% (w/v) o f  NaCl
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Figure 2. Calibration curve of RE/RA peak area ratio against RP concentration.
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APPENDIX II
Lumen
Lumen •Endothelial cell 
■Smooth muscle cell 
■Lipld-laden macrophage 
■ Extracellular lipid
•Necrotic cell
Figure 1. Fatty streak of atherosclerosis. The fatty streak, composed largely o f foamy macrophages, 
is presumed to be an early stage in the formation of atheroclerotic lesions. Note the intimai thickening 
in the left panel and the infiltrating cells in the enlargement on the right.
CAP Macrophage
LUMEN 
Smooth muscle cells
Endothelial cell
Lymphocytes
SHOULDER
Lipid-laden
macrophage
ELASTIC MEDIA
Figure 2. Fibrous plaque of atherosclerosis. In this fully developed fibrous plaque the core contains 
lipid-filled macrophages and necrotic smooth muscle cell debris. The ‘fibrous’ cap is composed 
largely o f smooth muscle cells, which produce collagen, small amounts of elastin, and 
glycosaminoglycans. Also shown are infiltrating macrophage and lymphocytes. Note that the 
endothelium over the surface o f the fibrous cap fi’equently appears intact.
(Benditt and Schwartz, 1988).
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APPENDIX III 
Consent form
EFFECT OF ETHANOL ON POSTPRANDIAL LIPID METABOLISM IN MAN
I have read the information sheet for participation in the study and have had the 
purpose and nature of the study explained to me by Dr. John Wright/Dr. Bruce
GritFm/Dr. Barry Gould.
a I have read and understand the Information Sheet for participation m the study, 
b I have been given the opportunity to question the investigators on all aspects of
.  ^  «■>
postprandial lipid metabolism in man . i, + cn
t  r Z Z i d  ftat l ' î S  withdraw from the study at any time without the need to
iustify my decision and without prejudice. ^ ^ .
g I understand that I will receive £50 expenses on completion of the study, 
h I understand that in the event of my suffering any significant deterioration m 
health or well-being caused directly by my participation m the study
commonly awarded for similar injuries by an English court if liability is admitted 
provided that such compensation may be reduced to the extent by reason of
contributory fault, am partly responsible for the mjuij. I understand & atthiso e 
of compensation does not prevent me from alternatively pursumg a claim 
basis of negligence or strict liability.
Signed by...........................................................(Volunteer)
NAME...............................................................(BLOCK CAPITALS)
Date.....................
Witnessed by........................................................
Name of witness....................................................... (BLOCK CAPITALS)
Date.....................
th a n k  y o u  f o r  a g r e e in g  t o  p a r t ic ip a t e  in  THIS STUDY
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APPENDIX IV
MEAN DATA FOR CONTROL AND ETHANOL IN ETHANOL STUDY 
CHAPTER FIVE
Table I. Postprandial plasma-paraeetamol concentration (mean ± SD) measnred in 8 
male subjects following meals containing 44 g fet either without ethanol (control) or 
with ethanol (ethanol)
TIME (MINUTES)
PLASMA-PARACETAMOL (mmol/1) 
44 s FAT MEAL
CONTROL ETHANOL
0 0.0 ±0.00 0.00 ±0.00
30 0.05 ±0.03 0.08 ±0.04
60 0.11 ±0.07 0.10 ±0.04
120 0.12 ±0.07 0.11 ±0.05
180 0.11 ±0.06 0.11 ±0.06
240 0.11 ±0.06 0.14 ±0.10
300 0.09 ±0.04 0.11 ±0.05
360 0.08 ±0.04 0.09 ±0.05
420 0.06 ±0.04 0.08 ±0.03
480 0.04 ±0.03 0.05 ±0.02
Table 2. Postprandial plasma-TAG concentration (mean + SD) measured in 8 male 
subjects following meals containing 44 g fat either without ethanol (control) or wit
ethanol (ethanol)
TIME (MINUTES)
PLASMA-TAG (mmol/1) 
44 2 FAT MEAL
CONTROL ETHANOL
0 1.28 ±0.60 1.24 ± 0.57
30 1.43 ± 0.55 1.44 ± 0.54
60 1.67 ± 0.56 1.72 ± 0.57
120 1.97 ± 0.58 1.99 ± 0.70
180 2.16 ± 0.75 2.11 ± 0.73
240 2.35 ± 0.75 2.32 ± 0.89
300 2.24 ± 0.86 2.61 ± 1.08
360 1.94 ± 0.83 2.58 ± 1.02
420 1.56 ± 0.83 2.55 ± 0.93
480 1.28 ± 0.66 2.07 ± 0.76
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Table 3 Postprandial TAGRL-TAG concentration (mean + SD) measured in 8 m^e
subjects following meals containing 44 g fat either without ethanol (control) or with
ethanol (ethanol)
TIME (MINUTES)
TAGRL-TAG (mmol/1) 
44 g FAT MEAL
CONTROL ETHANOL
0 0.39 ±0.27 0.46 ±0.40
30 0.45 ±0.28 0.51 ±0.43
60 0.70 ±0.51 0.74 ±0.48
120 1.06 ±0.52 1.00 ±0.58
180 1.07 ±0.57 1.14 ±0.65
240 1.27 ±0.58 1.41 ±0.83
300 1.27 ±0.64 1.46 ±0.93
360 0.99 ±0.58 1.66 ± 1.06
420 0.66 ± 0.48 1.43 ±0.80
480 0.41 ±0.37 1.06 ±0.66
Table 4. Postprandial TAGPL- TAG concentration (mean + SD) measnred in 8 male 
subjects following meals containing 44 g fat either without ethanol (control) or with
ethanol (ethanol)
TIME (MINUTES)
TAGPL-TAG (mmol/1) 
44 g FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
0.81+0.34 
0.79 + 0.28 
0.69 ±0.14 
0.76 ± 0.26 
0.75 ±0.18 
0.86 ±0.28 
0.78 ±0.24 
0.83 ±0.27 
0.80 ±0.29 
0.77 ±0.27
0.87 ±0.31 
0.74 ±0.17 
0.80 ±0.20 
0.76 ±0.19 
0.81 ±0.14 
0.82 ±0.16 
0.87 ±0.14 
0.82 ±0.11 
0.81 ±0.14 
0.87 ±0.18
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Table 5. Postprandial plasma- insulin concentration (mean + SEM) me^ured m
8 maie subjects following meals containing 44 g fat either without ethanol (control)
or with ethanol (ethanol)
TIME (MINUTES)
PLASMA INSULIN (mmol/1) 
44 g FAT MEAL
CONTROL ETHANOL
0 56.55 ±14.30 46.14 + 12.59
30 415.6 + 44.77 477.43 + 111.95
60 570.38 + 102.31 707.50 + 144.51
120 582.77 ± 155.29 497.55 + 111.07
180 355.44 + 108.41 363.17 + 117.44
240 137.66+33.30 262.22+42.91
300 57.47 ± 14.02 133.16 + 31.31
360 41.70 + 11.03 60.02 ± 12.67
420 67.54 ±30.63 55.96 + 7.47
480 62.34+29.13 36.03 + 9.56
Table 6. Postprandial plasma-glucose concentration (mean ± SD) measured in 8 male 
subjects following meals containing 44 g fat either without ethanol (control) or wit 
ethanol (ethanol)
TIME (MINUTES)
PLASMA GLUCOSE (mmol/1) 
44 g FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
5.61 ± 0.36 
7.30 ±1.50 
7.60 ±1.66
7.15 ±1.78 
6.37 ±1.55 
5.48 ±0.58 
5.18 ±0.77
5.15 ±0.45 
5.25 ±0.38 
5.32 ±0.25
5.50 ±1.35 
7.87 ±1.79 
7.92 ±1.52 
7.01 ±1.30 
6.73 ±1.93 
6.27 ±1.8
5.36 ± 0.75 
5.30 ±0.42
5.37 ±0.47
5.37 ±0.31
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Table 7. Postprandial plasma-NEFA eoneentration (mean ± SD) measured in 8 male
subjects followii^ meals containing 44 g fat either without ethanol (control) or wi
ethanol (ethanol)
TIME (MINUTES)
PLASMA NEFA (mmol/1) 
44 g FAT MEAL
CONTROL ETHANOL
0 0.40 ±0.19 0.38 ±0.16
30 0.26 ±0.16 0.27 ±0.16
60 0.26 ±0.12 0.16 ±0.06
120 0.16 ±0.04 0.14 ±0.04
180 0.18 ±0.06 0.24 ±0.29
240 0.29 ±0.12 0.14 ±0.04
300 0.52 ±0.19 0.20 ±0.05
360 0.61 ±0.11 0.37 ±0.19
420 0.75 ±0.17 0.53 ±0.25
480 0.69 ±0.21 0.57 ±0.33
Table 8. Postprandial plasma-cholesterol concentration (mean ± SD) measnred in 8 
male subjects following meals containing 44 g fat either without ethanol (control) or 
with ethanol (ethanol)
tim e  (MINUTES)
PLASMA CHOLESTEROL (mmol/1) 
44 g FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
4.74 ±1.13 
4.68 ±1.02
4.67 ±1.08
4.54 ±0.96 
4.46 ±0.91 
4.53 ±1.08 
4.52 ±1.05
4.55 ±1.02
4.67 ± 1.08 
4.63 ±1.04
4.45 ±1.27
4.74 ±0.95
4.70 ±0.86
4.71 ±0.83 
4.55 ±0.85 
4.69 ±0.72
4.74 ±0.85 
4.65 ±0.83 
4.77 ±0.98 
4.73 ±0.90
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Table 9. Postprandial plasma-total apo B concentration (mean ± SD) measured in 8
male subjects following meals containing 44 g fat either without ethanol (control) or
with ethanol (ethanol)
TIME (MINUTES)
PLASMA TOTAL APO B (g/1) 
44 g FAT MEAL
CONTROL ETHANOL
0 0.94 ±0.31 0.95 ±0.25
30 0.91 ±0.24 0.95 ±0.25
60 0.92 ±0.26 0.92 ±0.22
120 0.88 ±0.23 0.92 ±0.23
180 0.88 ±0.23 0.92 ±0.24
240 0.89 ±0.25 0.92 ±0.21
300 0.89 ±0.23 0.90 ±0.16
360 0.88 ±0.24 0.93 ±0.21
420 0.89 ±0.24 0.93 ±0.22
480 0.91 ±0.23 0.93 ±0.23
Table 10. Postprandial plasma-total protein concentration (mean ± SD) measured in 8 
male subjects following meals containing 44 g fat either without ethanol (control) or 
with ethanol (ethanol)
TIME (MINUTES)
PLASMA TOTAL PROTEIN (mmol/1) 
44 g FAT MEAL
CONTROL ETHANOL
0 68.4 ±3.2 70.4 ±4.4
30 71.1 ±5.9 69.4 ±4.5
60 71.3 ±6.3 69.9 ±2.1
120 68.0 ±4.2 71.0 ±2.8
180 67.5 ±3.4 71.6 ±3.8
240 69.1 ±4.5 68.3 ±3.3
300 69.1 ±5.0 71.7 ±5.0
360 69.0 ±5.0 72.3 ±6.6
420 69.6 ±6.1 71.4 ±4.2
480 68.3 ±3.9 70.5 ±5.3
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Table 11. Postprandial plasma-Apo B-48 concentration (mean ± SD) measured in
8 male subjects following meals containing 44 g fat either without ethanol (control)
or with ethanol (ethanol)
TIME (MINUTES)
PLASMA-Apo B-48 (pg/ml) 
44gFATMEAL
CONTROL ETHANOL
0 2.60 ± 1.25 2.11 + 1.45
30 2.87 ± 1.67 2.77 ± 1.39
60 2.52 ± 1.53 2.48 ± 1.71
120 3.44 ± 1.54 3.04 +1.35
180 3.20 ± 1.35 3.44 +1.92
240 2.90 ± 1.29 2.82 ± 1.42
300 2.67 ± 1.76 2.22 ±1.15
360 3.12 + 0.84 2.46 ±1.11
420 2.57 ± 1.41 1.99 ±1.26
480 2.45 ± 1.46 2.32 ± 1.38
Table 12. Postprandial TAGRL-Apo H48 eoneentration (mean ± SD) measured in 
8 male subjects followii^ meals containing 44 g fat either without ethanol (control) 
or with ethanol (ethanol)
tim e  (MINUTES)
TAGRL-Apo B-48 (pg/ml) 
44 g FAT MEAL
CONTROL ETHANOL
0 0.08 ±0.03 0.09 ±0.04
30 0.10 ±0.04 0.09 ±0.03
60 0.13 ±0.08 0.15 ±0.03
120 0.19 ±0.07 0.21 ±0.06
180 0.21 ±0.05 0.23 ±0.07
240 0.20 ±0.06 0.22 ±0.06
300 0.24 ±0.06 0.23 ±0.10
360 0.20 ±0.07 0.26 ±0.08
420 0.14 ±0.06 0.25 ±0.09
480 0.10 ±0.03 0.18 ±0.10
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Table 13. Postprandial TAGPL-Apo B-48 concentration (mean ± SD) meœured in
8 maie snbjects following meals containii^ 44 g fat either without ethanol (control)
or with ethanol (ethanol)
TIME (MINUTES)
TAGPL-Apo B-48 (pg/nü) 
44 g FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
3.41 ±0.80
3.69 ±0.95
3.38 ±0.74 
3.34 ±1.18
3.70 ±0.77
3.70 ±1.04 
3.81 ±1.12 
3.65 ±0.92
3.39 ±0.55 
3.11 ±0.73
3.12 ±0.80 
3.18 ±0.66 
3.16 ±0.86 
3.27 ±1.17 
3.42 ±0.82 
2.90 ±0.69 
3.05 ±0.54 
3.34 ±1.01 
2.76 ±0.64 
2.93 ±0.83
Table 14. Postprandial plasma-Apo B-48 concentration (mean ± SEM) measured in 
8 male subjects following meals eontainii^ 44 g fat either without ethanol (control) 
or with ethanol (ethanol) measured by SDS-PAGE
TIME (MINUTES)
PLASMA-Apo B-48 (% 
44 g FAT
of internal standard) 
MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
11.31 ±2.07 
13.92 ±2.34 
22.46 ±4.50
25.32 ±4.64 
24.39 ±5.01 
17.23 ±2.17 
15.25 ±4.17 
10.84 ±3.46 
8.53 ±3.94 
9.61 ± 3.75
12.14 ±3.10 
9.24 ±2.70 
15.56 ±3.56 
19.70 ±4.09 
20.93 ±4.56 
22.47 ±4.05 
20.64 ±2.73 
19.73 ±2.82 
18.11 ±3.34 
16.35 ±3.03
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Table 15. Postprandial TAGRL- Apo B-48 eoneentration (mean ± SD) measnred in
8 maie subjects following meals containing 44 g fat either without ethanol (control)
or with ethanol (ethanol) measured by SDS-PAGE
TIME (MINUTES)
TAGRL-Apo B
44
48 (% of internal standard) 
g FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
13.80 ±2.52 
21.96 ±3.27 
47.08 ±4.27
62.07 ±6.04 
74.01 ±7.22 
62.61 ±5.79 
67.66 ±7.54 
52.30 ± 10.33
37.07 ±10.11 
19.46 ±6.47
18.24 ±3.30
25.24 ±2.66 
49.71 ±6.34 
55.48 ±6.35 
53.55 ±5.89 
63.94 ±6.03 
65.46 ±6.09 
68.68 ±5.93 
56.98 ±7.55 
56.62 ± 8.84
Table 16. Postprandial plasma-RP concentration (mean + SD) me^nred in 
8 male snbjects following meals containii^ 44 g fat either without ethanol (control)
or with ethanol (ethanol)
PLASMA-RP (pg/ml)
tim e  (MINUTES) 44 g FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
0.15 ±0.11 
0.18 ±0.15 
0.69 ±0.57 
1.58 ±0.71 
1.53 ±0.40 
1.56 ± 0.58 
1.03 ±0.71 
0.93 ±0.56 
0.47 ±0.30 
0.26 ±0.14
0.13 ±0.07 
0.12 ±0.07 
0.67 ±0.43 
1.83 ±1.21 
1.56 ±0.68 
1.92 ±0.70 
1.18 ±0.50 
1.39 ±0.65 
0.93 ±0.37 
0.63 ±0.42
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Table 17. Postprandial TAGRL-RP concentration (mean ± SD) measured in
8 male subjects following meals containing 44 g fat either without ethanol (control)
or with ethanol (ethanol)
TAGRL-RP (pg/ml)
TIME (MINUTES) 44 2 FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
0.03+0.02 
0.03 ±0.03 
0.61 ±0.50 
1.50 ±0.74 
1.36 ±0.39 
1.18 ±0.49 
0.78 ±0.63 
0.66 ±0.53 
0.23 ±0.17 
0.13 ±0.09
0.03 ±0.02 
0.04 ±0.03 
0.52 ±0.41 
1.52 ±1.10
1.59 ±0.59
1.59 ±0.67 
0.96 ±0.44 
1.07 ±0.63 
0.79 ±0.35 
0.48 ±0.35
Table 18. Postprandial TAGPL-RP concentration (mean ± SD) measured in 
8 male subjects following meals containing 44 g fat either without ethanol (control)
or with ethanol (ethanol)
TAGPL-RP (pg/ml)
TIME (MINUTES) 44 g FAT MEAL
CONTROL ETHANOL
0
30
60
120
180
240
300
360
420
480
0.12 ±0.10 
0.19 ±0.13 
0.09 ±0.03 
0.20 ±0.12 
0.21 ±0.14 
0.26 ±0.20 
0.25 ±0.19 
0.22 ±0.15 
0.27 ±0.18 
0.16 ±0.11
0.10 ±0.07 
0.09 ±0.07 
0.15 ±0.09 
0.32 ±0.24 
0.26 ±0.19 
0.28 ±0.09 
0.22 ±0.21 
0.32 ±0.25 
0.26 ±0.10 
0.15 ±0.10
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